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ABSTRACT 
The global burden of HIV and AIDS coupled with the limitations of current oral tenofovir (TNF) 
administration drives the need to develop strategies such as the use of alternate routes of administration to 
improve drug therapy. Transdermal drug delivery (TDD) offers numerous advantages and is an attractive 
alternative for the systemic delivery of TNF. Although the inherent protective barrier property of skin is 
one of the major challenges in the design of TDD systems,  the use of chemical permeation enhancers 
(CPEs) such as fatty acids (FA) and their esters or the use of nano drug delivery systems have the potential 
to overcome this limitation. To date there are no reports on TDD permeation enhancement strategies or a 
nanoemulgel (NEG) as a TDD formulation for TNF. Novel lipidic approaches that reversibly decrease the 
barrier properties of the skin as well as the use lipid based nano drug delivery systems such as NEGs to 
enhance the TDD of TNF remain to be investigated. The broad aim of this study was therefore to explore 
the potential of novel lipid-based strategies for enhancing transdermal permeation of TNF. The specific 
research aims of this study were to: (1) Synthesize and characterize novel biocompatible dendritic ester 
derivatives of unsaturated FAs (UFAs) and explore their potential as promising permeation enhancers for 
the transdermal delivery of TNF. (2) Evaluate the novel application of UFA esters of cholesterol as 
promising transdermal permeation enhancers using TNF as a model drug. (3) Synthesize and characterize 
novel biocompatible mono, di and tri-ester derivatives of FAs and explore their potential as promising 
transdermal permeation enhancers using TNF as a model drug. (4) Explore the potential of novel linolenic 
acid based heterolipid, LLA1E (a novel transdermal permeation enhancer), as an oily phase in the 
development of a nanoemulgel for the transdermal drug delivery of TNF. 
UFAs [palmitoleic (PA), linoleic (LA), linolenic (LLA) and arachidonic acid (AA)] were used to synthesize 
novel dendritic ester derivatives [PA1E, LA1E, LLA1E and AA1E]. The structural features of the biosafe 
derivatives were confirmed by FTIR, NMR (1H and 13C) and HRMS. All synthesized novel dendritic ester 
derivatives at 1% w/w were found to be more effective enhancers with LLA1E being identified as the most 
superior with an ER of 6.11 at 2% w/w. Histomorphological analysis displayed no significant loss in the 
integrity of the skin and also indicated that TNF utilized both the transcellular and intercellular route of 
transport, with the drug and enhancer treatment having no permanent effects on the epidermis. Therefore 
these novel dendritic ester derivatives of UFAs can be considered as effective transdermal permeation 
enhancers for TNF. 
ix 
The TDD potential of TNF using UFA esters of Cholesterol (Chol) viz., oleate, linoleate and 
linolenate, as CPEs showed that all Chol UFA esters at 1% w/w were found to be more effective 
enhancers when compared to their respective parent FAs and saturated FAs counterparts. 
Cholesteryl linolenate (Chol-LLA) showed the most superior performance with the greatest ER 
of 5.93 being achieved at a concentration of 2% w/w. The histomorphological and 
transepithelial electrical resistance (TEER) evaluations displayed no damage to the integrity of 
the epidermis and skin exposure to the permeation enhancer had only temporary effects on its 
barrier property. Therefore Chol UFA esters can be considered as new CPEs for exploitation 
in transdermal formulations for various classes of drugs.   
The synthesized mono, di and tri-ester derivatives were non-toxic and displayed better 
transdermal permeation enhancement capabilities as compared to their respective parent FAs. 
The in vitro permeation results showed that the mono oleate derivative (MOAPE) displayed 
the greatest ER for TNF (5.87) at 1% w/w. Histological investigations of the rat skin treated 
with MOAPE revealed fluidization of the stratum corneum. Histological and TEER studies 
revealed no significant change to the viable epidermis of the skin after 1% MOAPE exposure. 
The TEER findings also suggested that the permeation enhancement effects of MOAPE were 
not permanent and showed a return towards original skin integrity after removal of the enhancer 
formulation.  These findings therefore indicate that the novel mono ester derivative of OA 
(MOAPE) adds to the pool of CPEs available to formulation scientists and can be safely 
incorporated into TDD systems for several classes of drugs. 
LLA1E served as an effective oily phase in the formulation of nanoemulsions (NEs). TNF 
loaded nanoemulsions (TNEs) were prepared and incorporated into TNF nanoemulgels 
(TNEGs) which were subsequently evaluated for their ex vivo transdermal permeation efficacy. 
TNEs had a mean globule diameter (MGD) of 129.06 ± 3.35 nm, polydispersity index (PDI) 
of 0.192 ± 0.038 and zeta potential (ZP) of 20.9 ± 2.02 mV with an incorporation efficiency of 
91.94 ± 0.84%. There was no significant change is these properties after incorporation of TNEs 
into a hydrogel as MGD, PDI and ZP of TNEGs were found to be 136.13 ± 5.21 nm, 0.182 ± 
0.020 and -20.9 ± 2.08 mV respectively. Ex vivo permeation studies showed that the TNEG 
significantly enhanced the TNF permeation by 39.65-fold, with a cumulative amount of 
1866.54 ± 108.62 µg.cm -2.  Histological and TEER assessments showed no permanent effects 
on the skin by TNEG. Therefore, this novel TNEG nanosystem has the potential of further 
translation into clinical trials for optimal treatment alternatives for HIV/AIDs patients.  
x 
The findings of this study therefore identified and developed novel lipid based approaches that 
were successful in reversibly decreasing the barrier of the skin and was able to promote the 
transdermal delivery of TNF. Novel lipid based strategies such as dendritic ester derivatives of 
UFAs; UFA esters of cholesterol; mono, di and tri-ester derivatives of FAs and TNF loaded 
NEGs therefore have the potential of enhancing TDD of TNF. This study has therefore made 
significant contributions towards improving TDD and TNF therapy for optimal treatment 
alternatives for HIV/AIDs patients.  
Keywords: fatty acids; synthesis; esterification; chemical permeation enhancers; tenofovir; 
transdermal;  cholesterol; nanoemulsion; nanoemulgel 
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CHAPTER 1 
INTRODUCTION 
1.1 Introduction 
This chapter includes the background to the study, describing the prevalence of HIV and AIDS 
and the limitations of current oral tenofovir (TNF) administration. It further describes the use and 
advantages of TDD as an alternate route of drug administration and highlights the limitations 
of this route. It provides strategies to overcome the limitations and details of promising 
approaches to optimize TDD. Details of the aims and objectives, novelty and significance of the 
study are also included. 
1.2 Background to this study 
Globally, human immunodeficiency virus (HIV) infection and acquired immune deficiency 
syndrome (AIDS) is still one of the most serious public health diseases. Although antiretroviral 
(ARV) therapy has revolutionised the treatment of HIV and AIDS [1, 2], some ARVs require 
frequent administration at high doses due to their low bioavailability as these drugs are prone to 
extensive gastrointestinal (GIT) degradation, first pass metabolism and have a short half-life [3]. 
This treatment regimen leads to severe dose-dependent adverse effects which results in a 
decreased patient compliance. These limitations therefore hinder the effective treatment of HIV 
and AIDS. The prevalence of HIV and AIDS together with the drawbacks of current oral ARV 
treatment necessitates the identification of innovative and alternate ARV drug delivery strategies 
[3].   
TNF is classified as a nucleotide analog type ARV drug that has the ability to specifically inhibit 
reverse transcriptase thereby terminating/blocking the process of viral replication. The oral 
administration of TNF has numerous limitations and is therefore currently administered as an 
ester prodrug (tenofovir disoproxil fumarate) to overcome its hydrophilicity and poor intestinal 
permeability [4, 5]. TNF is administered in high doses due to its poor bioavailability which 
results in multiple dose-dependent GIT associated adverse effects such as irritation of the 
intestinal lining, diarrhea, nausea and inflammation. [6, 7]. These limitations lead to a significant 
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decrease in patient compliance. Although there are several disadvantages associated with its 
current oral administration, TNF is still considered as the most successful ARV to treat and 
prevent HIV and AIDS and appears on the world health organization’s (WHO) list of essential 
medicines [8]. In an attempt to improve the therapy of TNF, alternate routes of administration 
and novel drug delivery systems have been explored as strategies to overcome the above 
mentioned limitations. The vaginal, rectal and buccal route have attracted interest as alternate 
routes of TNF administration as they are capable of preventing exposure to the GIT by delivering 
drugs directly into the systemic circulation [9, 10]. Transdermal drug delivery (TDD) offers an 
attractive alternative for the delivery of TNF directly into systemic circulation as it has shown 
promise for several classes of drugs by avoiding several limitations associated current oral drug 
delivery [11, 12].  
TDD has numerous advantages as the application and removal of dosage forms are convenient 
and stable plasma drug levels can be easily achieved by administering long acting TDD 
formulations. TDD avoids the hepatic first-pass effect and passage through the GIT, which 
results in a higher drug bioavailability and decreased GIT associated adverse effects [11, 12]. 
Furthermore, TDD is reported for the alternate administration of donepezil, diclofenac 
sodium, ketoprofen and peroxicam which are drugs that cause GIT distress in patients 
[13-16]. The administration of TNF via the transdermal route could therefore ensure 
adequate drug bioavailability and a decrease in the dose dependent GIT adverse effects, 
leading to an increase in patient compliance.  
Despite the numerous advantages of TDD, a critical limitation to this route is the 
natural protective barrier layer of the skin, the stratum corneum (SC) [17]. The SC is the 
uppermost layer of the epidermis and is composed of corneocytes that are surrounded by 
extracellular lipids such as ceramides, cholesterol and free fatty acids. This layer presents a 
formidable barrier and only allows substances that are either lipid soluble and of a low molecular 
weight to pass through [18-20]. This barrier does not allow therapeutically relevant 
quantities of many drugs to transverse the skin unaided, therefore strategies need to be 
developed to overcome the hindrance provided by the SC.  To increase the number of drugs 
that can be delivered in therapeutically relevant quantities, it is necessary to temporarily 
decrease the barrier properties of the skin. There have therefore been significant efforts using 
chemical, biochemical or physical approaches 
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to develop new strategies to reduce skin’s barrier properties and improve TDD [18]. Chemical 
permeation enhancers (CPEs) have often been considered as excipients used to promote the 
transdermal penetration of drugs [21, 22]. CPEs have the ability to enhance TDD by increasing 
the partition of the drug into the SC, or interacting with the corneocytes, or by reversibly 
disrupting the extracellular lipid matrix thereby altering its nanostructure and increasing its 
fluidity (Figure 1) [21-23]. While the corneocytes forms the framework for the extracellular lipid 
matrix in the SC, the focal point of TDD approaches has been on the manipulations of the 
extracellular lipid region. While lipid soluble drugs are able to accumulate in the lipid matrix 
thereby facilitating their slow release, the presence of aqueous pores in this region also provides 
additional novel drug delivery opportunities in this area[12, 18]. 
Figure 1. Mechanism of permeation enhancement: fluidization and transport pathways across the 
SC layer. 
Fatty acids (FAs) are natural components of skin and have progressed as one of the most 
promising classes of transdermal CPEs. By altering the organization of the extracellular lipid 
matrix and increasing the fluidity of the SC, FAs are able to promote TDD by expanding the 
intercellular domains which effectively decreases the barrier properties [21, 24, 25]. 
Physicochemical characteristics such as carbon chain length, lipophilicity and structural 
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orientation of FAs have been implicated as features that determine their performance as a 
transdermal permeation enhancer [16, 21, 22]. Although saturated fatty acids (SFAs) and 
unsaturated fatty acids (UFAs) such as lauric acid (LuA), stearic acid (SA), oleic acid (OA), 
palmitoleic acid (PA), linoleic acid (LA), linolenic acid (LLA) and arachidonic acid (AA) have 
all been studied as transdermal permeation enhancers [15, 24, 26, 27]; literature reports that 
UFAs are more effective as compared to their SFAs counterparts[15, 28, 29]. Further, UFAs 
with an 18 carbon chain length have been reported as being the most successful transdermal 
permeation enhancers [21]. The notion that derivatives display greater enhancement than 
their parent materials is well supported by the literature [14, 21, 30-33]. FA derivatives such 
as diethyl sebacate, diisopropyl adipate and oleodendrimers of OA have all displayed 
significant permeation enhancement across the skin. One of the contributing factors to these 
derivatives displaying a greater performance has been attributed to their greater lipophilicity as 
compared to their parent material [14, 32]. Studies report that the formation of ester derivatives 
of FAs yields new superior chemical entities which display significantly greater permeation 
enhancement potential than their respective parent material. FA esters such as ethyl oleate, 
isopropyl decanoate and sucrose laurate have therefore shown promise as effective 
transdermal permeation enhancers for both hydrophilic and hydrophobic drugs [24]. 
Although FAs and their ester derivatives have been explored as enhancers for TDD of 
various classes of drugs, only one ARV drug (zidovudine) has been investigated using a 
FA as a transdermal permeation enhancer [34]. Recent reports further confirm the 
applicability of FA esters as novel dendritic esters of OA have displayed superior transdermal 
and buccal permeation enhancement of diclofenac sodium and didanosine 
respectively [14, 33]. Although there is a continuous search for new chemical entities, the 
identification of new CPEs is slow. Therefore, the modification of existing CPEs to 
produce novel chemical entities with superior performance is highly desirable.  
Biocompatible nanomaterials have emerged as one of the recent strategies developed to enhance 
TDD. Nanomaterials offer unique properties that are not present in their bulk 
counterparts. Features such as size, biocompatibility, shape, surface chemistry, optical and 
electrical properties play key roles in improving many medical applications [35-38]. 
The formulation of nanomaterials as an approach to improve drug delivery and therapeutics 
are gaining huge interest in pharmaceutical sciences. Literature reports that nano sized 
transporters/ vehicles below 150 
Introduction Chapter 1 
6 
nm are able to effectively deliver drugs transdermally despite the natural barrier properties of the 
SC [38]. Lipid based nano formulations such as nano or microemulsions and nanoemulgels have 
shown promise to enhance the delivery of drugs across the skin [35-37, 39].  
Nanoemulsions (NEs) have been explored for TDD applications as they display unique size 
features ranging from 20- 500 nm and have favorable morphological and chemical properties 
[40]. NEs are formulated through the combination of oil and water interface that is 
simultaneously stabilized using one or more surfactant or co-surfactants. The application of NEs 
in drug delivery offers many benefits such as decreased preparation costs, the absence of organic 
solvents or other toxic by-products, improved thermodynamic stability and increased storage 
stability [41, 42]. NEs also display large surface areas to volume ratios, a feature common to all 
nano-sized formulations. This inherent property can be utilized for the efficient delivery of drugs 
through the dermal route. The larger surface area of the nano-sized emulsion allows for increased 
and rapid penetration through the SC layer, promoting the entry of the drug into systemic 
circulation [41, 43].   
The formulation of oil in water (o/w) NEs have an oil core surrounded by water and a 
combination of surfactants/ co-surfactants that stabilize the oil-water interface [41, 42]. The oil 
phase of an o/w NE is critically important due to its capacity to solubilize lipophilic drug 
molecules, thereby increasing its absorption through lipid membranes [43]. Interestingly it has 
been demonstrated that nanoemulsions have higher drug permeation when compared to 
conventional transdermal formulations such as gels and emulsions [41, 42]. Despite the 
advantages of NEs, the clinical applications of NEs are limited mainly due to the inconvenience 
of its low viscosity properties [44]. Literature illustrates that the use of hydrogels to thicken and 
increase the viscosity of NEs have displayed better rheological features and higher stability 
which leads to more effective TDD systems that display improved permeation properties [44]. 
The term nanoemulgels (NEGs) is derived from the combination of NEs and hydrogel matrices. 
NEGs exhibit unique features from both NEs and gels that synergistically function to increase 
drug permeation enhancement across the skin tissue and improve transdermal applications [45, 
46]. These advantages have promoted the use of NEGs for TDD of various classes of drugs. 
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Despite several classes of drugs explored using NEGs, there is no report for the formulation of 
TNF NEs or NEGs for transdermal drug delivery applications. Although the literature is 
expanding with myriad research on novel biomaterials that increase, improve and enhance drug 
permeation through the transdermal route, there still remains limited information on their 
translation into a dosage form or delivery systems that are essential for the development of 
successful therapeutics. 
1.3 Problem statement 
HIV and AIDS is one of the most serious, prevalent public health diseases globally. TNF is 
currently the most successful ARV drug to HIV infection. The oral administration of TNF has 
numerous limitations which necessitates its current administration as an ester prodrug, tenofovir 
disoproxil fumarate. Due to its high dose administration there are several GIT associated adverse 
effects which lead to a decrease in patient compliance. There is therefore a justifiable need to 
explore alternate strategies to improve the systemic delivery of TNF. In order to address the 
limitations of TNF, the use of novel drug delivery systems and alternate routes of drug 
administration have been investigated, however the transdermal permeability potential of TNF is 
yet to be explored. TDD of TNF could allow administration of the drug directly into systemic 
circulation in it’s basic to native form which would also prevent the drug from passing through 
the GIT. This would eliminate the GIT associated side effects and result in an increased patient 
compliance. TDD system for TNF could also require lowering of the loading dose to 
achieve adequate bioavailability for therapeutic efficacy. Thus there would be benefits for 
both the patient and product manufacturer. Although there are numerous benefits to TDD, 
a major limitation to this route is the upper most layer of the skin, the SC, which is a natural 
barrier that prevents the entry of drugs through the skin. The use of transdermal permeation 
enhancers that are able to reversibility decrease the barrier property of the SC have shown 
promise to overcome this limitation and offer an effective means of increasing the number 
of drugs that can be delivered via this route. CPEs are most frequently used as transdermal 
permeation enhancers; however the identification of new CPEs is slow. Chemically modified 
entities have displayed greater permeation enhancement capabilities; therefore the 
modification of existing CPEs to produce superior novel derivatives will increase the 
pool of available excipients for TDD systems.  
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1.4 Aims and objectives of this study 
The broad aim of this study was to explore the potential of lipid-based strategies for enhancing 
transdermal permeation of TNF. The specific research aims and objectives of two series of novel 
FA ester derivatives and the novel application of UFA esters of cholesterol as CPEs for TDD, as 
well as the novel formulation of a TNF nanoemulgel for transdermal application are highlighted 
in the chapters they are presented in.  
1.4.1 Chapter: 2 
The specific aim of this study was to synthesize and characterize novel biocompatible dendritic 
ester derivatives of UFAs and explore their potential as promising permeation enhancers for the 
transdermal delivery of TNF. 
In order to achieve this aim, the objectives of the study were to: 
1.4.1.1 Synthesize novel ester dendritic derivatives of palmitoleic (PA), linoleic (LA), linolenic 
(LLA) and arachidonic acid (AA) and characterize the derivatives using FTIR, NMR (1H 
and 13C) and HRMS techniques.  
1.4.1.2 Determine the lipophilicity, pH responsiveness and the in vitro biosafety of the novel 
ester derivatives. 
1.4.1.3 Explore the in vitro potential of the novel FA ester derivatives as transdermal permeation 
enhancers for TNF and assess the effects of the enhancer treatment on the skin using 
transepithelial electrical resistance as well as light and transmission electron microscopy.  
1.4.2 Chapter: 3 
The specific aim of this study was to evaluate the novel application of UFA esters of cholesterol 
as promising transdermal permeation enhancers using TNF as a model drug.  
In order to achieve this aim, the objectives of the study were to: 
Introduction Chapter 1 
9 
1.4.2.1 Synthesize cholesterol ester derivatives of oleic (OA), linoleic (LA), linolenic (LLA), 
Lauric (LuA), Palmitic (PA) and stearic acid (SA) and characterize the derivatives using 
FTIR, NMR (1H and 13C) techniques as well as determining their lipophilicity.  
1.4.2.2 Explore the in vitro potential of the cholesterol ester derivatives as transdermal 
permeation enhancers for TNF and assess the effects of the enhancer treatment on the 
skin using transepithelial electrical resistance and light microscopy. 
1.4.3 Chapter: 4 
The specific aim of this study was to synthesize and characterize novel biocompatible mono, di 
and tri-ester derivatives of FAs and explore their potential as promising transdermal permeation 
enhancers using TNF as a model drug.  
In order to achieve this aim, the objectives of the study were to: 
1.4.3.1 Synthesize novel mono, di and tri-ester derivatives of FAs bearing β-alanine t-butyl ester 
head group using oleic (OA), linoleic (LA), linolenic (LLA) and stearic acid (SA) and 
characterize the derivatives using FTIR, NMR (1H and 13C) and HRMS techniques.  
1.4.3.2 Determine the lipophilicity and the in vitro biosafety of the novel ester derivatives.  
1.4.3.3 Explore the in vitro potential of the novel ester derivatives as transdermal permeation 
enhancers for TNF and assess the effects of the enhancer treatment on the skin using 
transepithelial electrical resistance and light microscopy.  
1.4.4 Chapter 5: 
The specific aim of this study was to explore the potential of novel linolenic acid based 
heterolipid, LLA1E (a novel transdermal permeation enhancer), as an oily phase in the 
development of a nanoemulgel for the transdermal drug delivery of TNF. 
In order to achieve this aim, the objectives of the study were to: 
1.4.4.1 To determine the optimal ratio of surfactant and co-surfactant (Smix) to oil (LLA1E) by 
constructing pseudo-ternary phase diagrams.  
1.4.4.2 Formulate and evaluate the TNF NE and TNF NEG in terms of mean globule diameter, 
polydispersity index, zeta potential, viscosity, morphology and stability. 
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1.4.4.3 Explore the ex vivo potential of the novel TNF nanoemulgel to enhance the transdermal 
delivery of TNF and assess the effects of the nano formulation on the skin using 
transepithelial electrical resistance and light microscopy.  
1.5 Novelty of the study 
The novelty of the research is presented in the four different experimental chapters as follows: 
1.5.3 Chapter:2 
The research performed in this study is novel for the following reasons: 
• The synthesized dendritic ester derivatives explored in this paper as chemical permeation
enhancers are novel, non-cytotoxic to mammalian cells and have not been previously
reported for any drug delivery applications.
• The novelty of the study also lies in the fact that this is the first report on transdermal
permeation efficacy of TNF, an ARV drug with potential clinical significance.
• Additionally, all the synthesized dendritic ester derivatives consist of tertiary nitrogen in
their structure and their potential to show pH dependency has been proven
experimentally. Therefore, these derivatives can also be considered as a novel class of
biocompatible pH responsive excipients for pH dependant drug delivery systems.
1.5.4 Chapter:3 
The research performed in this study is novel for the following reasons: 
• This is the first report that utilizes UFAs esters of cholesterol as transdermal permeation
enhancers for any drug class.
1.5.5 Chapter: 4 
The research performed in this study is novel for the following reasons: 
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• The synthesized mono, di and tri-ester derivatives of FAs bearing β-alanine t-butyl ester
head group are novel, non-cytotoxic to mammalian cells and have not been previously
reported for any drug delivery applications.
• Additionally, a UK Patent (Application No. 1614120.2) was registered for the synthesis
and transdermal permeation enhancement application of these novel derivatives.
1.5.6 Chapter: 5 
The research performed in this study is novel for the following reasons: 
• This study identified the potential of a novel dendritic heterolipid, LLA1E previously
synthesized and reported by our group, as an oily phase excipient in the preparation of a
performance efficient novel transdermal TNF NEG. This study reports for the first time
the applicability of LLA1E in a pharmaceutical preparation.
• In addition to the novelty of the formulated nanosystem, this is the first report on the
formulation of TNF NEs and NEGs for transdermal delivery.
1.6 Significance of the study 
All four TNF transdermal permeation enhancement approaches proposed in this study are novel 
and could contribute to overcoming the natural barrier properties of the skin thereby allowing a 
larger variety of drugs to be delivered via this route. The novel approaches of this study could 
also demonstrate that therapeutically relevant doses of TNF can be delivered transdermally and 
therefore this route could function as an attractive alternative to overcome the limitations of 
current oral TNF administration. The significance of this study is highlighted below: 
New pharmaceutical products: 
The proposed ester dendritic derivatives of PA, LA, LLA and AA and the mono, di and tri-ester 
of OA, LA, LLA and SA which bear β-alanine t-butyl ester head group as well as the TNF 
loaded NEG are new pharmaceutical products not yet reported that can promote and improve 
innovate drug delivery approaches in industrial pharmaceutical R&D.  
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Improved patient therapy and disease treatment:  
All the proposed permeation enhancement approaches could decrease the barrier properties of 
the skin, which should enhance the transdermal delivery of TNF. This could improve patient 
therapy by minimizing doses, lowering side effects and increasing patient compliance. These 
approaches may therefore improve patient amenability to this treatment regimen.   
Creation of new knowledge to the scientific community:  
The proposed research would lead to the dissemination of new scientific knowledge within the 
domains of pharmaceutical sciences and biomaterials chemistry.  
• In the novel dendritic ester derivatives study, new knowledge from the development of
superior biocompatible novel CPEs from parent FAs will be generated. Additionally, the
applicability of TNF for transdermal delivery will be established, and its possible route of
transport across the skin could be elucidated from light and transmission electron
microscopy.
• In the UFAs esters of cholesterol study, new knowledge can be generated from the
identification and combination of existing materials which possess advantageous inherent
features which would contribute favourably to their novel applicability in TDD
approaches.
• In the mono, di and tri-ester FA derivatives study, new knowledge can be generated from
the design and synthesis of novel biosafe derivatives that target the lipid domains of the
SC to decrease the barrier properties of the SC.
• In the TNF NEG study, new knowledge can be generated from the translation of
previously identified novel CPEs into nano TDD dosage forms which is essential to
realise their downstream pharmaceutical applications.
Stimulation of new research: 
The proposed strategies designed for the enhancement of TNF permeation across the skin has the 
potential to improve drug delivery via the transdermal route. Additionally, this work has the 
capacity to stimulate innovative approaches in various research areas, such as: 
• Due to the likely pH titratable nature of the synthesized novel FA dendritic ester
derivatives they are potential excipients in the development of pH responsive drug
delivery systems for antimicrobial or cancer therapeutic applications.
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• If the UFAs esters of cholesterol show transdermal permeation enhancement potential
they can therefore also be considered as multifunctional lipids (as CPEs and membrane
stabilizers) in the future formulation development of transdermal liposomes for the
treatment of multiple disease conditions.
• Additionally, the novel FA dendritic ester derivatives and the mono, di and tri-esters of
FAs could also be further exploited for their potential applications in lipid based
colloidal drug delivery systems such as nanoemulsions, self-microemulsifying drug
delivery systems and nanostructured lipid carriers for several classes of drugs.
• The formulated NEG would demonstrate the translation of previously identified
excipients into efficient nano drug delivery systems. This would encourage further
research utilising reported materials in the design and implementation of effective
dosage forms for various biomedical applications.
1.7 Overview of thesis 
The research presented in this thesis is in the manuscript format, which is in line with the 
University of Kwa-Zulu Natal, College of Health Sciences guidelines, which specifies the 
inclusion of a brief introductory chapter, manuscripts in preparation/submitted/published and a 
final chapter on the conclusions. A PhD study requires at least 3 first authored 
manuscripts/papers, 2 of which must be experimental.  
CHAPTER 1. INTRODUCTION: This chapter includes the background to the study, 
describing the prevalence of HIV and AIDS and the limitations of current oral TNF 
administration. It further describes the use and advantages of TDD as an alternate route 
of drug administration and highlights the limitations of this of this route. It provides 
strategies to overcome the limitations and details of promising approaches to optimize 
TDD. Details of the aims and objectives, novelty and significance of the study are also 
included.  
CHAPTER 2. EXPERIMENTAL PAPER 1: This chapter addresses aim 1.4.1 and is a first 
authored experimental article published in the Journal of Materials Chemistry B (Impact 
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Factor = 4.872) which is an ISI international journal. This article reports the synthesis, 
characterization, and in vitro permeation enhancement effect of a novel series of UFA 
ester dendritic derivatives for the transdermal delivery of TNF. 
CHAPTER 3. EXPERIMENTAL PAPER 2: This chapter addresses aim 1.4.2 and is a first 
authored experimental article manuscript published in an ISI international journal i.e. 
Drug Delivery and Translational Research (Impact Factor = 1.887). This article reports 
the synthesis, characterization and novel TDD application of a series of UFA esters of 
cholesterol using TNF as the model drug.  
CHAPTER 4. EXPERIMENTAL PAPER 3: This chapter addresses aim 1.4.3 and is a first 
authored experimental article manuscript submitted the European Journal of 
Pharmaceutical Sciences (Impact Factor = 3.773) which is an ISI international journal, 
manuscript number: EJPS-D-16-01525. This manuscript reports the synthesis, 
characterization, biosafety and in vitro permeation enhancement effect of a novel series 
of mono, di and tri-ester derivatives of FAs bearing β-alanine t-butyl ester head group 
for the transdermal delivery of TNF. 
CHAPTER 5. EXPERIMENTAL PAPER 4: This chapter addresses aim 1.4.4 and is a first 
authored experimental article published in Colloids and Surfaces B: 
Biointerfaces (Impact Factor = 3.902) which is an ISI international journal. This 
article reports the use of a novel linolenic acid based heterolipid, LLA1E (a novel 
transdermal permeation enhancer), as an oily phase in the development of a 
nanoemulgel for the transdermal drug delivery of TNF. 
CHAPTER 6. CONCLUSION: This chapter details the general conclusions from the research 
outcomes of the study. It describes the significance and impact of the research and 
further recommends future research in the field of TDD and improved ARV 
therapeutics.   
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CHAPTER 2 
Experimental paper 1 
2.1 Introduction 
This chapter addresses aim 1.4.1 and is a first authored experimental article published in the 
Journal of Materials Chemistry B (Impact Factor = 4.872) which is an ISI international journal. 
This article reports the synthesis, characterization, and in vitro permeation enhancement effect 
of a novel series of UFA ester dendritic derivatives for the transdermal delivery of TNF. 
Mr. S. Rambharose contributed to the design of the project, modification and optimisation of 
methods as well as synthesis and characterisation of UFA ester dendritic derivatives. Mr. S. 
Rambharose conducted all experimental work including in vitro cytotoxicity, rat skin tissue 
harvesting, in vitro transdermal permeation experiments, TEER experiments and light and 
transmission electron microscopy evaluations. Mr. S. Rambharose also wrote the paper.  Dr. 
R.S. Kalhapure assisted with the overall design of the project and the methods of preparation 
and characterisation as well as editing of the paper. Prof K.G. Akamanchi supervised the 
synthesis of the UFA ester dendritic derivatives in this work. Prof. T. Govender served as 
supervisor and was responsible for project conceptualisation, editing of paper and abstract and 
general supervision of the study.    
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2.2 Graphical abstract 
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Abstract 
This study was aimed at exploring the potential of unsaturated fatty acids (UFAs) [palmitoleic (PA), linoleic 
(LA), linolenic (LLA) and arachidonic acid (AA)], and their newly synthesized dendritic esters [PA1E, 
LA1E, LLA1E and AA1E] having basic tertiary nitrogen as the branching element as transdermal 
permeation enhancers for the delivery of tenofovir. The structures of the derivatives were confirmed by 
FTIR, NMR (1H and 13C) and HRMS. The in vitro cytotoxicity study revealed their biocompatibility. 
Amongst the UFAs, only PA and LLA exhibited transdermal enhancer potential [enhancement ratio (ER) 
of 2.9 and 1.35 respectively]. All synthesized derivatives at 1% w/w were found to be more effective 
enhancers as compared to their parent UFAs,  with LLA1E  being identified as the most  superior (ER = 
5.31). Further, the concentration effect study revealed that at 2% w/w LLA1E had a greater ER (6.11) as 
compared to its parent (ER=3.85). The permeability data correlated with the observations made in the 
histomorphological and transepithelial electrical resistance (TEER) evaluations. There was no significant 
loss in the integrity of the epidermis, transcellular and intercellular route of transport across the epidermis, 
with drug and enhancer treatment having no permanent damage on the epidermis. The novel dendritic ester 
derivatives of the UFAs therefore can be considered as effective transdermal permeation enhancers. 
Keywords: Tenofovir, transdermal, fatty acids, permeation enhancers 
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Introduction 
Transdermal drug delivery (TDD) involves the transport of drugs across the epidermis, into the blood 
vessels located within the dermis resulting in systemic distribution of a desired drug 1, 2. This route avoids 
the first pass effect for drugs that are rapidly metabolized by the liver when taken orally. Drugs that require 
consistent plasma concentrations are very good candidates, as peaks and troughs in plasma level can be 
avoided. Since this route avoids direct effects on the gastrointestinal tract (GIT), drugs that cause GIT 
distress would benefit from TDD. These systems can be used as a substitute delivery method for patients 
who cannot tolerate oral dosage forms. The relative ease of these systems is due to the possibility of self-
administration, with drug therapy being terminated rapidly by removal of medication from site of 
application. This simple, painless and non-invasive application lends to improved patient compliance and 
comfort1, 3-6. The use of TDD is therefore highlighted as being especially suitable for pediatrics as compared 
to several oral formulations7, 8. TDD has the potential to improve bioavailability of various drugs, decrease 
dosages required and reduce drug side effects. Controlled drug release can also be achieved using this 
system, resulting in decreased frequency of administration 9, 10. TDD can therefore enhance therapeutic 
effects, compliance and adherence. In light of these benefits various classes of drug and permeants have 
therefore been explored for their transdermal permeation potential. These include amongst others 
tenoxicam, aceclofenac, ketoprofen 11, diclofenac sodium 11, 12, peroxicam13, testosterone 14, niacinamide 
15, vitamin B12 
16, donepezil 17, lamivudine 18, Stavudine 19, zidovudine 20-22 and pyrimidinedione IQP-410 
23. There are already many commercially available transdermal drug patches and topical applications in the
market for numerous acute and chronic disease conditions. Additionally, many drugs proposed for 
transdermal delivery are currently within various stages of clinical trials. TDD therefore has the potential 
to facilitate the transport of a huge selection of drugs that can treat various disease conditions 24, 25.  
The major shortcoming of drug delivery across the skin is its natural barrier property. This barrier property 
of the skin is mainly due to the thin outer layer of the epidermis, stratum corneum (SC). The SC is 
commonly termed the “brick and motar” structure due to the structurally organized proteins and lipids in 
this protective layer. The structured lipids found in this layer function to prevent water loss from the body, 
and thereby impede the movement of most topical applied permeants through the skin, unless they are of a 
low molecular weight and lipid-soluble 4, 12, 26. This barrier prevents movement of permeants from the 
superficial surface of the skin. In order to deliver therapeutically relevant doses of a drug across the skin, 
strategies need to be developed to overcome the hindrance provided by the SC.  
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Literature reports physical and chemical methods employed to modify the barrier properties of the SC, such 
as the use of chemical penetration enhancers (CPEs) as excipients to promote permeation enhancement is 
often considered27-30. CPEs could act through one or more of the following mechanisms (i)   by improving 
partition of the drug into the SC, (ii) by interaction with the intercellular protein, (iii) alteration of SC highly 
ordered lipid structure and its fluidity 28, 31, 32.  
Being endogenous constituents of skin, fatty acids (FAs) are the most attractive skin permeation enhancers 
employed for TDD 13, 33. The physicochemical properties of a compound can determine its efficacy as a 
permeation enhancer. A variety of contributing factors such as carbon chain length, structural configuration 
and lipophilicity of a compound have been implicated as factors that determine the effectiveness of a 
transdermal permeation enhancer 17, 27, 28. Depending on their subclass, FAs retain differing structural 
properties which can influence their efficacy as transdermal penetration enhancers. These properties include 
variations in carbon chain length, number, position and configuration of their double bonds as well as their 
branching substituents 13. FAs can decrease the barrier properties of the SC by disturbing the packing of 
the lipid bilayer, thereby increasing its fluidity12, 31, 33. A large selection of saturated and unsaturated fatty 
acids (UFAs) such as lauric acid, myristic acid, capric acid, oleic acid (OA), palmitoleic acid (PA), linoleic 
acid (LA), linolenic acid (LLA) and arachidonic acid (AA) have been studied as transdermal permeation 
enhancers 13, 34. However, OA, an 18 carbon chain monounsaturated FA has been reported as being the 
most prevalent FA for having transdermal permeation enhancement. In addition literature shows evidence 
that saturated FAs are less effective in enhancing transdermal permeation as compared to their unsaturated 
counterparts 17, 27, 35. Though there is ongoing intensive search for new chemical entities, discovery and 
development of new CPEs is at very slow rate 9.  
The findings of many reported studies support the notion that derivatives of parent compounds exhibit 
greater permeation enhancement efficacy12, 27, 36-39. Therefore, there is a justified need to synthesize novel 
derivatives from compounds that display positive CPE properties. The derivatives of  FAs such as, diethyl 
succinate, diethyl adipate, diethyl sebacate, diisopropyl adipate 38 and oleodendrimers from OA 12 have all 
shown promising transdermal permeation enhancement of the drug studied, which has been attributed to 
increased lipophilicity of the FA derivatives. FAs and their ester derivatives have been extensively studied 
as transdermal permeation enhancers for various classes of drugs other than ARVs 12, 38. The only exception 
is OA which was studied as an enhancer for the transdermal delivery of zidovudine 22. Previous findings 
suggest that functionalization of OA with dendritic esters as head groups significantly improves the 
transdermal permeation of diclofenac sodium 12 and buccal permeation of didanosine 39, an ARV drug. The 
possible enhanced drug permeation by dendritic ester derivatives of other UFAs remain to be explored. 
Therefore, the evaluation of UFAs as well as the synthesis, characterization and to assess the transdermal 
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permeation enhancement efficacy of their novel dendritic ester derivatives will contribute to expanding the 
pool of available safe and effective excipients for transdermal delivery systems. 
Oral antiretroviral (ARV) drug therapy has significantly improved the treatment of human 
immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) 40, 41. 
However, some ARV drugs have low bioavailabilities due to extensive gastrointestinal degradation, first 
pass metabolism and short half-lives, requiring high doses and frequent drug administration. This leads to 
severe dose-dependent side-effects, which further exacerbate the decrease in patient compliance 42.  These 
limitations with oral therapy negatively impact on the effective treatment of HIV and AIDS. The HIV and 
AIDS crisis coupled with limitations of oral ARV therapy therefore drive the need for identifying 
innovative drug delivery strategies. In order to address these limitations of oral ARV treatment, formulation 
scientists have been exploring the use of novel drug delivery systems and alternate routes of drug 
administration 42. Alternate routes of drug administration that obviate the gastrointestinal tract as well as 
hepatic first pass metabolism and deliver drug directly into the systemic circulation will be beneficial to 
many ARVs that are susceptible to the above mentioned limitations 43, 44. More specifically, in addition to 
the buccal 39, 45-47, rectal 48 and vaginal 48 routes, transdermal delivery of ARV drugs is receiving increasing 
interest and is currently being investigated as an alternate route of administration for overcoming limitations 
associated with oral ARV therapy 7, 23, 42, 49. 
TNF is a nucleotide analog which is widely used in the treatment of HIV and AIDS. Although there are 
limitations to the administration of TNF, it is still currently considered the most successful drug to HIV 
infection 50. Due to its hydrophilicity and poor intestinal permeability, it is currently administered orally as 
the ester prodrug, tenofovir disoproxil fumarate. The dosage is one 300 mg tablet taken once daily, with a 
low bioavailability of 25%51. Additionally, there are numerous GIT associated side effects reported for oral 
TNF administration leading to a decrease in patient compliance52, 53. Alternate routes of TNF administration 
that have been reported to overcome its disadvantages include buccal 45 and the rectal and vaginal route 48. 
The transdermal permeability potential of TNF has not been reported to date. TDD of TNF could allow 
administration of the drug directly into systemic circulation in it’s basic to native form instead of 
synthesizing the ester prodrug, thereby decreasing manufacturing costs. It would also obviate the drug from 
passing through the GIT; thereby eliminating the GIT associated side effects, hence increasing patient 
compliance. TDD system for TNF could also require lower the loading dose to achieve adequate 
bioavailability for therapeutic efficacy. Thus there would be benefits both to the patient and product 
manufacturer. Fig 1. Illustrates transdermal permeability due to a combination of the specified drug and 
fatty acid derivative within a polymer medium that supports the formulation. The fatty acid derivative 
would interact with the integrity of the outer most barrier, the stratum corneum (SC), facilitating enhanced 
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transdermal drug permeability via the two potential routes of transport viz. intercellular or paracellular. The 
concentration of the fatty acid derivative is a crucial aspect in designingand implementing successful 
formulations for enhanced transdermal drug delivery.  Therefore, the aim of this study was to identify the 
transdermal permeability potential of TNF and to explore the applicability of various UFAs (PA, LA, LLA 
and AA) as well as their respective newly synthesized dendritic ester derivatives (PA1E 2, LA1E 3, LLA1E 
4, and AA1E 5) as potential CPEs for the transdermal delivery of TNF. 
Fig. 1 Illustrates enhanced transdermal drug permeability through the application of novel fatty acid 
derivatives and drugs within a polymer formulation  
Results and discussion 
Characterization and stability of newly synthesized dendritic esters 
FT-IR, 1H NMR, 13C NMR and HRMS techniques were used to characterize the synthesized ester 
derivatives of UFAs. Transformation of acid function of UFA into ester was easily monitored using FT-IR 
by observing the peak around 1710-1730 cm-1. 
PA1E 2 
1H NMR (400 MHz, CDCl3) δ: 0.89 (t, 3 H, J = 13.6 Hz), 1.25-1.30  (m, 16 H), 1.44 (s, 18 H), 1.59-1.66 
(m, 4 H), 1.79 (qt, 2 H, J = 28 Hz),  2.03 (q, 4 H, J = 20 Hz), 2.04-2.35 (m, 4 H), 2.49 (t, 2 H, J = 16 Hz), 
2.73 (m, 4 H), 4.1 (t, 2 H, J = 12.9), 5.32-5.36 (m, 2 H). 13C NMR (100 MHz, CDCl3) δ: 14.09, 22.64, 
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24.98, 26.68, 27.16, 27.21, 28.09, 28.98, 29.11, 29.16, 29.18, 29.69, 31.77, 33.80, 34.35, 49.40, 50.14, 
62.44, 80.31, 129.76, 129.98, 171.98, 173.86. HRMS (ES-TOF): [M]+ calcd for C33H61NO6H
+ 568.45; 
found 568.4619.  
LA1E 3 
1H NMR (400 MHz, CDCl3) δ: 0.87 (t, 3 H, J = 13.4 Hz), 1.29-1.33  (m, 14 H), 1.42 (s, 18 H), 1.59-1.61 
(m, 2 H), 1.72-1.75 (m, 2 H), 2.05 (q, 4 H, J = 19.2 Hz), 2.24-2.33 (m, 6 H), 2.47 (t, 2 H, J = 13.2), 2.67-
2.76 (m, 6 H), 4.07 (t, 2 H, J = 12.8), 5.29-5.36 (m, 4 H). 13C NMR (100 MHz, CDCl3) δ: 14.04, 22.54, 
24.96, 25.6, 26.65, 27.17, 27.87, 28.07, 29.10, 29.13, 29.16, 29.32, 29.58, 31.50, 33.77, 34.32, 49.39, 50.13, 
62.41, 80.28, 127.89, 128.01, 130.01, 130.17, 171.91, 173.79. HRMS (ES-TOF): [M]+ calcd for 
C35H63NO6H
+ 594.47; found 594.4768.  
LLA1E 4   
1H NMR (400 MHz, CDCl3) δ: 0.99 (t, 3 H, J = 15.2 Hz), 1.31  (br s, 8 H), 1.44 (s, 18 H), 1.69 (t, 2 H, J = 
39.6), 1.71-1.77 (m, 4 H), 1.78-2.09 (m, 2 H), 2.26-2.35 (m, 6 H), 2.45 (t, 2 H, J = 14), 2.69 (m, 4 H), 2.82 
(m, 4 H), 4.09 (t, 2 H, J = 12.88), 5.40 (m, 6 H). 13C NMR (100 MHz, CDCl3) δ: 14.26, 20.54, 24.97, 25.52, 
25.60, 26.68, 27.20, 28.09, 29.12, 29.14, 29.18, 29.58, 33.80, 34.34, 49.40, 50.14, 62.45, 80.30, 127.11, 
127.71, 128.25, 128.28, 130.26, 131,95, 171.97, 173.84. HRMS (ES-TOF): [M]+ calcd for C35H61NO6H
+ 
592.45; found 592.4572. 
AA1E 5 
1H NMR (400 MHz, CDCl3) δ: 0.90 (t, 3 H, J = 12 Hz), 1.25-1.36 (m, 6 H), 1.42 (s, 18 H), 1.68-1.77 (m, 4 
H), 2.04-2.35 (m, 6 H), 2.45-2.49 (m, 6 H), 2.73 (t, 2 H, J = 40 Hz), 2.79-2.82 (m, 4 H), 2.83-2.85 (m, 4 
H), 4.10 (t, 2 H, J = 16 Hz), 5.34-5.40 m (8 H). 13C NMR (100 MHz, CDCl3) δ: 14.10, 22.56, 24.83, 25.61, 
26.59, 26.91, 27.21, 28.09, 28.28, 29.69, 31.51, 33.72, 34.66, 49.39, 50.14, 62.53, 80.30, 127.54, 127.86, 
128.17, 128.20, 128.57, 128.79, 128.99, 130.47, 171.96, 173.57. HRMS (ES-TOF): [M]+ calcd for 
C37H63NO6H
+ 618.47; found 618.4776. 
All the synthesized dendritic derivatives are prone to oxidation and hydrolysis on long term storage due to 
the unsaturation in aliphatic chain and the presence of ester linkages. Therefore, samples were stored in an 
inert atmosphere in amber coloured bottles at 4 oC to avoid their degradation. The stability of samples stored 
at these conditions for > 2 years was confirmed by comparing their physical appearance and 13C  
NMR data with the freshly prepared samples. There was no change in physical appearance and the spectra 
were identical. The most important observations were presence of unsaturated and ester carbons in the range 
of 127-130 and 171-174 ppm respectively (Table S1 and Fig. S1-S8 of Supporting Information). The 
presence of these characteristic peaks and absence of any other extra peaks in the samples stored in an inert 
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atmosphere for > 2 years was a strong indication of the stability of the synthesized materials under the given 
storage conditions. 
Acid-base titration 
The synthesized dendritic lipids were expected to be basic in nature due to the presence of tertiary nitrogen 
in their structure. An Acid-base titration study was performed to confirm their basicity. In the case of the 
blank sample (0.1 M NaCl), addition of only 10 μl of 1 M HCl resulted in a steep decrease in pH from 13 
to 3.4 indicating no buffering capacity. On the contrary, there was no sudden fall of the pH upon addition 
of 1 M HCl to the solutions of dendritic lipids. The horizontal trend of the plot for the dendritic lipids 
confirmed the considerable buffering capacity of the dendritic lipids over almost the  
entire pH range (Fig 2). The results obtained proves the basic nature of the synthesized dendritic lipids and 
are in good agreement with previous findings where pH responsive poly(L-histidine) exhibited the same 
trend in the graph of HCl versus pH 54. 
Fig. 2 Acid-base titration profile of dendritic derivatives and 0.1 M NaCl (n = 3; RSD < 10%). 
Cytotoxicity evaluation  
Following the successful synthesis and characterization of all the FA derivatives (PA1E 2, LA1E 3, LLA1E 
4, and AA1E 5), an in vitro cell culture system was used to determine the biological safety of these 
derivatives. Cytotoxicity evaluations were performed on HeLa cells using the MTT assay. The assay is 
based on the biochemical reduction of MTT dye by viable cells by testing their enzymatic dehydrogenase 
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activity 55. The MTT assay results showed that none of the synthesized FA derivatives were toxic against 
the HeLa cell line. The percentage cell viability was between 85 to 95 % (Fig 3) for all derivatives for the 
concentration ranges studied. There were also no dose dependent trends observed on the % cell viability of 
HeLa cells within the concentration range studied (Fig 3). A one-way ANOVA, with a non-parametric 
Kruskal-Wallis test revealed that there were  no significant differences between the results obtained for all 
the synthesized derivatives when compared to the control (p = 0.7625). These findings therefore suggest 
that the use of the synthesized FA derivatives in biological studies would be safe 
Fig. 3 Cytotoxicity assay displaying percentage cell viability after exposure to various concentrations of 
the FA derivatives on HeLa cells. Results are presented as mean ± SD. (n = 6).   
In Vitro transdermal permeation 
I) Permeability of TNF in absence of enhancers
In this study we report for the first time the transdermal permeability potential of TNF. The in vitro 
experiments revealed that at the end of six h, the cumulative amount of TNF that permeated through the 
skin was 226.85 ± 33.89 µg/cm2 (Table 1, Fig 4). TNF was able to permeate the skin without any permeation 
enhancer with a steady state flux value of 31.48 ± 6.21 µg/cm2 h (Table 1). This permeability parameter is 
similar to a study by Singh et al., where the transdermal permeability potential of the ARV zidovudine was 
confirmed. This study reported a flux value of 38.2 µg/cm2 h for the zidovudine treatment without enhancer 
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22. Permeants can transverse the skin either via the intercellular or the paracellular route, or both routes
simultaneously, to cross the SC and reach the blood vessels located in the dermis. The route across the SC 
by the permeant is determined by its physicochemical properties31. Since TNF is hydrophilic its preferred 
route of transport could be through the intracellular route, via passive diffusion 56. The permeability 
parameters displayed by TNF suggest that it can be exploited for delivery via the skin as an alternate drug 
delivery route to overcome the limitations presented when administered orally.  
Table 1. Effect of the various derivatives as compared to their parent lipid on the transdermal permeability 
properties of TNF. * Indicates significant difference i.e p < 0.05 (all values compared to control)  
II) Effects of UFAs on TNF permeability
Due to the barrier properties of the skin being an obstacle to the movement of drugs across the SC of the 
skin, permeation enhancers are employed to aid the transport of drugs to ensure therapeutically relevant 
doses reach the systemic circulation 17, 27. Numerous CPE’s have been described in the literature, with FAs 
being advocated as the most promising for the enhanced delivery of hydrophilic compounds through skin 
27, 31, 57. This study therefore explored the use of PA, LA, LLA and AA, and their respective newly 
synthesized derivatives PA1E 2, LA1E 3, LLA1E 4, and AA1E 5 as potential permeation enhancers for the 
transdermal delivery of TNF.   
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The results indicate that amongst the four FAs studied at a concentration of 1% w/w; only LLA and PA 
were able to enhance the permeability of TNF across the skin (Table 1, Fig 4). LLA increased the steady 
state flux and cumulative amount of TNF permeated from 31.48 ± 6.21 to 91.316 ± 3.244 µg/cm2 h and 
226.85 ± 33.89 to 560.72 ± 20.01 µg/cm2, respectively with an ER of 2.9 (Table 1, Fig 3). The increases in 
the permeability parameters due to the addition of LLA were statically significant (p = 0.0243) (Table 1).  
The ER displayed by LLA is comparable to a report by Wen et al., where an ER of 3.10 was achieved using 
span 80 as a transdermal enhancer for the delivery of daphnetin across rat skin 58. PA was also able to 
increase the permeability of TNF with an increase in the steady state flux to 42.588 ± 0.69 µg/cm2 h and 
cumulative amount permeated to 269.99 ± 5.16 µg/cm2, with an ER of 1.35 (Table 1, Fig 4). However, 
these increases in the permeability parameters were not statistically significant (p = 0.6860) (Table 1). 
Although the increases are not statistically significant, the ER is still within the reported range for 
transdermal permeation enhancers, such as methanol (ER=1.17) and Oleic acid (ER=1.52) for the delivery 
of daphnetin 58. In a separate study, tween 80 as an enhancer was also able to increase the ER of zidovudine 
to 1.4 as compared to the unenhanced control 22. 
Fig 4. The effect newly synthesized derivatives as compared to their parent FA on the cumulative amount 
of TNF permeated across the skin.  Results are presented as mean ± SD. (n = 6).  
Experimental paper 1  Chapter 2 
33 
The literature reports that permeation enhancement using UFAs is related to carbon chain length, the degree 
of unsaturation i.e. the number of double bonds present and the “kink” isomer at the double  bond 17, 27, 30, 
59, 60. Of the four FAs studied, PA has the lowest molecular weight of 254.41 g.mol-1 (Table 2).  
Table 2. Structure, molecular formula, number of unsaturations and molecular weight of the 
UFA/derivative studies 
It is probable that the low molecular weight of PA was responsible for the slight degree of enhancement 
observed, as lower molecular weight compounds permeate the skin more readily 32, 61. Although LLA has 
a slightly higher molecular weight (278.44 g.mol-1) than PA (Table 2), its molecular weight is still lower 
than that of LA and AA which therefore places LLA at a slighter advantage. A combination of carbon chain 
length and number of double bonds present in LLA sets it apart from the other FAs studied (Table 2).  
Reports from extensive experiments show that UFAs with a carbon length of C18 are optimal for permeation 
enhancement 27. Studies also describe the bent cis-configuration of UFAs disturbs intercellular lipid packing 
and creates mobile free volumes that could increase the fluidity, allowing molecules to enter the free 
volumes of the kinks at the double bonds and migrate across the membrane thereby lending to the 
permeation enhancement effect of these compounds. The number of kinks tends to increase with the number 
of double bonds in the UFA. Therefore the permeation enhancement effect of UFAs are expected to increase 
with the increase in the number of double bonds 17, 27, 59, 60. Although LA and LLA have the same carbon 
chain length of C18, LLA has a slightly lower molecular weight, and also possesses one more double bond 
than LA (Table 2). On the other hand AA has a greater number of double bonds, a longer carbon chain 
length of C20, and a higher molecular weight of 304.46 g.mol
-1 (Table 2) when compared to LLA. PA has 
a shorter carbon chain length of C16, and only one double bond (Table 2) which therefore renders PA, LA 
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and AA less effective as transdermal permeation enhancers when compared to LLA. Amongst the FAs 
studied LLA possesses the ideal properties that constitute an optimal UFA transdermal permeation enhancer 
as described above, and therefore displayed superior permeation enhancement of TNF.    
III) Effects of novel dendritic derivatives on TNF permeability
The study further determined the effect of structural modifications to the UFAs via the transformation of 
carboxylic acid function into a branched tert-butyl ester function on the permeation enhancement efficacy. 
The findings of the study were compared to both the respective parent material as well as to the control. 
The addition of the branched tert-butyl ester functional group to the periphery of the parent FAs increases 
their liphophilicity 12, 39. All the derivatives synthesized in this study had a higher lipophilicity as compared 
to their respective parent FA as indicated by the calculated log P values (Table 3) 62.  
Table 3. Log P values of UFAs and their respective newly synthesized derivatives. 
UFA/ Derivative Log P 
PA 5.89 
PA1E 7.95 
LA 6.42 
LA1E 8.48 
LLA 6.06 
LLA1E 8.11 
AA 6.59 
AA1E 8.64 
This is a desirable property as the greater the lipophilic nature of an enhancer, the greater the permeability 
across the skin, as there is a greater disruption of the lipids in the SC thereby decreasing the barrier 
properties 12, 38, 63. Indeed, permeation results showed that all of the synthesized derivatives at a 
concentration of 1% w/w were able to increase the permeability of TNF across the rat skin (Table 1, Fig 4) 
and it was to a greater extent than the respective parent FA at similar concentrations. Interestingly, these 
results show that the addition of the tert-butyl ester functional group to the periphery of the parent FAs 
increases the permeability enhancement potential of even the FAs which had originally displayed no 
permeation enhancement (LA and AA) (Table 1, Fig 4). When compared to the control, LA1E 3 increased 
the steady state flux and the cumulative amount permeated from 31.48 ± 6.21 to 82.308 ± 4.33 µg/cm2 h 
and 226.85 ± 33.89 to 514.79 ± 26.89 µg/cm2 respectively, with an ER of 2.61 (Table 1, Fig 3). The data 
Experimental paper 1  Chapter 2 
35 
highlights the fact that LA1E 3 displayed an ER of 1.68 higher than that obtained by its parent LA. The 
increases displayed by the derivative were however not statistically significant when compared to the 
control (p = 0.2039) (Table 1). AA1E 5 was able to increase the steady state flux and cumulative amount 
permeated to 83.466 ± 1.58 µg/cm2 h and 510.18 ± 15.19 µg/cm2 respectively and presented an ER of 2.65 
(Table 1, Fig 4). AA1E 5 increased the ER of TNF across the skin by 1.71 times than its parent (AA). The 
enhanced permeability due to AA1E 5 was also not significantly different when compared to the control (p 
= 0.0832) (Table 1). Although the increases in the permeability parameters by the parent PA were not 
significantly different from the control, the increases in the permeability parameters by the derivative PA1E 
2 were significantly different from the control ( p = 0.0039) (Table 1). PA1E 2 increased both the steady 
state flux and cumulative amount to 110.3 ± 10.73 µg/cm2 h and 707.84 ± 37.36 µg/cm2 respectively, and 
displayed an ER of 3.5 (Table 1, Fig 4). The derivative has an ER of 2.15 higher than that of the parent 
(PA). LLA displayed the best enhancement potential when compared to the other FAs studied. In the same 
way, this was also true for its derivative LLA1E 4, which showed the greatest increase in the permeability 
parameters of TNF when compared to the rest of the synthesized derivatives. LLA1E 4 exhibited an ER of 
5.31 (Table 1). LLA1E 4 increased the steady state flux to 167.3 ± 3.49 µg/cm2 h and the cumulative amount 
to 1014.57 ± 24.90 µg/cm2 (Table 1, Fig 4). The difference between the ER of derivative and parent was 
2.41 in the case of LLA.  
The ER range acquired by these derivatives was equivalent and higher than the ER (2.02 to 3.39) reported 
by an independent study, that employed dendrimers with either amide or ester linkages as transdermal 
permeation enhancers for the delivery of diclofenac sodium (DS). Interestingly, that report showed that the 
dendrimers with ester linkages displayed superior enhancement of DS, which was attributed to their greater 
lipophilicity due to the ester linkage between UFA and the dendron, as well as the presence of tert-butyl 
ester at the periphery 12. The physicochemical properties of an enhancer plays a major role in its ability to 
increase the permeability of a drug/permeant across the membrane. It is evident from this data that the 
structural modification by addition of the tert-butyl ester function augments the enhancement activity of 
the parent FAs. This may be due to the increase in the lipophilicity of the FAs with the addition of this 
functional group (Table 3). Studies have shown that an increase in enhancer lipophilicity results in an 
increase in permeation 12, 38, 39, 63, also possible ionic conjugation between basic dendritic derivatives and 
the acidic drug could aid in the movement of the TNF across the epidermis of the skin. This rational could 
explain the increase in permeation observed for LA1E 3 and AA1E 5, as their parent materials displayed 
no enhancement activity. For LLA1E 4 and PA1E 2, the increase in lipophilicity has had an additive effect 
to the already superior enhancement activity displayed by their respective parent material.  From the current 
study it was observed that LLA1E 4 had all the ideal characteristics viz., optimal FA chain length (C18), 
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number of unsaturations (3) and lipophilicity. Therefore, further concentration effects on transdermal 
permeation enhancement efficacy were carried out on LLA and LLA1E 4. 
IV) Concentration effect of LLA and LLA1E 4 on the permeability of TNF
The effects of varying concentrations of LLA and LLA1E 4 on the transdermal permeability parameters of 
TNF were then investigated (Table 4, Fig 5) to facilitate the establishment of the optimal concentrations of 
either LLA or LLA1E 4 to be potentially incorporated as an enhancer into a future TDD system for TNF. 
The results showed that all the concentrations (0.5, 1, 2, 4, 6 % w/w) both LLA and LLA1E 4 were able to 
enhance the permeability of TNF (Table 4, Fig 5). There was a statistically significant difference between 
all the concentrations studied for both the parent and the derivative when compared to the control. Although 
both LLA and LLA1E 4 displayed enhanced permeation, the derivative LLA1E 4 exhibited a greater degree 
of enhancement at all similar concentrations as compared to its parent material LLA (Table 4, Fig 5). The 
profile of permeation enhancement across the concentration range studied was similar for both LLA and 
LLA1E 4 with an initial increase in permeation enhancement at the lower concentrations (0.5 and 1% w/w), 
reaching optimal permeation enhancement at a concentration of 2% w/w with a subsequent decrease in 
permeation as the enhancer concentration was further increased to 4 and 6% w/w. For the optimal 
enhancement, LLA at 2% w/w increased the steady state flux to 121.47 ± 10.20 µg/cm2 h and the cumulative 
amount to 773.37 ± 45.13 µg/cm2 displaying an ER of 3.85 when compared to the control. The derivative 
LLA1E 4 at 2% w/w increased the steady state flux of the control to 192.37 ± 17.58 µg/cm2 h and the 
cumulative amount to 1214.88 ± 87.33 µg/cm2 with an ER of 6.11 (Table 4, Fig 5).  
Fig. 5 Concentration effects of LLA and LLA1E 4 on the flux of TNF (n=6) 
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Table 4. Effect of the various concentrations of LLA and LLA1E 4 on the transdermal permeability 
properties of TNF. *Indicates significant difference i.e p < 0.05 (all values compared to control) 
The IC50 range for tenofovir is reported to be between 0.55 – 2.2 µM
64, which is 158 – 632 µg.  The amount 
of tenofovir permeated per cm2 in this study using the newly synthesized dendritic ester derivatives as CPEs 
is between 510.18 – 1214.88 µg which is adequate to achieve the desired therapeutic effect. 
The flux values and ER obtained with 2% w/w LLA were similar to that obtained in a separate study where 
5 %  w/v cineole displayed a flux value of 122.4 µg/cm2 and ER of 3.13 when it was employed as a 
transdermal enhancer for the delivery of zidovudine 22. The ER achieved by 2% w/w LLA1E 4 is 
comparable to that achieved by 5 % (w/w) of either N-methyl-2-pyrrolidone (NMP) or transcutol P, which 
in an independent study displayed ER of 6.99 and 6.28 respectively for the transdermal delivery of 
daphnetin 58. Even at lower concentrations, both LLA and LLA1E 4 displayed similar or higher ER to 
reported compounds that show promise as transdermal permeation enhancers. With an increase in the 
concentration of the lipophilic enhancer in the drug formulation, there would be a corresponding increase 
in the lipophilicity of the formulation. The increase in lipophilicity should thereby allow a greater disruption 
of the lipids in the SC with a corresponding decrease in the barrier properties provided by these lipids. This 
assertion is corroborated by the trend observed in this study where there was a direct correlation with the 
increase in permeability of the TNF with an increase in the concentration of enhancer in the formulation 
from 0.5 to 2% w/w. Further increases to 4 and 6% w/w of the enhancers didn’t elicit a similar trend in the 
permeability; rather there was a progressive decrease in the permeability of the drug as the concentrations 
of the enhancers were increased. This could be due to the increased viscosity at the epidermal surface as 
concentrations of the enhancers were increased, which could thereby reduce the movement of the drug 39. 
Previous studies report that FA at higher concentrations in gel formulations could also slow down the 
partitioning of the drug from the formulation  
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thereby decreasing the amount of drug permeating 39, 65. The findings in this study are consistent with 
findings from other studies that reported that increasing enhancer concentrations displayed an initial 
increase in the permeability, however further increases in enhancer concentrations led to a decrease in 
permeability 39, 45, 65. 
TEER studies 
TEER measurements are useful in establishing the integrity of cellular barriers. The values obtained 
quantitatively measure the integrity of tight junction dynamics that maintain the barrier properties. TEER 
measurements across biological barriers taken before they are evaluated for the transport of chemicals or 
drugs are strong indicators of its original integrity 66, 67. A reduction in the resistance values would be 
indicative of the opening of transport pathways that could decrease the barrier properties of the membrane. 
The difference in TEER measurements pre and post experiment can quantifiably establish the change in the 
barrier properties brought on by the drug treatment 66, 67.  
This study aimed to establish if the TNF gel formulation containing the optimal enhancers, either LLA or 
LLA1E 4, at the optimal concentrations of 2% w/w did not affect the integrity of the skin during the 
permeation experiment. The results indicated that as compared to the control, both LLA and LLA1E 4 gel 
formulations at a concentration of 2% w/w were able to decrease the TEER values after 6 h permeation 
study (Fig 5). LLA treatment reduced its control resistance from 326 ± 28 to 311 ± 28 Ω /cm2, which 
represents a 4.6% reduction in the resistance of the barrier. LLA1E 4 treatment was able to reduce the 
resistance of its control from 348 ± 15 to 319 ± 22 Ω /cm2, which signifies an 8.3% reduction in the 
resistance of the barrier (Fig 6). These results correlate with the data from the permeability studies that 
display that LLA1E 4 had a greater permeability enhancement effect than LLA at a concentration of 2% 
w/w (Table 4). This may have been due to LLA1E 4 being able to decrease the barrier properties to a larger 
extent when compared to LLA. Interestingly, the factor by which LLA1E 4 has greater ER over LLA is 
similar to the factor by which LLA1E 4 has greater reduction in TEER as compared to LLA. The findings 
from both these separate studies are therefore in good agreement with each other. One of the characteristics 
of an ideal transdermal permeation enhancer is that upon its removal, the skin should regain its barrier 
properties i.e. its effects on the barrier should be temporary27-29, 31.  
The 2 h post experiment evaluation of TEER was assessed to determine if there was any recovery of the 
barrier function upon removal of the drug formulations. The results displayed that of the original decrease 
recorded for LLA (4.6%) there was a 1.33 % increase in resistance after 2 h post experiment (Fig 6). This 
represents a 28 % recovery in the barrier property of the skin after removal of the gel formulation. In the 
LLA1E 4 study, of the original decrease (8.3%) there was a 2.1% increase in the resistance after 2 h post 
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experiment (Fig 6). This signifies a 25% recovery in the barrier property. These findings are a reflection of 
the recovery of the barrier properties, and suggest a return to the initial measured integrity over time. The 
TEER values obtained in this study indicates that dermal integrity was not irreversibly affected by the drug 
formulations 46, 47. 
Fig 6. Percentage change in TEER values after TNF permeation with either LLA or LLA1E 4 at a 
concentration of 2% w/w (n = 6).  
Light and Transmission Electron Microscopy 
Histomorphological evaluations of the rat skin treated with TNF gel formulations were performed to 
establish whether tissue morphology or cellular integrity of the skin was compromised. These investigations 
were undertaken on the enhancer free TNF gel, and on TNF gel containing enhancer, either LLA or LLA1E 
4 respectively at a concentration of 2% w/w. Two major routes have been proposed for movement of 
molecules across the skin i.e. intercellular and transcellular 30, 35, 56. From these studies it may be possible 
to make inferences on the route of transport of this drug, or the mode of action of the enhancers68-71. 
Permeants need to transverse the epidermis of the skin to get to blood vessels found in the dermis to enter 
the systemic circulation. The epidermis is composed of four layers: 1) the basal layer which is the germinal 
layer of the epidermis supplying new keratinocytes to replace those lost by normal wear and tear; 2) the 
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prickle cell layer which contains cells that is in the process of growth and early keratin synthesis, 3) the 
granular layer which contain cells with intracellular granules which contribute to the process of 
keratinization and 4) the SC, which has been identified as the main barrier, consisting of flattened, fused 
remnants composed mainly of fibrous protein and lipids, with the intracellular keratin having an ordered 
pattern 5, 72. The area of skin chosen for this study was from the abdominal region of the rat which is 
analogous with other reports that performed transdermal permeation studies 12, 58, 73, 74. Skin from this region 
is termed “thin skin” and the individual cellular layers are more difficult to discern as compared to “thick 
skin”. In comparison with thick skin, the SC is thin and the combined thickness of the other layers is reduced 
to a lesser extent 72. This description above closely resembles the control image (Fig 7a) demonstrating that 
the skin used in the study represented healthy tissue with normal morphology.  
Fig 7. Photomicrographs of the control and the treated skin selections for light microscopy (LM) stained 
with H&E ; (× 40) a control/untreated, b treated with TNF gel, c treated with 2% w/w LLA TNF gel, d 
treated with 2% w/w LLA1E 4 TNF gel. (D: dermis; E: epidermis; SC: stratum corneum). 
All of the four layers described above were visible in the H&E preparations and were distinguishable from 
one another. The enhancer free TNF gel treatment (Fig 7b) is similar to the control image, with no signs of 
morphological changes to the tissue which indicates no adverse effect of TNF gel treatment. The 
micrographs of the enhancer treatments (Fig 7c and 7d) were comparable to that of the control, with cell 
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layers showing normal morphology with no observable cellular distortions. The basal layer is intact; with 
the granular layer appearing darkly stained depicting no decrease in the activity of either the regenerative 
cells or cells in the granular layer as compared to their counterparts in the control image. There was however 
some observable distortions of the SC in both the LLA (Fig 7c) and the LLA1E 4 (Fig 7d) treated images. 
These distortions were of a lesser extent in the LLA treatment as compared to LLA1E 4. These changes 
could be due to the disruption of the highly ordered lipids in the SC by the permeation enhancers. The 
disruptions or fluidization of the SC by these enhancers thereby reduce the barrier property of the SC and 
enhance the permeation of TNF across the skin. These findings also correlate with the results of the 
permeability and TEER studies that displayed an increase in the permeation parameters of TNF (Table 4) 
and decrease in the resistance of the skin (Fig 6) in the presence of these enhancers.  
LM evaluations do not permit ultrastructural analysis of the treated tissue. TEM analyses were thus 
performed to allow for closer evaluations which would give greater insight to the cellular response/reaction 
of the cells that make up the tissue. The assessments of these images can also contribute to the establishment 
of potential routes of transport for the drug and the enhancer across the epidermis of the skin. The 
comparison of the histomorphological components that make up the barriers to the transport of molecules 
across the epidermis between control and the treated samples can aid in establishing the potential routes of 
transport. Similar to the LM investigations, the TEM control sample also displayed normal skin 
morphology. The particular areas of interest in this study were the SC which provides the barrier function 
of the epidermis, as well as the tight junctions/desmosomes which connect adjacent cells to each other 
preventing free movement of molecules between cells 75.  
In the control images the SC appeared to be uniform and intact and depicted a functional barrier system as 
described in the literature (Fig 8a). The control images display typical tight junctions/desmosomes with no 
spaces between them, therefore implying the minimal movement of molecules between these cells via 
intercellular transport (Fig 8b). There were no significant observable changes in the morphology of the 
enhancer free drug formulation when compared to the assessments made on the control images. It should 
be noted that, as described above, since the skin samples used in the study were of thin skin that have 
reduced thickness of the cellular layers, the minute changes needed in the structural morphology to allow 
the movement of small amounts of the drug through the epidermis may not be identified as significantly 
different from that of the control. However, in the LLA and LLA1E 4 treated samples there were structural 
changes observed in the SC layer of the epidermis. The SC appears to be more loosely packed with larger 
spaces and disorganization between the sheets of keratin (Fig 8c and 8e respectively). The effects appear 
to be more prominent in the LLA1E 4 treatment as compared to the LLA treatment, which also correlate 
with the assessments from the LM study for these samples. These morphological changes could have been 
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brought about by the lipophilic enhancers (LLA and LLA1E 4) by disrupting the lipids within the SC, 
thereby causing fluidization of the lipids within this layer. There were also noticeable changes in the size 
of the intercellular spaces between cells in the LLA1E 4 treated sample, which were caused by the 
stretching/expansion of the tight junctions/desmosomes (Fig 8f). These effects were minimal to none in the 
LLA treated group (Fig 8d). The increase in intercellular spaces enables the movement of molecules 
through the paracellular route, which is therefore suggestive that TNF utilizes this route across the 
epidermis. The contributing factors leading to the decrease in the barrier properties of the epidermis 
identified in this study explains the reductions in resistance values observed for the respective treatments 
in the TEER study. Interestingly, there was also some degree of vacuolization observed within the LLA1E 
4 sample (Fig 8f). The appearance of vacuoles in drug treated epidermal tissue has been previously reported 
as being an indication of possible transcellular transport of the drug across the membrane 45, 76. The basal 
cell layer and basement membrane appeared to be unaffected and intact in the treated samples.  
The findings of the TEM study corroborate the findings of the permeability, the TEER as well as the LM 
studies. Histomorphologically the superior ER of the LLA1E 4 sample in this study could be attributed to 
a combination of factors that allowed greater permeability of TNF across the epidermis. The observed 
disruptions of the SC would have decreased the main barrier of the epidermis thereby facilitating easier 
transport of TNF across the epidermis. The formation of larger intercellular spaces caused by the stretching 
of the tight junctions/desmosomes would have aided the movement of the drug through the cellular layers, 
and the formation of vacuoles could be a potential indication that the drug was also being transported via 
the intracellular route as well. The enhancing effect of LLA could be largely credited to its disruption of 
the SC and the consequent decrease in its barrier properties thus allowing the increased permeability of 
TNF.    
Morphological changes observed to the superficial layers caused by the drug treatment should not be 
considered permanent as these layers are being continuously replaced by the cell layers beneath it. Data 
from the TEER study also suggest that the skin would recover its barrier properties upon removal of the 
enhancer (Fig 6). Both LM and TEM evaluations revealed no loss in cellular integrity of the treated samples 
as compared to the control. These studies therefore confirm that the exposure of TNF gel formulations with 
or without the incorporation of either LLA or LLA1E 4 as an enhancer at a concentration of 2% w/w do 
not have any adverse effect on the skin.  
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Fig. 8 Electron micrographs of the control and the treated skin selections for transmission electron 
microscopy (TEM) : a/b control/untreated  (× 8000), c treated with 2% w/w LLA TNF gel (× 8000), d 
treated with 2% w/w LLA TNF gel (× 10000), e  treated with 2% w/w LLA1E 4 TNF gel (× 8000), f treated 
with 2% w/w LLA1E 4 TNF gel (× 12000). (SC: stratum corneum; TJ/DS: tight junctions/desmosomes; N: 
nucleus; BM: basement membrane; V: vacuoles). 
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Experimental section 
Materials 
TNF was purchased from Sinobright Pharmaceutical Co.Ltd (Nanshan, China). Male Wistar rats (200-250 
g) were obtained from the Biomedical Resource Unit (BRU), University of KwaZulu Natal (UKZN). PA,
LA, α-LLA, AA, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDAC.HCl), p-
dimethylaminopyridine (DMAP) and 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) were obtained from Sigma (St. Louis, MO). 3- Amino-1-propanol and tert-butyl acrylate were 
purchased from Alfa-Aesar (Karlsruhe, Germany). Acetyl chloride (AcCl) and dichloromethane (DCM) 
were from Merck Chemicals (Hohenbrunn, Germany). Merck precoated Silica-gel 60F254 plates were used 
for thin layer chromatography and hydroxypropyl methyl cellulose (HPMC) was purchased from Sigma-
Aldrich (Steinheim, Germany).  All other reagents and solvents used were of analytical grade and were 
procured from Merck Chemicals. Milli-Q purified water was obtained from the purification system 
(Millipore Corp., Billerica, MA) in our laboratories. 
Methods 
Synthesis and characterization of dendritic esters of UFAs 
Synthesis of dendritic esters of UFAs as shown in scheme 1. 
To a stirred mixture of dendron 1 (1.2 equiv.), synthesized using a previously reported method  12 and 
DMAP (0.75 equiv.) in DCM was added EDAC.HCl (1.5 equiv.) followed by an UFA (1 equiv.). The 
resulting reaction mixture was magnetically stirred at room temperature for a 48 h period. The organic layer 
was washed with brine solution and concentrated in vacuo. The crude product obtained was purified by 
column chromatography (silica gel # 60-100 mesh, hexane/EtOAc; 9:1).   
Structural characterization and stability of dendritic esters 
FT-IR spectra of all the compounds were recorded on a Bruker Alpha-p spectrometer with diamond ATR 
(Germany). 1H NMR and 13C NMR measurements were performed on a Bruker NMR spectrometer (United 
Kingdom) at 400 and 100 MHz respectively. HRMS was performed on a Waters Micromass LCT Premier 
TOF-MS (United Kingdom). The stability of the synthesized derivatives was confirmed by 13C NMR 
analysis of samples stored at 4 oC in air tight amber coloured bottles.  
Experimental paper 1 Chapter 2 
45 
Calculation of log P values 
The lipophilicity of the parent UFAs as well as their respective dendritic ester derivatives was determined 
by calculating their log P values using an online tool, chemicalize 62. 
Scheme 1. Synthesis of dendritic esters of UFAs. 
Acid-base titration 
As the synthesized dendritic ester derivatives have a tertiary nitrogen in their structure, their ability to 
protonate over a 13 to 2 pH range was determined by acid-base titration 54. A 20 ml solution of each 
dendritic ester in ethanol (10 mg/ml) was adjusted to pH 13 by using aqueous 1 M NaOH. This solution 
was then titrated with aqueous 1 M HCl solution in various volume increments and the pH was recorded at 
each addition point. The graph of volume of HCl added versus pH was generated for all the dendritic lipids. 
All the experiments were performed in triplicate. 
Experimental paper 1 Chapter 2 
46 
In vitro cytotoxicity  
Cell culture 
Human cervix cancer cell line (HeLa) was cultured with complete medium supplemented with 10 % bovine 
calf serum, 100 units/ml of penicillin, and 100 mg/ml of streptomycin. The cells were maintained at 37˚C 
in a humidified atmosphere of 5 % CO2 in air. 
Solutions 
The derivatives (PA1E 2, LA1E 3, LLA1E 4 and AA1E 5) were dissolved in DMSO and distilled water as 
a stock solution, and further diluted in the culture medium to give final concentrations of 20, 40, 60, 80 and 
100 µg/ml 77. 
MTT assay 
The culture medium was removed and replaced with fresh medium (100 µL per well) together with the 
solutions described above to achieve final concentrations in the wells seeded equivalently (2.4 x 103) with 
HeLa cells into a 96-well plate and incubated for 24 h. The control wells were prepared by addition of 
culture medium only whereas wells containing culture medium without cells were used as blanks. After the 
48 h incubation, the culture medium and compounds were removed and replaced with fresh medium (100 
µL) and MTT solution (100 µL of 5 mg/mL in PBS) in each well. The media and MTT solution were 
removed and 100 µL of DMSO was added to each well to solubilize the MTT formazan after 4 h of 
incubation. The optical density of each well was measured on a microplate spectrophotometer (Mindray 
MR-96A) at a wavelength of 540 nm (A540: absorbance at a wavelength of 540 nm ) 77. All the experiments 
were performed with six replicates. The percentage cell viability was calculated as follows: 
% 𝐶𝑒𝑙𝑙 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝐴540 𝑛𝑚 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐴540 𝑛𝑚 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 𝑥100  𝑒𝑞. (1) 
Ethical Clearance 
Ethical clearance was obtained from the University of KwaZulu-Natal Ethics committee in 2014 
(054/14/Animal), and renewed in 2015 (015/15/Animal). 
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Transdermal permeation studies 
Formulation of gels for permeation studies. To determine the transdermal permeability of TNF across skin, 
a gel containing 2% w/w TNF and 4% w/w HPMC were prepared and served as the control. To determine 
the enhancement effect of the UFAs or their respective derivatives, 1% w/w UFA or their respective 
dendritic ester derivatives, 4% w/w HPMC and 2% w/w TNF gels were prepared. For the concentration 
effect experiments, varying concentrations of either LLA or LLA1E 4 were added to the control formulation 
at concentrations of 0.5, 2, 4, 6% w/w 39.  
Preparation of rat skin.  The rats were housed at the BRU (UKZN) in polycarbonate cages in a room with 
controlled temperature and humidity45, 46, and a 12-h light/dark cycle. They were fed a rodent pellet food 
and water ad libitum. The rats were sacrificed by CO2 euthanasia followed by removal of the hair by 
shaving. Full thickness abdominal skin was harvested and then excised using surgical scissors to remove 
any subcutaneous fat. The tissues were stored at -20˚C and used within three months 12. PBS (pH 7.4) was 
used to thaw the skin at room temperature before the start of permeation studies.  
In vitro permeation studies. In vitro permeation studies were conducted at 37 ± 1˚C using modified vertical 
Franz type diffusion cells 5, 66 (PermeGear, Inc., Bethlehem, USA) with a diffusional area of 0.786 cm2. A 
circular section of the skin was mounted onto the diffusional area between the donor and receptor cells, and 
was equilibrated with PBS (pH 7.4) at 37 °C for 30 minutes.  The donor compartment contained either TNF 
loaded gel or TNF loaded gel in the presence of the various FAs or their respective derivatives (PA, PA1E 
2, LA, LA1E 3, LLA, LLA1E 4, AA, AA1E 5) at a concentration of 1% w/w in respective experiments for 
the enhancer screening study. The receptor compartments were filled with PBS and stirred with a teflon-
coated magnetic bar. Samples were removed from the receptor compartments at predetermined time 
intervals and replaced with the same volume of drug–free (fresh) PBS. Each experiment represents a 
minimum of six replicates. The drug was quantified by a validated UV spectrophotometry method at a λmax 
of 262 nm  using UV Spectrophotometer 1650 (Shimadzu, Japan) 45. Once the optimal enhancer (LLA1E 
4) was identified, for the subsequent concentration effect studies TNF gels were prepared using 0.5, 2, 4,
6% w/w of either LLA1E  4 or the parent FA LLA 39. 
Permeability data analysis  
The cumulative amount of drug (TNF) permeated per unit surface area was plotted against time. The steady 
state flux (Jss) was determined from the linear part of the permeability curve by linear regression analysis 
(Microsoft Excel 2010, USA). The permeability coefficient (P) was calculated as follows 39, 45, 46:
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𝑷 =
(
𝑑𝑄
𝑑𝑇
)
𝐴
 𝑥 𝐶𝑑 =
𝐽𝑠𝑠
𝐶𝑑
 𝑒𝑞. (2) 
dQ/dt is the cumulative amount permeated per unit time, A is the diffusion area and Cd is the drug 
concentration in the donor compartment. The enhancement ratio (ER) was calculated using the following 
equation 45, 46: 
𝑬𝑹 =
𝑃 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑝𝑟𝑒𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑟
𝑃 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑎𝑏𝑠𝑒𝑛𝑐𝑒 𝑜𝑓 𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑟
 𝑒𝑞. (3) 
Transepithelial electrical resistance (TEER) studies 
TEER measurements using a Millicell ERS meter (Millipore, USA) connected to a pair of chopstick 
electrodes (STX01) were used to determine the integrity of the skin. TEER measurements were taken across 
the skin prior to, and at the end of the permeation experiment. TEER values at time zero were used as 100%. 
The rebound effect of the skin post drug treatment was measured by removing the drug loaded gel from the 
donor compartment after a period of 6 h and replacing it with fresh PBS for a period of 2 h with subsequent 
TEER measurements 46, 47. 
Light and Transmission Electron Microscopy 
Histological evaluations were performed on freshly harvested excised skin. Untreated skin was transferred 
directly after excision from normal saline into 10 % buffered formalin without any equilibration in PBS 
and served as the control. Treated samples comprised of skin that were exposed to enhancer free drug 
loaded gel, and drug loaded gels containing either LLA or LLA1E 4 at a concentration of 2 % w/w. 
Permeation experiments were carried out with these gels in the donor compartment; and with the freshly 
excised skin placed between donor and receptor compartments as described above, without drug 
quantification 45-47. For light microscopy (LM) evaluations, the skin was removed from the Franz diffusion 
cells at the end of the experiment, cut into cross sections and fixed in 10 % buffered formalin. Both the 
control and treated skin were fixed in formalin for 7 days at room temperature. Skin was dehydrated using 
an ethanol gradient ranging from 50 % up to 96 % and embedded in paraffin wax. The skin sections were 
collected on slides, dried and stained with hematoxylin and eosin (H&E). Sections were examined using a 
light microscope (Nikon 80i, Japan) and bright field images were digitally captured using NIS Elements D 
software and a camera (Nikon U2, Japan). The samples for transmission electron microscopy (TEM) were 
obtained after the above mentioned permeation experiments. The samples were then cut into pieces not 
exceeding 0.5 mm3, and fixed for 24 h (4 °C) using Karnovsky’s fixative 78 buffered to pH 7.2. For TEM, 
each sample was processed and embedded in epoxy resin using standard protocols. Ultrathin sections (90 
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nm) were cut and contrasted with uranyl acetate and lead citrate and viewed with a TEM (JEOL 1010, 
Japan). All experiments were performed using a minimum of three replicates 39, 45-47. 
Statistical Analysis 
The results, expressed as mean ± standard deviation (SD), were analyzed using one-way analysis of 
variance (ANOVA) followed by the non-parametric Kruskal-Wallis test and t tests followed by the non-
parametric Mann-Whitney test were performed using GraphPad Prism® (Graph Pad Software Inc., Version 
5., USA). A p value of less than 0.05 was considered statistically significant. 
Conclusions 
This study reported the effect of novel dendritic ester derivatives of UFAs on the transdermal 
permeability parameters of TNF. TNF gel formulations with 1% w/w of PA, LA, LLA or AA 
showed that only LLA and PA had transdermal enhancing potential. The novel dendritic derivatives 
of the studied UFAs were successfully synthesized. In vitro cytotoxicity studies revealed the safety 
of these derivatives for biological applications. All the newly synthesized dendritic derivatives 
PA1E 2, LA1E 3, LLA1E 4 and AA1E 5 at a concentration of 1% w/w displayed permeation 
enhancement of TNF across the skin. LLA and LLA1E 4 were identified as most effective 
permeation enhancers with ERs of 2.9 and 5.31 respectively. The highest ER by LLA1E 4 was 
attributed to carbon chain length, optimum number of double bonds and the increase in the 
lipophilicity by the addition of the tert-butyl ester function. The concentration dependent study 
revealed that both LLA and LLA1E 4 at 2% w/w displayed the highest ER of 3.85 and 6.11 
respectively. 
The histomorphological studies suggest enhancement of TNF permeability by 2% w/w LLA and 
LLA1E 4 was due the disruption and fluidization of lipids in the SC. The highest permeation 
achieved by LLA1E 4 was strongly supported by the LM and TEM evaluations which display a 
greater disruption and fluidization of the SC and stretching/expansion of the tight 
junctions/desmosomes thereby facilitating better intercellular transport of TNF across the 
epidermis. Vacuole formation was also suggestive of TNF transport using the intracellular pathway. 
LM and TEM evaluations showed no adverse effects on the tissue after exposure to the 2% w/w 
concentration of either LLA or LLA1E 4.  
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This study has therefore identified the transdermal delivery properties of TNF and has confirmed 
the superiority of newly synthesized dendritic ester derivatives over their parent UFAs as 
transdermal permeation enhancers. LLA1E 4 was identified as the superior transdermal permeation 
enhancer and is therefore a promising CPE candidate for the development of transdermal drug 
delivery systems of TNF.    
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Table S1. 13C NMR spectra of dendritic ester derivatives before and after storage. 
Dendritic ester derivative 13C NMR 
Fresh 2 year storage 
PA1E 2 14.09 14.09 
22.64 22.65 
24.98 24.98 
26.68 26.61 
27.16 27.17 
27.21 27.22 
28.09 28.09 
28.98 28.98 
29.11 29.11 
29.16 29.15 
29.18 29.18 
29.69 29.69 
31.77 31.77 
33.80 33.71 
34.35 34.34 
49.40 49.36 
50.14 50.15 
62.44 62.41 
80.31 80.37 
129.76 129.76 
129.98 129.98 
171.98 171.91 
173.86 173.86 
LA1E 3 14.04 14.06 
22.54 22.56 
24.96 24.97 
25.60 25.62 
26.65 26.67 
27.17 27.19 
28.07 28.09 
29.10 29.12 
29.13 29.14 
29.16 29.18 
29.32 29.33 
29.58 29.60 
31.50 31.51 
33.77 33.79 
34.32 34.33 
49.39 49.40 
50.13 50.14 
62.41 62.42 
80.28 80.30 
Continued…… 
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127.89 127.90 
128.01 128.02 
130.01 130.04 
130.17 130.19 
171.91 171.94 
173.79 173.81 
LLA1E 4 14.26 14.26 
20.54 20.54 
24.97 24.97 
25.52 25.52 
25.60 25.61 
26.68 26.63 
27.20 27.20 
28.09 28.09 
29.12 29.12 
29.14 29.14 
29.58 29.18 
33.80 33.74 
34.34 34.33 
49.40 49.38 
50.14 50.15 
62.45 62.41 
80.30 80.33 
127.11 127.11 
127.71 127.71 
128.25 128.24 
128.28 128.27 
130.26 130.26 
131.95 131.94 
171.97 171.91 
173.84 173.81 
AA1E 5 14.10 14.06 
22.56 22.56 
24.83 24.82 
25.61 25.61 
26.59 26.52 
26.91 26.58 
27.21 27.20 
28.09 28.08 
29.69 29.31 
31.51 31.50 
33.72 33.63 
34.66 33.71 
49.39 49.31 
50.14 50.12 
62.53 62.50 
80.30 80.37 
127.54 127.53 
127.86 127.86 
Continued…… 
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128.17 128.16 
128.20 128.20 
128.79 128.56 
128.99 128.80 
130.47 130.47 
171.96 171.88 
173.57 173.58 
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Fig. S1. 13C NMR of PA1E 2 (day 0). 
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Fig. S2. 13C NMR of PA1E 2 (2 years). 
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Fig. S3. 13C NMR of LA1E 3 (day 0). 
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Fig. S4. 13C NMR of LA1E 3 (2 years). 
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Fig. S5. 13C NMR of LLA1E 4 (day 0). 
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Fig. S6. 13C NMR of LLA1E 4 (2 years). 
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Fig. S7. 13C NMR of AA1E 5 (day 0). 
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Fig. S8. 13C NMR of AA1E 5 (2 years). 
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CHAPTER 3 
EXPERIMENTAL PAPER 2 
3.1 Introduction 
This chapter addresses aim 1.4.2 and is a first authored experimental article published in  
an ISI international journal i.e. Drug Delivery and Translational Research (Impact Factor = 
1.887). This article reports the synthesis, characterization and novel TDD application of a 
series of UFA esters of cholesterol using TNF as the model drug. 
Mr. S Rambharose contributed to the design of the project, modification and optimisation of 
methods as well as synthesis and characterisation of UFAs and SFAs esters of cholesterol. Mr. 
S. Rambharose conducted all experimental work including rat skin tissue harvesting, in vitro 
transdermal permeation experiments, TEER experiments and light microscopy evaluations. 
Mr. S. Rambharose also wrote the paper.  Dr. R.S. Kalhapure and Dr. M. Jadhav assisted with 
the overall design of the project and the methods of preparation and characterisation as well as 
editing of the paper. Prof. T. Govender served as supervisor and was responsible for project 
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Abstract 
The intrinsic protective barrier property of skin, one of the major challenges in the design of 
transdermal drug delivery systems, can be overcome through the use of chemical permeation 
enhancers (CPEs).   Herein we explore the potential of unsaturated fatty acid (UFA) esters of 
Cholesterol (Chol) viz., oleate, linoleate and linolenate, as transdermal CPEs using tenofovir 
(TNF) as a model drug.  All Chol UFA esters at 1% w/w were found to be more effective 
enhancers when compared to their respective parent FAs and saturated FA counterparts. 
Cholesteryl linolenate (Chol-LLA) showed the most superior performance (ER = 3.71). The 
greatest ER for Chol-LLA (5.93) was achieved at a concentration of 2% w/w. The 
histomorphological and transepithelial electrical resistance (TEER) evaluations supported the 
results of the permeability studies. These findings showed no significant loss in the integrity of 
the epidermis, with drug and enhancer treatment having temporary effects on the barrier 
property of the epidermis. Chol UFA esters can therefore be considered as new CPEs for 
exploitation in topical formulations for various classes of drugs.   
Keywords: unsaturated fatty acids; cholesterol; esterification; chemical permeation enhancers; 
tenofovir; transdermal.  
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1. Introduction
Transdermal drug delivery (TDD) offers numerous advantages over the oral route by delivering 
the drug directly into systemic circulation. The major advantages are avoiding of first-pass 
metabolism, resulting in higher bioavailability of a drug and decreased GIT associated adverse 
effects [1, 2]. The administration of long acting TDD formulations allows for decreased dosing 
frequency and maintenance of stable plasma levels, which is essential for drugs that have a 
narrow therapeutic index. This lends to the decrease in the dose dependent side effects. 
Furthermore, the application of transdermal dosage forms is convenient and can be easily 
removed if there are any adverse reactions. These advantages should result in an increase in 
patient compliance [3, 2]. TDD therefore offers an attractive alternative for several classes of 
drugs as it avoids several limitations of current oral drug delivery [4, 5]. 
Tenofovir (TNF), an antiviral reverse transcriptase inhibitor, is used to prevent and treat HIV 
and AIDS. The oral administration of TNF has numerous limitations such as poor intestinal 
permeability, which necessitates its current administration as an ester prodrug, tenofovir 
disoproxil fumarate. Due to its low bioavailability, it is administered in high doses which 
results in several GIT associated adverse effects which lead to a decrease in patient compliance 
[6, 7]. Despite the current limitations of its oral delivery, TNF is still the most successful ARV 
drug to HIV infection [8]. With TNF being on the world health organization’s (WHO) list of 
essential medicines [9] and HIV and AIDS continuing as one of the most serious, prevalent 
public health diseases globally [10] there is a justifiable need to explore alternate strategies to 
improve the systemic delivery of TNF. To overcome the limitations of current TNF oral 
administration, the buccal, rectal, vaginal and more recently the transdermal route have been 
explored for the delivery of TNF [11-13]. Our recent report showed that TNF in its basic to 
native form could be delivered in therapeutically relevant quantities via the transdermal route 
using a lower loading dose [12]. This route of administration has potential benefits for both the 
patient and the product manufacturer as there is no need to administer the ester prodrug thereby 
decreasing manufacturing costs and as the drug no longer passes through the GIT there is no 
risk of GIT associated adverse effects [12]. There is therefore a need to identify strategies for 
potentiating the transdermal delivery of TNF. 
Although TDD offers promising benefits, a major drawback is the natural barrier property of 
the skin. One of the skin’s main physiological functions is to regulate what enters and exits the 
body via this route. The skin’s significant barrier property is largely due to the stratum corneum 
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(SC) which makes up the upper most layer of the epidermis. The SC is made up of corneocytes 
that are surrounded by extracellular lipid domains. These structured lipids such as ceramides, 
Chol and free fatty acids of the SC function to prevent excessive water loss from the body and 
prevent the entry of topically applied substances [3, 5, 2, 14] This barrier poses a significant 
challenge to the topical administration of drugs, unless they are lipid soluble and of low 
molecular weight.  
Despite the formidable barrier presented by the skin, drug delivery via the transdermal route is 
a very attractive option and is extensively utilized for both local and systemic therapy [15, 16, 
3]. A temporary reduction in the barrier properties of the skin is desirable in order to increase 
the number of drugs that can be administered via this route [17]. Significant efforts have 
therefore been expended on the development of new approaches to enhance TDD. These 
strategies can be broadly subdivided into chemical, biochemical and physical approaches [3]. 
Chemical permeation enhancers (CPEs) include compounds that interact with the lipid matrix 
of the SC to alter its nanostructure and thereby increasing permeability [18, 19, 17]. Although 
the corneocytes forms a scaffold for the extracellular lipid matrix, the main focus of drug 
delivery strategies has been on the manipulations of the extracellular lipid environment. In 
addition to the ability of lipid-soluble drugs being able to accumulate in the extracellular matrix 
enabling slow release, this region also provides additional opportunities for novel drug delivery 
strategies due to the presence of aqueous pores within the extracellular matrix [3, 2]. Fatty acids 
(FAs) are integral components of skin and have emerged as one of the most attractive CPEs 
employed for TDD. FAs have the ability to reduce the barrier properties of the SC and increase 
its fluidity by extracting extracellular lipids and altering SC lipid organization thereby 
increasing transdermal delivery by expanding intercellular domains [20-22].  
Chol is an amphiphilic biomolecule that contains both a polar hydroxyl group and a non-polar 
tetracylic steroidal ring structure with a branched hydrocarbon tail. Chol has the property of 
orientational ordering and displays liquid crystalline behavior capable of binding with 
amphiphilic lipid membranes [23]. Chol has several effects on membrane properties which 
include membrane fluidity, phase transition and permeation of polar and non-polar molecules 
[24, 25]. Chol is regularly employed to modify the physicochemical properties of lipid bilayers 
and has been widely used to stabilize liposomes for their application in transdermal drug 
delivery [23, 26]. Regulating the Chol content of liposomes has been one of the crucial ways 
to control the permeability to solutes both in vivo and in vitro [23]. Chol has been shown to 
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alter the order and movement of the phospholipids in the bilayer and additional reports specify 
that the amount of Chol is important for the effective delivery of transdermal liposomes [27]. 
A study by Coderch et al reported an increase in the transdermal transport of a liposome 
entrapped substance with the addition of 20% Chol [28]. The conjugation of Chol onto 
molecules has been used for several biomedical applications such as a variety of Chol 
containing polymers for different micelles, nanoparticles, polymersomes, nanotubes, or 
nanogels [23]. Saturated (SFA) and unsaturated (UFA) fatty acids/FA esters have been reported 
as effective permeation enhancers for a variety of drugs [29]. Recent studies show that the 
application of ester derivatives or chemical modifications to the structure of the parent FAs are 
able to produce new chemical entities that display superior permeation enhancement 
capabilities [21, 30, 12, 31, 32].  
Chol SFAs esters ranging from C6 to C18 have been previously studied as transdermal 
permeation enhancers for phenazepam with promising results [33, 34]. However, the Chol UFA 
esters, although commercially available, have not been explored as permeation enhancers for 
any route. Literature reports that UFAs have superior permeation enhancement efficacy when 
compared to their SFA counterparts [35, 36, 22]. Further, UFAs with C18 have been identified 
as the optimal chain length lipids for superior permeation enhancement efficacy [17]. 
Considering the applicability of C18 UFAs as CPEs and the potential shown by the Chol SFA 
esters as transdermal permeation enhancers for phenazepam [33, 34], this study aimed to 
explore the use of Chol C18 UFA esters as transdermal permeation enhancers using TNF as the 
model drug. Chol SFA esters were used in the study for comparison in order to establish 
transdermal permeation enhancement potential of Chol UFA esters.   The intention of this study 
was to identify chemical entities which can act as new efficient CPEs, thus widening the pool 
of available CPEs for transdermal drug delivery.  
Materials and methods 
1.1. Materials 
TNF was procured from Sinobright Pharmaceutical Co. Ltd (China). Oleic Acid, Linoleic Acid, 
Linolenic Acid, Lauric Acid, Palmitic Acid, Stearic Acid, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDAC.HCl), p-dimethylaminopyridine (DMAP) and 
precoated Silica-gel 60F254 plates and hydroxypropyl methyl cellulose (HPMC) was 
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purchased from Sigma-Aldrich Co. Ltd., (USA). 3-(4,5-dimethylthiazole-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and all other reagents and solvents used for synthesis and 
purification were of analytical grade and were purchased from Merck Chemicals (Germany). 
Purified water was acquired from a Milli-Q water purification system (Millipore corp., USA). 
200-250 g Wistar rats (Male) were acquired from the Biomedical Resource Unit (BRU),
University of KwaZulu Natal (UKZN).
1.2. Methods 
1.2.1. General procedure for synthesis of Chol-FA esters (Scheme 1) 
To a stirred mixture of Chol (1 mmol), EDAC.HCl (1.01 mmol) and DMAP (0.5 mmol) in dry 
DCM (20 mL), FA (1.01 mmol) under a nitrogen atmosphere at room temperature (RT) was 
added.  The resulting reaction mixture was further stirred at RT for 12 h, solvent was removed 
in vacuo and the crude residue was purified by column chromatography (silica gel #70-230 and 
2-5% ethyl acetate in hexane as eluent) to obtain the final product (3a-f).
Scheme 1. Synthetic scheme for Chol esters. 
1.2.2. Structural characterization of Chol esters 
FT-IR spectra of all the compounds were recorded on a Bruker Alpha-p spectrometer with 
diamond ATR (Germany). 1H NMR and 13C NMR measurements were performed on a Bruker 
NMR spectrometer (United Kingdom) at 400 and 100 MHz respectively.  
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1.2.3. Calculation of log P values 
In order to determine their lipophilicities, an online tool (chemicalize) was used to calculate 
the log P values of the Chol esters and their respective parent FAs [37]. 
1.2.4. Formulation of transdermal gels for in vitro permeation studies 
The transdermal permeation enhancement efficacy of the FAs (2a-f) or their respective Chol 
esters (3a-f) was evaluated by formulating their gels. The composition of the gel was 1% w/w 
FA or Chol FA derivative, 4% w/w HPMC and 2% w/w TNF.  A gel without enhancer was 
used as the control. To determine the optimal concentration of most promising enhancer gels 
containing 0.5, 2, 4, 6% w/w of either LLA 2a or Chol-LLA 3a were prepared and evaluated. 
[30, 12].  
1.2.5. Transdermal permeation studies 
The animal research ethics committee from the University of KwaZulu-Natal granted ethical 
clearance for this study in 2014 (054/14/Animal), and was subsequently renewed 
(015/15/Animal). The rats used in this study were contained at the BRU (UKZN) under 
controlled light, temperature and humidity conditions. The animals were fed a standard rodent 
diet and received water ad libitum. The animals were euthanized using CO2 once they were at 
the desired weight range and body hair was removed through shaving. Abdominal skin was 
harvested and subcutaneous fat was removed with surgical scissors. The excised skin samples 
were stored at -20 ˚C and utilised within three months [21, 12]. The samples were defrosted in 
PBS (pH 7.4) at room temperature before its use in permeation studies. 
Vertical Franz diffusion cells (PermeGear, Inc., Bethlehem, USA) with a diffusional area of 
0.786 cm2 was used to study the in vitro permeation at 37 ± 1˚C [38, 12]. The donor chamber 
contained either drug loaded gel or drug loaded gel in combination with the parent FAs or their 
respective Chol esters (Chol-OA 3a, Chol-LA 3b, Chol-LLA 3c, Chol-LuA 3d, Chol-PA 3e, 
and Chol-SA 3f) at a concentration of 1% w/w. The receptor compartments contained 25 ml of 
PBS (stirred with a teflon-coated magnetic bar). Skin samples were mounted between the donor 
and receptor chambers, and were equilibrated with PBS (pH 7.4) at 37 °C for 30 minutes. 
During the experiment, the receptor chamber was sampled at pre-set intervals and replenished 
with an equivalent amount of fresh PBS. The experiments were performed with a minimum of 
n = 6. The drug was measured by a UV spectrophotometry method at a λmax of 262 nm using 
UV Spectrophotometer 1650 (Shimadzu, Japan). Once the optimal enhancer (Chol-LLA 3c) 
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was established, the concentration effect studies were conducted on TNF gels that contained 
0.5, 2, 4, 6% w/w of either Chol-LLA 3c or the parent FA LLA 2c [12, 30]. 
The cumulative amount of TNF permeated per unit surface area was plotted against time. 
Linear regression analysis was used to determine the steady state flux (Jss) from the linear part 
of the permeability curve (Microsoft Excel 2010, USA). The permeability coefficient (P) was 
calculated as follows [13, 39, 30]: 
P = (dQ/dT)/A x Cd = Jss/Cd      
dQ/dt is the cumulative amount permeated per unit time, A is the diffusion area and Cd is the 
drug concentration in the donor compartment. The enhancement ratio (ER) was calculated 
using the following equation [13, 39]: 
ER = P of the drug in the presence of enhancer/P of the drug in the absence of enhancer 
1.2.6. Transepithelial electrical resistance (TEER) studies 
The integrity of the treated skin tissue sections (TEER measurements) was determined using a 
Millicell ERS meter (Millipore, USA) connected to a pair of chopstick electrodes (STX01). 
The original integrity of the skin was recorded by obtaining TEER values before the addition 
of the test samples. This represented time zero and served as the control. Further measurements 
were made at the end of the 6h experiment to establish the change in the integrity of the skin 
samples by the drug treatment. Subsequently, the drug treatment was removed from the donor 
chamber and replenished with fresh PBS for a period of 2 h.  The TEER values recorded at this 
point would be indicative of the rebound effect of the skin’s barrier properties 2 h post drug 
treatment [40, 12, 13].  
1.2.7. Histomorphological evaluation 
Morphological assessments were conducted on control and treated skin samples. Freshly 
excised skins sections served as the control skin samples. These samples were fixed in 10% 
buffered formalin directly after skin harvesting and excision. Skin samples that were used 
during the 6h in vitro permeation study for either the enhancer free TNF gel or TNF loaded 
gels containing either 2% w/w LLA 2a or Chol-LLA 3a served as the treated samples. At the 
end of the permeation experiment, the treated skin samples were removed from the Franz 
diffusion cells and fixed in 10% buffered formalin. After 7 days, the skin samples were 
removed from fixative and dehydrated using an ethanol gradient from 50 to 96% followed by 
embedding in paraffin wax. The tissue samples were sectioned using a microtome (Leica 
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RM2235, Leica Biosystems Germany) and skin sections were collected on slides, dried and 
stained with hematoxylin and eosin (H&E). Sections were examined with Leica slide scanner 
(SCN 400, Leica Biosystems Germany). All experiments were performed in triplicate [12, 13, 
30, 40]. 
1.2.8. Statistical Analysis 
The results are expressed as mean ± standard deviation (SD). Data was statistically analysed 
using GraphPad Prism® (Graph Pad Software Inc., Version 5. USA). The data was analysed 
by either one-way analysis of variance (ANOVA) followed by the non-parametric Kruskal-
Wallis test or Dunn’s multiple comparison test or t tests were performed followed by the non-
parametric Mann-Whitney test. A p value of less than 0.05 was considered statistically 
significant. 
2. Results and discussion
2.1. Characterization of Chol esters
FT-IR, 1H NMR and 13C NMR were used to characterize the synthesized Chol esters.
Transformation of acid function of FA into ester was easily monitored using FT-IR by
observing the peak around 1732-1739 cm-1.
Cholesteryl oleate (Chol-OA) 3a 
FT-IR: 2923.16, 2853.06, 1737.03, 1462.24, 1247.49, 1170.49, 1011.14 cm-1.  1H NMR 
(CDCl3) δH (ppm): 0.61 (s; 3H; C13-CH3). 0.80 (dd; 6H; C25-(CH3)2), 0.82 (s; 3H; C18-CH3), 
0.85 (d; 3H; C20-CH3), 0.95 (s; 3H; C10-CH3), 1.19 – 2.23 (m; 56H), 2.26 (t; 2H; -CH2COO-), 
4.54 (m; 1H; -C3-H), 5.26 (m; 2H; -CH=CH-), 5.31 (d; 1H; C6-H). 13C NMR (CDCl3) δC (ppm): 
11.86, 14.12, 18.72, 19.32, 21.04, 22.56, 22.70, 22.82, 23.84, 24.29, 25.06, 27.17 - 29.78, 
31.87, 31.91, 34.72, 35.80, 36.20, 37.01, 38.17, 39.52, 42.32, 50.04, 56.14, 56.70, 73.69, 
122.58, 129.77, 129.99, 139.73, 173.30. 
Cholesteryl linoleate (Chol-LA) 3b 
FT-IR: 2959.46, 2927.02, 2853.94, 1733.55, 1462.73, 1257.87, 1169.83, 1009.12 cm-1.  1H 
NMR (CDCl3) δH (ppm): 0.61 (s; 3H; C13-CH3). 0.79 (dd; 6H; C25-(CH3)2), 0.82 (s; 3H; C18’-
CH3), 0.85 (d; 3H; C20-CH3), 0.95 (s; 3H; C10-CH3), 1.03 – 2.24 (m; 52H), 2.69 (t; 2H; -
CH2COO-), 4.54 (m; 1H; -C3-H), 5.25 (m; 4H; -CH=CH-), 5.32 (d; 1H; C6-H). 13C NMR 
(CDCl3) δC (ppm): 11.86, 14.08, 18.72, 19.32, 21.04, 22.58, 22.70, 22.82, 23.83, 24.29, 25.06, 
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27.20 - 29.70, 31.53, 31.87, 34.72, 35.80, 36.18, 36.60, 37.00, 38.17, 39.52, 42.32, 50.04, 
56.14, 56.70, 73.70, 122.59, 127.92, 128.04, 130.07, 130.22, 139.73, 173.30. 
Cholesteryl linolenate Chol-LLA 3c 
FT-IR: 2927.12, 2853.46, 1733.98, 1462.84, 1247.00, 1171.09, 1083.77 cm-1.  1H NMR 
(CDCl3) δH (ppm): 0.61 (s; 3H; C13-CH3). 0.78 (dd; 6H; C25-(CH3)2), 0.80 (s; 3H; C18’-CH3), 
0.85 (d; 3H; C20-CH3), 0.95 (s; 3H; C10-CH3), 1.03 – 2.25 (m; 48H), 2.69 (t; 2H; -CH2COO-), 
4.54 (m; 1H; -C3-H), 5.27 (m; 6H; -CH=CH-), 5.30 (d; 1H; C6-H). 13C NMR (CDCl3) δC (ppm): 
11.86, 14.12, 18.72, 19.32, 21.04, 22.56, 22.70, 22.82, 23.83, 24.29, 25.06, 27.20 - 29.70, 
31.87, 31.91, 34.71, 35.80, 36.19, 36.60, 37.00, 38.17, 39.74, 42.32, 50.04, 56.14, 56.70, 73.70, 
122.59, 127.12, 127.72, 128.26, 128.28, 130.28, 131.96, 139.72, 173.29. 
Cholesteryl laurate (Chol-LuA) 3d 
FT-IR: 2923.09, 2852.13, 1732.03, 1463.03, 1165.93 cm-1.  1H NMR (CDCl3) δH (ppm): 0.61 
(s; 3H; C13-CH3). 0.78 (dd; 6H; C25-(CH3)2), 0.81 (s; 3H; C12’-CH3), 0.85 (d; 3H; C20-CH3), 
0.95 (s; 3H; C10-CH3), 1.05 – 2.20 (m; 48H), 2.25 (t; 2H; -CH2COO-), 4.53 (m; 1H; -C3-H), 
5.31 (d; 1H; C6-H). 13C NMR (CDCl3) δC (ppm): 11.86, 14.17, 18.72, 19.32, 22.56, 23.84, 
24.29, 27.82 - 29.60, 31.87, 34.73, 35.80, 36.60, 37.01, 38.17, 39.74, 42.32, 50.04, 56.70, 
73.67, 122.57, 139.73, 173.32. 
Cholesteryl palmitate (Chol-PA) 3e 
FT-IR: 2914.33, 2848.65, 1738.64, 1463.66, 1172.02 cm-1.  1H NMR (CDCl3) δH (ppm): 0.61 
(s; 3H; C13-CH3). 0.79 (dd; 6H; C25-(CH3)2), 0.81 (s; 3H; C16’-CH3), 0.85 (d; 3H; C20-CH3), 
0.95 (s; 3H; C10-CH3), 1.03 – 2.22 (m; 56H), 2.25 (t; 2H; -CH2COO-), 4.53 (m; 1H; -C3-H), 
5.30 (d; 1H; C6-H). 13C NMR (CDCl3) δC (ppm): 11.57, 14.12, 18.72, 19.32, 22.57, 23.84, 
24.29, 27.82 - 29.70, 31.87, 31.94, 34.73, 35.80, 36.60, 37.01, 38.17, 39.52, 42.32, 50.04, 
56.14, 56.70, 73.67, 122.58, 139.73, 173.32. 
Cholesteryl stearate (Chol-SA) 3f 
FT-IR: 2914.43, 2848.73, 1739.09, 1463.91, 1172.36 cm-1.  1H NMR (CDCl3) δH (ppm): 0.61 
(s; 3H; C13-CH3). 0.79 (dd; 6H; C25-(CH3)2), 0.81 (s; 3H; C18’-CH3), 0.85 (d; 3H; C20-CH3), 
0.95 (s; 3H; C10-CH3), 1.03 – 2.17 (m; 60H), 2.20 (t; 2H; -CH2COO-), 4.54 (m; 1H; -C3-H), 
5.31 (d; 1H; C6-H). 13C NMR (CDCl3) δC (ppm): 11.86, 14.12, 18.72, 19.33, 22.70, 22.82, 
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23.83, 24.29, 27.82 - 29.71, 31.87, 31.94, 34.73, 35.80, 36.60, 37.01, 38.17, 39.52, 42.32, 
50.04, 56.14, 56.70, 73.67, 122.58, 139.73, 173.33. 
2.2. Transdermal permeation studies 
The six h in vitro transdermal permeation experiments showed that the cumulative amount of 
TNF that penetrated through the skin was 253.1 ± 23.84 µg/cm2 (Table 1, Fig. 1). The steady 
state flux was 40.91 ± 4.93 µg/cm2 h (Table 1). These findings correlate well with our previous 
report for the transdermal permeability of TNF [12]. The study provided evidence suggesting 
that TNF permeates the skin via both the intercellular or the paracellular route, or both routes 
simultaneously, to reach the blood vessels located in the dermis [12]. The transdermal 
permeability potential displayed by TNF therefore provides an attractive alternate drug delivery 
route for this drug, as compared to conventional delivery routes. 
Table 1. Effect of the various Chol ester derivatives on the transdermal permeability properties 
of TNF. *Indicates significant difference i.e. p < 0.05 (all values compared to control). 
Treatment Amount permeated 
(µg.cm -2) 
Jss (flux)  
(µg.cm -2.h-1) 
Permeability (Px10-2) ER 
TNF (Control) 253.10 ± 23.84 40.91 ± 4.93 0.204 ± 0.02 1 
Chol 270.40 ± 18.92 45.44 ± 3.13 0.227 ± 0.01 1.11 
Chol-OA 3a 389.75 ± 47.66 62.19 ± 7.87 0.310 ± 0.03 1.52 
Chol-LA 3b* 424.42 ± 24.42 69.23 ± 3.01 0.346 ± 0.01 1.69 
Chol-LLA 3c* 909.57 ± 63.51 152.1 ± 13.11 0.760 ± 0.06 3.71 
Chol-LuA 3d 298.01 ± 21.63 50.01 ± 3.65 0.250 ± 0.01 1.22 
Chol-PA 3e 347.99 ± 15.78 57.54 ± 2.98 0.287 ± 0.01 1.4 
Chol-SA 3f 363.53 ± 19.02 60.18 ± 3.60 0.300 ± 0.01 1.47 
Only a few drugs have sufficient unaided transdermal permeability which enables 
therapeutically relevant amounts of the drug reaching systemic circulation. One of the 
approaches to aid the transport of drugs across the SC would be the addition of a substance that 
is able to temporarily decrease the skin barrier properties thereby delivering necessary 
quantities of the drug across the skin [17]. The addition of 1% w/w Chol to the gel displayed a 
slight enhancement in TNF permeability; however, the increases were not statistically 
significant (p > 0.05). The cumulative amount and steady state flux increased from 253.1 ± 
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23.84 to 270.40 ± 18.92 µg/cm2 and 40.91 ± 4.93 to 45.44 ± 3.13 µg/cm2 h respectively. This 
signified a 1.11-fold increase in the ER of TNF (Table 1, Fig. 1).  Thus we further explored the 
potential of synthesized Chol esters (Chol-OA 3a, Chol-LA 3b, Chol-LLA 3c, Chol-LuA 3d, 
Chol-PA 3e and Chol-SA 3f) as transdermal permeation enhancers for TNF (Table 2). 
Table 2. Molecular formula, number of unsaturation’s and molecular weight of the Chol-FAs 
studied. 
FA-Derivative Molecular 
formula 
Molecular weight (g mol-
1) 
No. of 
unsaturations 
CHOL-OA 3a C45H78O2 651.12 01 
CHOL-LA 3b C45H76O2 649.10 02 
CHOL-LLA 
3c 
C45H74O2 647.09 03 
CHOL-LuA 
3d 
C39H68O2 568.97 00 
CHOL-PA 3e C43H76O2 625.08 00 
CHOL-SA 3f C45H80O2 653.13 00 
Fig. 1 The effect of synthesized Chol esters on the cumulative amount of TNF permeated across 
the skin. Results are presented as mean ± SD. (n = 6). 
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2.2.1. Effects of Chol esters on TNF permeability 
This investigation evaluated the permeation enhancement efficiency of the synthesized Chol 
FA esters. The lipophilicity of all the synthesized Chol esters was greater than their respective 
parent FA as shown by the log P values represented in Table 3. This is a favourable attribute 
as enhancers with higher lipophilicities are able to cause greater disruption of the organised 
lipids in the SC. This allows larger quantities of drug to permeate as there is a greater reduction 
in the barrier properties [21, 41, 42]. The permeation results confirmed that all of the Chol 
esters were able to enhance the permeation of TNF to a greater extent than Chol at similar 
concentrations (Table 1, Fig. 1). However, the Chol esters containing unsaturated aliphatic 
chain (Chol-OA 3a, Chol-LA 3b and Chol-LLA 3c) were able to achieve a higher permeation 
enhancement effect as compared to those containing saturated aliphatic chain (Chol-LuA 3d, 
Chol-PA 3e and Chol-SA 3f). This is in good agreement with literature which reports that 
UFAs have better permeation enhancement potentials than saturated fatty acids SFAs [35, 36, 
22]. Although all of the Chol esters with saturated aliphatic chain enhanced the transdermal 
permeation of TNF, there were no statistically significantly increases (p > 0.05) in the 
permeation of TNF across the skin from these esters (Table 1). Chol-PA 3e increased the 
cumulative amount permeated and steady state flux from 253.1 ± 23.84 and 40.91 ± 4.93 to 
347.99 ± 15.78 µg/cm2 h and 57.54 ± 2.98 µg/cm2 respectively, with an ER of 1.4 (Table 1, 
Fig. 1). Chol-SA 3f displayed the greatest enhancement potential with an ER of 1.47 displaying 
a cumulative amount permeated of 363.53 ± 19.02 µg/cm2 h and a steady state flux of 60.18 ± 
3.60 µg/cm2 (Table 1, Fig. 1). Chol-LuA 3d achieved an ER of 1.22 and marginally increased 
the cumulative amount permeated to 298.01 ± 21.63 µg/cm2 h and the steady state flux to 50.01 
± 3.65 µg/cm2 (Table 1, Fig. 1). Increase in carbon chain length from 12 to 18 resulted in 
increases in transdermal permeation of TNF. The order of enhancement was Chol-SA 3f > 
Chol-PA 3e > Chol-LuA 3d. In contrast to the SFAs, the UFA esters displayed greater ER and 
permeability parameters. When compared to the control, Chol-OA 3a increased the steady state 
flux and cumulative amount from 253.1 ± 23.84 and 40.91 ± 4.93 to 389.75 ± 47.66 µg/cm2 
and 62.19 ± 7.87 µg/cm2 h respectively with an ER of 1.52 (Table 1, Fig. 1). However, the 
increases displayed by Chol-OA 3a were not statistically significant when compared to the 
control (p > 0.05) (Table 1). Chol-LA 3b increased the steady state flux and cumulative amount 
permeated to 69.23 ± 3.01 µg/cm2 h and 424.42 ± 24.42 µg/cm2 respectively and displayed an 
ER of 1.69 (Table 1, Fig. 1). The increase in permeability due to Chol-LA 3b was statistically 
significant when compared to the control (p < 0.05) (Table 1).  Amongst all the synthesized 
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Chol FA esters, Chol-LLA 3c exhibited the highest increases in the permeability parameters of 
TNF. Chol-LLA 3c significantly increased both the steady state flux and cumulative amount 
to 152.1 ± 13.11 µg/cm2 h and 909.57 ± 63.51 µg/cm2 respectively (p < 0.05), and displayed 
an ER of 3.71 (Table 1, Fig. 1). The Chol-LLA 3c derivative displayed an ER of 1.51-fold 
higher than LLA 2c.  
Table 3. Log P values of FAs and their respective synthesized Chol derivatives. 
FA/Derivative Log P 
Chol 7.11 
OA 2a 6.78 
Chol-OA 3a 14.56 
LA 2b 6.42 
Chol-LA 3b 14.20 
LLA 2c 6.06 
Chol-LLA 3c 13.84 
LuA 2d 4.48 
Chol-LuA 3d 12.26 
PA 2e 6.26 
Chol-PA 3e 14.03 
SA 2f 7.15 
Chol-SA 3f 14.92 
It should be noted that the ER range acquired by all the Chol esters in our study (1.22 to 3.71) 
was greater than the ER (1.15 to 2.81) of previously reported FA esters of isopulegol (ISO) as 
transdermal permeation enhancers for the delivery of flurbiprofen (FP) and amlodipine (AM) 
[43]. That reported study revealed that the chemical linkage of the FAs with ISO was critical 
for the enhancement and the ester derivatives displayed superior enhancement of FP and AM. 
The study by these researches suggested that the different effects of the FAs and their esters 
derivatives would be due to their respective effect on the different lipid domains. They 
indicated that the FAs could possibly exist in the ordered lipid domain, whereas the esters 
derivatives could partition into the less ordered lipid domain to produce the permeation effect 
[43]. In another study, FA esters of propylene glycol (PG) were explored as transdermal 
permeation enhancers for the delivery of lidocaine [44].  The results showed that only SA and 
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LA PG derivatives were able to enhance the transdermal permeation of lidocaine across the 
skin as compared to their parent lipid, whilst the OA and LLA PG derivatives displayed a lower 
ER than their respective parent lipid. The addition of the enhancers at a concentration of 1% 
w/w showed an ER of 0.93, 1.91, 1.68 and 1.70 fold for the SA, OA, LA and LLA PG ester 
derivatives. In our case, with the exception of Chol-OA 3a the other respective Chol esters 
(Chol-SA 3f, Chol-LA 3b and Chol-LLA 3c) were able to achieve superior permeation 
enhancement than the PG ester derivatives counterparts [44]. 
To assess whether the superior enhancement effect observed with the Chol esters were due to 
the structural modifications of Chol with FAs, we evaluated the parent FAs (OA 2a, LA 2b, 
LLA 2c, LuA 2d, PA 2e and SA 2f) as transdermal permeation enhancers of TNF. The results 
indicated that the enhancement by these acids was statistically significantly lower than their 
Chol esters (p < 0.05) 
 All of the FAs studied at a concentration of 1% w/w; enhanced the permeability of TNF across 
the skin (Table S1 of Supporting Information). The UFAs displayed better permeation 
enhancement than SFAs. Similarly, those Chol esters containing unsaturation in their aliphatic 
chain were better than those having saturation. Of all the FA studied LLA 2c displayed the 
highest ER (2.2) for TNF (Table S1 of Supporting Information). The increases in the 
permeability parameters due to LLA 2c were statistically significant (p < 0.05) (Table S1 of 
Supporting Information).  The ER displayed by LLA 2c in this study is comparable to other 
reports that used rat skin to evaluate various other CPEs for transdermal delivery. In a similar 
study, the enhancing effect of UFAs (OA, LA and LLA) on flurbiprofen permeation from 
CMCNa hydrogels was determined. The results displayed that LLA showed greater permeation 
than OA and LA. At an enhancer concentration of 5%, the permeation studies through rat skin 
reported an ER of 1.55, 1.66 and 1.83 for OA, LA and LLA respectively [45]. Significantly, in 
our study LLA 2c was able to surpass this ER at much lower concentration. In another report, 
the CPE myrcene was used as transdermal permeation enhancer for the delivery of piroxicam 
[46]. The study revealed that the addition of myrcene as a transdermal permeation enhancer at 
a concentration of 5, 10 and 15% (w/v) displayed an ER of 2.28, 2.36 and 2.45 respectively 
[46]. LLA 2c was able to achieve the similar ER as Myrcene but at a significantly lower 
concentration (Table S1 of Supporting Information).  
Superior transdermal penetration enhancement using UFAs has been linked to carbon chain 
length and the degree of unsaturation of the UFA [47, 48, 16, 49, 17]. Extensive experimental 
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reports in the literature agree that a carbon length of C18 is ideal for a UFA permeation enhancer 
[17]. The UFAs studied in this report have 18 carbons in their structures but their degree of 
unsaturation is different. Additionally, UFAs are able to increase the fluidity of the skin as their 
bent cis-configuration interrupts the intercellular lipid assembly. This creates mobile free 
volumes which allow molecules to enter at the kinks of the double bonds and migrate across 
the skin more readily. The number of kinks formed is directly proportional to the number of 
double bonds in the UFA. Therefore, as the number of double bonds increase in a UFA, the 
permeation enhancement effect is also expected to increase [47-49, 17]. Although OA 2a, LA 
2b and LLA 2c have the same carbon chain length of C18, LLA 2c possesses one more double 
bond than LA 2b and two more than OA 2a (Table 2). LLA 2c therefore retains a combination 
of the most desirable characteristics of a UFA permeation enhancer and displayed greatest ER 
for TNF.    
The efficacy of an enhancer is influenced by its physicochemical characteristics. This study 
shows that condensation of Chol with FAs to form Chol esters amplifies the enhancement 
potential of the parent FAs. The increase in the lipophilicity of the esters due to the presence 
of Chol moiety (Table 3) could have resulted in the increase in transdermal permeation of TNF 
[41, 21, 30, 12, 42]. This interaction could justify the increase in permeation activity observed 
for all the Chol esters. Interestingly Chol UFAs esters displayed a greater degree of permeation 
enhancement when compared to their SFAs counterparts. (Table 1, Fig. 1). For the Chol UFA 
esters, the increase in lipophilicity (Table 3) has improved the inherent superior transdermal 
permeation enhancement capabilities shown by their respective UFAs.  The findings of this 
study show that Chol-LLA 3c possesses all the ideal features of an effective UFA permeation 
enhancer, such as lipophilicity, optimal FA chain length (C18) and number of unsaturations (3). 
Consequently, additional concentration effects on transdermal permeation enhancement 
efficacy were performed on Chol-LLA 3c using LLA 2c as a control and are reported here 
under. 
2.2.2. Concentration effect of Chol-LLA 3c 
The concentration effect of Chol-LLA 3c on the transdermal permeability parameters of TNF 
were explored (Table 4, Fig. 2) to establish the optimal concentrations of Chol-LLA 3c to be 
potentially employed as a CPE into a future TDD system for TNF. The findings displayed that 
Chol-LLA 3c was able to significantly (p < 0.05) enhance the permeability of TNF as compared 
to the control, at all of the concentrations studied (0.5, 1, 2, 4, 6 % w/w) (Table 4, Fig. 2). Chol-
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LLA 3c also exhibited statistically significant (p < 0.05) increases in the enhancement of TNF 
permeation at similar concentrations to its parent material LLA 2c (Table 4, Fig. 2). Both LLA 
2c and Chol-LLA 3c displayed a similar concentration dependant permeation enhancement 
profile (Fig. 2). The greatest ER was obtained at 2% w/w, with a subsequent decrease in ER 
with further increases in enhancer concentration (Fig. 2). 
Table 4. Effect of the various concentrations of LLA 2c and Chol-LLA 3c on the transdermal 
permeability properties of TNF. *Indicates significant difference i.e. p < 0.05 (all values 
compared to control), #Indicates significant difference when compared to LLA 2c at similar 
concentration. 
Amount permeated 
(µg.cm -2) 
Jss (flux)  (µg.cm -2.h-1) ER 
Control 253.10 ± 23.84 40.91 ± 4.93 1 
Concentrations [% 
w/w] 
LLA 2c Chol-LLA 
3c 
LLA 2c Chol-LLA 
3c 
LLA 
2c 
Chol-
LLA 3c 
0.5 395.08 ± 
20.26 
485.17 ± 
42.15 
66.31 ± 
3.24* 
82.30 ± 
7.72*# 
1.62 2.01 
1 531.96 ± 
51.84 
909.57 ± 
63.51 
90.15 ± 
9.39* 
152.1 ± 
13.11*# 
2.20 3.71 
2 656.04 ± 
72.18 
1479.53 ± 
79.10 
110.52 ± 
12.49* 
242.64 ± 
13.47*# 
2.70 5.93 
4 598.84 ± 
53.64 
809.57 ± 
49.30 
100.76 ± 
9.63* 
134.47 ± 
7.89*# 
2.46 3.28 
6 484.55 ± 
40.63 
513.12 ± 
49.96 
82.19 ± 
6.54* 
84.80 ± 
8.22*# 
2.00 2.07 
Chol-LLA 3c at the optimal concentration of 2% w/w increased the steady state flux of the 
control to 242.64 ± 13.47 µg/cm2 h and the cumulative amount to 1479.53 ± 79.10 µg/cm2 with 
an ER of 5.93 compared to the control (Table 4, Fig. 2), interestingly this signified a 2.2-fold 
increase in the permeability of TNF as compared to the parent FA at the same concentration.  
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Fig. 2 Concentration effects of LLA 2c and Chol-LLA 3c on the flux of TNF (n = 6). 
The IC50 range for TNF is between 0.55 – 2.2 µM [50], at approximately 158 – 632 µg 
respectively [12]. This study shows that the Chol esters able to deliver therapeutically relevant 
doses of TNF via the transdermal route as the cumulative amount of TNF permeated per cm2 
in this report is between 485.17 – 1479.53 µg. 
The enhancer concentration verses ER trend observed in this study is similar to other reports, 
where an initial increase in ER was reported for lower enhancer concentrations, reaching a 
maximum as the concentration is increased and then a subsequent decrease in ER at higher 
enhancer concentrations [51-53, 30, 12]. In an independent report, the concentration effect (0.5, 
1, 2.5 and 5% w/w) of tween 80 on the enhancement of lorazepam through rat skin was 
investigated. The study revealed that there was an initial increase at the lower concentration, 
reaching a maximum ER (3.75) at 1% w/w and further increase in tween 80 concentration 
resulted in a decrease in the ER [53]. In the present report, Chol-LLA 3c was able to achieve a 
comparable ER (3.71) at the same concentration (1% w/w), however a further increase in Chol-
LLA 3c concentration elicited a higher ER (value) than tween 80 (Table 4, Fig. 2).  A study by 
H. Chaudary et al. explored the effects of varying concentrations (5, 10, 12.5 and 15% w/v) of
3-Carene as a transdermal permeation enhancer for the delivery of piroxicam across rat skin
[46]. The results displayed that there was an initial increase in the permeation of piroxicam up
until 12.5%, however increasing the concentration to 15% decreased the permeability [46].
The ER achieved in that study ranged from 2.85 at 5% to a maximum of 4.55 at 12.5%.
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Interestingly, Chol-LLA 3c displays similar or higher ER at significantly lower concentrations 
to other reported promising transdermal permeation enhancers. 
The initial increase in ER observed in this study from 0.5% to 2% w/w could be due to the 
increase in the lipophilicity of the formulation due to the increase in the concentration of the 
lipophilic enhancer. This would enable a greater disruption of the lipids in the SC, thereby 
facilitating higher quantities of the drug to cross the skin. The progressive decline in the ER at 
concentrations greater that 2% w/w could be attributed to the increased viscosity at the 
epidermal surface as the concentration of the enhancer was increased in the gel formulations 
[12, 30]. This, in combination with a decrease in the partitioning of the drug from the gel 
formulation as the FA concentration is increased, could have resulted in the decreased 
movement of TNF across the skin [12, 30, 52].  
2.3. TEER studies 
TEER evaluations are critical parameters used in assessing the integrity status of cellular 
barriers. TEER measurements can be used to quantitatively determine the integrity of the 
barrier properties of the skin. TEER measurements across biological barriers of the skin 
recorded prior to their utilisation for the transport of molecules can be indicative of its original 
integrity [12, 38, 54]. A decrease in the TEER would suggest an increase in the transport 
pathways across the skin, thereby causing a resultant decline in the barrier function. The change 
in resistance values pre and post experiments allows for quantifiable determination of the 
changes in the barrier properties brought on by the drug/enhancer treatment [12, 38, 54].  
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Fig. 3 % Change in TEER values after TNF permeation with either LLA 2c or Chol-LLA 3c 
at a concentration of 2% w/w (n = 6). 
In order to establish if the optimal permeation enhancers did not irreversibly affect the barrier 
property/ integrity of the skin, TEER measurements were recorded on skin samples that were 
treated with TNF gel formulations containing either Chol-LLA 3c or its parent material LLA 
2c at 2% w/w. The findings showed that both LLA 2c and Chol-LLA 3c at 2% w/w were able 
to decrease the TEER after the 6 h in vitro permeation study as compared to the control (TEER 
at 0 h) (Fig. 3). After 6h the LLA 2c treatment reduced the skin’s resistance from 480 ± 34 to 
460 ± 17 Ω /cm2, which symbolises a 4.2% decline in the resistance of the barrier. The Chol-
LLA 3c treatment was able to decrease the TEER of from 479 ± 42 to 429 ± 26 Ω /cm2, which 
signifies a 10.4% decline in the barrier of the skin after 6 h (Fig. 3). This indicates that Chol-
LLA 3c reduces the TEER values 2.47-fold more than LLA 2c. These findings support the data 
from the permeability studies which displayed that Chol-LLA 3c had a 2.2-fold greater 
permeability enhancement than LLA 2c at 2% w/w (Table 4).  
Ideally the barrier properties of the skin should be restored upon removal of the permeation 
enhancer i.e. the disruption or fluidisation of the SC should be reversible [18, 20, 19, 17]. In 
order to establish if the skin regained its barrier properties, TEER measurements were recorded 
2 h post removal of the gel formulations. The measurements revealed that there was a 1.11 % 
increase in TEER 2 h post experiment for the LLA 2c treated samples (Fig 4). This shows 26.22 
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% retrieval of the original barrier function. In the Chol-LLA 3c study, there was a 2.99% 
increase in the TEER 2 h post experiment (Fig. 3). This shows that the skin regained 28.66 % 
of its barrier function. These findings suggest that after the removal of the drug treatment, there 
is a rebound of the skin’s barrier property/integrity. These findings therefore indicate that the 
barrier properties/skin integrity was only temporarily affected by the drug formulations [40, 
12]. The results also showed that Chol-LLA 3c did not cause any permanent changes in the 
epidermal layer.  
2.4. Histomorphological analysis 
The skin samples treated with the drug and enhancer formulation were assessed 
histomorphologically to establish whether there were any adverse effects after treatment for 6 
h. The light microscopy (LM) analysis was performed on the skin samples exposed to enhancer
free TNF gel, and on TNF gel containing either LLA 2c or Chol-LLA 3c respectively at a
concentration of 2% w/w. From the morphological changes in the SC and the epidermis it may
be possible to make inferences on the mode of action of the enhancers [55-58]. In order to
deliver drugs into the systemic circulation located in the dermis, topically applied permeants
need to cross the epidermal layer of the skin. The SC is the primary obstacle to the movement
of drugs across the epidermis. The SC is flattened and primarily contains fibrous protein and
lipids, with the intracellular keratin having an ordered pattern [59, 60]. Skin from the abdominal
region of rats is frequently used for transdermal permeation [21, 61-63]. Skin is comprised of
four layers with the stratum corneum (SC) as the most superficial layer followed by the stratum
granulosum (SG), the stratum spinosum (SS) and terminates at the stratum basale (SB) which
interfaces with the dermis (D). The control image (Fig 4a) closely resembles this description
indicating that the tissue used in the study was healthy, normal skin.
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Fig. 4 Photomicrographs of the control and the treated skin selections for LM stained with 
H&E; (A) control/untreated, (B) treated with TNF gel, (C) treated with 2% w/w LLA 2c TNF 
gel, (D) treated with 2% w/w Chol-LLA 3c TNF gel. (D: dermis; E: epidermis; SC: stratum 
corneum). 
The epidermal layers were clearly visible and distinguishable in the H&E images. The TNF 
gel treatment (Fig 4b) is morphologically similar to the control (Fig 4a), without any visible 
indication of adverse effects by the enhancer free TNF gel treatment. The LLA 2c and Chol-
LLA 3c enhancer treatments (Fig 4c and 4d) displayed comparable morphology to the control 
image with regards to the underlying cell layers. The SG, SS and SB layers displayed normal 
morphology with no observable cellular distortions. There were no observable changes in the 
SB layer which suggests that the formulations did not induce any permanent changes. The SB 
layer is the regenerative layer made up of keratinocytes that divide to form the cells of the SS 
which migrate superficially [60]. The SG appeared darkly stained which suggest that there is 
no change in the functionality of these cells in comparison to the control. However, there was 
clearly noticeable distortions/disruption of the SC in both the LLA 2c (Fig 4c) and the Chol-
LLA 3c (Fig 4d) treated images. The Chol-LLA 3c samples displayed a greater degree of SC 
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disruption as compared to LLA 2c (Fig 4c and 4d). These changes are indicative of the 
disruption of the lipids in the SC by LLA 2c or Chol-LLA 3c respectively. These disruptions 
cause fluidization of the SC, thus decreasing the natural barrier property of the SC and 
increasing the transport of TNF across the skin. Interestingly, the histomorphological 
observations directly correlate with the data from the in vitro permeation and TEER 
evaluations, which showed a significant increase in the permeation TNF (Table 4) and a 
decrease in the TEER of the skin (Fig. 3) in the presence of these enhancers. 
3. Conclusions
In the present paper we have successfully demonstrated the potential of UFA esters of Chol as
promising transdermal permeation enhancers for the delivery of small drug molecules using
TNF as a model. Chol-LLA 3c was identified as the best transdermal permeation enhancer with
an ER of 3.71 at 1% w/w concentration. Attributes such as increased lipophilicity, optimal
carbon chain length and the optimum number of double bonds favor Chol-LLA 3c as the
superior permeation enhancer. Additionally, the concentration dependent study showed that
Chol-LLA 3c at 2% w/w displayed the highest ER of 5.93. The permeation enhancement
effects of the Chol esters of UFAs were superior to their respective parent UFAs and Chol
esters of SFAs.  The histomorphological studies revealed that the disruption and fluidization
of lipids in the SC was responsible for the permeability enhancement of TNF by Chol-LLA 3c
(2% w/w). The LM assessments revealed that the 2% w/w treatment of Chol-LLA 3c displayed
no adverse effects on the skin’s integrity.
This study has therefore identified Chol-UFA esters as transdermal permeation enhancers for 
active pharmaceutical ingredients using TNF as a model drug. In future these Chol-UFA esters 
can be evaluated as dual functional materials, as CPEs and providers of membrane integrity, in 
transdermal liposomal formulations.     
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Table S1. Effect of the various FAs on the transdermal permeability properties of TNF. 
*Indicates significant difference i.e. p < 0.05 (all values compared to control).
Treatment Amount permeated 
(µg.cm -2) 
Jss (flux)  
(µg.cm -2.h-1) 
Permeability (Px10-2) ER 
TNF (Control) 253.10 ± 23.84 40.91 ± 4.93 0.204 ± 0.02 1 
Chol 270.40 ± 18.92 45.44 ± 3.13 0.227 ± 0.01 1.11 
OA 2a 318.06 ± 37.57 52.25 ± 5.85 0.261 ± 0.02 1.27 
LA 2b 256.69 ± 28.77 41.73 ± 4.07 0.208 ± 0.02 1.02 
LLA 2c* 531.96 ± 51.84 90.15 ± 9.39 0.450 ± 0.04 2.2 
LuA 2d 265.63 ± 29.29 43.81 ± 4.58 0.219 ± 0.02 1.07 
PA 2e 297.88 ± 14.94 48.65 ± 1.65 0.243 ± 0.008 1.19 
SA 2f 296.59 ± 12.31 47.37 ± 2.35 0.236 ± 0.011 1.16 
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CHAPTER 4 
EXPERIMENTAL PAPER 3 
4.1 Introduction 
This chapter addresses aim 1.4.3 and is a first authored experimental article manuscript 
submitted to the European Journal of Pharmaceutical Sciences (Impact Factor = 3.773) which 
is an ISI international journal, manuscript number: EJPS-D-16-01525. This manuscript 
reports the synthesis, characterization, biosafety and in vitro permeation enhancement effect 
of a novel series of mono, di and tri- ester derivatives of FAs bearing β-alanine t-butyl ester 
head group for the transdermal delivery of TNF. 
Mr. S. Rambharose contributed to the design of the project, modification and optimisation of 
methods as well as synthesis and characterisation of all the novel mono, di and tri-ester 
derivatives of FAs. Mr. S. Rambharose conducted all experimental work including in vitro 
cytotoxicity, rat skin tissue harvesting, in vitro transdermal permeation experiments, TEER 
experiments and light microscopy evaluations. Mr. S. Rambharose also wrote the paper.  Dr. 
R.S. Kalhapure and Dr. M. Jadhav assisted with the overall design of the project and the 
methods of preparation and characterisation as well as editing of the paper. Prof. T. Govender 
served as supervisor and was responsible for project conceptualisation, editing of paper and 
abstract and general supervision of the study.    
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4.2 Graphical abstract 
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*Corresponding author at:
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Abstract 
The use of chemical permeation enhancers (CPEs) has widened the pool of drugs that can be 
delivered via the transdermal route. This study explored the synthesis and characterization of 
novel mono, di and tri-fatty acid (FA) esters bearing β-alanine t-butyl ester head group as 
transdermal permeation enhancers using tenofovir (TNF) as a model drug. The synthesized 
compounds were non-toxic to mammalian cells confirming their safety for pharmaceutical 
applications. All the synthesized derivatives displayed better transdermal permeation 
enhancement capabilities as compared to their respective individual FAs. The results showed 
that there was no correlation between number of aliphatic carbon chains and enhancement ratio 
(ER). The mono oleate derivative (MOAPE) displayed the greatest ER for TNF (5.87) at 1% 
w/w. Histological investigations of the rat skin treated with MOAPE revealed fluidization of 
the stratum corneum. Histological and transepithelial electrical resistance (TEER) studies 
corroborated with the findings of the in vitro permeation experiments and revealed that there 
was no significant change to the viable epidermis of the skin after 1% MOAPE exposure. The 
TEER findings also suggested that the permeation enhancement effects of MOAPE were not 
permanent and the results indicated a return towards original skin integrity after removal of the 
enhancer formulation.  
Keywords: fatty acids; esterification; synthesis; chemical permeation enhancers; tenofovir; 
transdermal 
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1. Introduction
There is increasing interest in the skin as an alternative site for the delivery of drugs to the
systemic circulation. The numerous advantages of the transdermal route make the skin an
attractive alternative to conventional oral dosage forms (Bavaskar et al., 2015; Vavrova et al.,
2005) . However, the stratum corneum (SC) layer presents a challenging obstruction to drug
permeation which reduces its bioavailability. Most drugs are not able to permeate the skin in
therapeutically relevant quantities, which has led to the development of strategies to improve
their delivery and increase the range of drugs that can be delivered via this route (Ham and
Buckheit Jr, 2015; Prausnitz and Langer, 2008).
One approach in improving transdermal drug delivery is by reversibly decreasing the barrier 
property by the use of chemical penetration enhancers (CPEs). CPEs are chemicals which 
interact with the constituents of the SC and promote the passage of drug across the skin 
(Hussain et al., 2014; Lane, 2013; Saini et al., 2014) Fatty acids (FAs) have been widely used 
as CPEs due to their interactions with the SC and their ability to increase the fluidity by 
disrupting the packing of the lipids, thereby modifying the skin’s barrier (Chantasart et al., 
2004; Williams and Barry, 2012). In general FAs display greater permeability as compared to 
other classes of transdermal penetration enhancers (Babu et al., 2015). Although both 
unsaturated FAs (UFAs) and saturated FAs (SFAs) have been used as penetration enhancers 
for hydrophilic and lipophilic drugs (Williams and Barry, 2012), UFAs are well recognized as 
being more effective permeation enhancers (Babu et al., 2015; Oh et al., 2001). There are 
several reports on the effect of carbon chain length of FAs on the skin permeation enhancement 
of drugs; with the optimal chain length identified for UFAs being C18. Moreover, cis-
configuration UFAs are more effective penetration enhancers than trans-configuration. Cis-
configuration FAs are more effective in disrupting the lipid packing order within the bilayers 
(Choi et al., 2012; Hussain et al., 2014; Williams and Barry, 2012). The C18 UFAs oleic acid 
(OA), linoleic acid (LA) and linolenic acid (LLA) have been shown to be superior transdermal 
permeation enhancers for numerous drugs (Babu et al., 2015; Chi et al., 1995; Fang et al., 2003; 
Gwak and Chun, 2002; Gwak et al., 2004) with oleic acid showing the greatest promise (Baek 
et al., 2012; Dimas et al., 2004; Shah et al., 2012). These cis-confirmation UFAs have been 
shown to form separate domains within the SC lipids which effectively decreases either 
resistance or the length of the diffusional path (Babu et al., 2015; Ongpipattanakul et al., 1991). 
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OA in particular has been shown to be readily absorbed into the SC causing a decrease in the 
order of the lipid bilayer and increasing the fluidity. Due to its cis double bond, it is suggested 
that OA disrupts the packed structure of the intercellular lipids; in contrast the C18 SFA 
counterpart [stearic acid (SA)] is not as efficient in increasing the fluidity of the skin’s 
membrane (Babu et al., 2015; Neubert et al., 1997; Oh et al., 2001).   
Literature reports greater permeation enhancement using derivatives as compared to their 
parent material (Kalhapure and Akamanchi, 2013; Ojewole et al., 2014; Rambharose et al., 
2015; Sinha and Kaur, 2000; Takahashi et al., 2002; Williams and Barry, 2012; Zhao et al., 
2008), this therefore drives the need to modify existing CPEs to obtain novel CPEs with better 
performance.  Recent studies suggest that ester derivatives of FAs have a greater transdermal 
enhancement potential than their respective parent FAs (Kalhapure and Akamanchi, 2013; 
Ojewole et al., 2014; Rambharose et al., 2015). FA esters such as isopropyl myristate, isopropyl 
decanoate, isopropyl palmitate, sucrose laurate, methyl laurate, and ethyl oleate among others 
have been widely explored as transdermal permeation enhancers (Babu et al., 2015). FA esters 
have been shown to exhibit good enhancing effect on the transdermal absorption of numerous 
hydrophilic and hydrophobic permeants such as 6-carboxyfluorescein, hydrocortisone, 5-
fluorouracil, diclofenac, metoprolol, lidocaine, ketoprofen, indomethacin and isosorbide 
dinitrate (Babu et al., 2015; Chen et al., 2014). FA esters usually decrease the skin’s barrier by 
partitioning themselves in the ordered lipid domains of the SC (Babu et al., 2015). Recent 
reports have indicated that esters increase the partition coefficient to enhance the permeation 
of drugs. Additionally, the physicochemical properties such as the lipophilicity (log P) of a 
permeant significantly determines its ability to passage through the skin (Patel et al., 2002; 
Potts and Guy, 1992; Xie et al., 2016). Therefore, the chemical modification of FAs to obtain 
more lipophilic CPEs which can promote permeation of hydrophilic as well as hydrophobic 
drugs through the skin by reversible disruption and fluidization of the SC is a promising 
strategy.  
Tenofovir (TNF) is an antiretroviral (ARV) drug classified by its ability to specifically inhibit 
the enzyme reverse transcriptase and causing the process of viral replication to be terminated 
or blocked. In the present situation, TNF is a drug which is considered to be most successful to 
manage HIV and AIDS (Cressey et al., 2015; Diblíková et al., 2014). The metabolic release of 
TNF occurs within the gastrointestinal tract (GIT), resulting in the onset of several GIT 
associated adverse side effects such as nausea, diarrhea, inflammation and irritation of the 
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intestinal lining (Chapman et al., 2003; Fernandez-Fernandez et al., 2011). Formulation 
scientists have explored various target sites such as vaginal, buccal, rectal and dermal routes 
for the alternative administration of TNF to by-pass its side effects (Rambharose et al., 2015). 
The delivery of TNF through skin could be the most attractive route of administration as it 
presents several advantages that contribute to increasing patient compliance.  
Although transdermal drug delivery (TDD) is an attractive alternate route of administration, 
the number of ARV drugs explored for this route is limited (Rambharose et al., 2015). The 
natural barrier properties of the skin combined with the low number of CPE’s limit the 
applicability of this route for many drugs. While new chemical entities are being discovered at 
a rapid rate, the number of new CPE molecules has plateaued (Karande et al., 2005). The 
identification of new CPEs is critical in achieving the full potential of these materials in TDD. 
Therefore, the aim of our investigation was to explore the use of novel mono, di and tri-ester 
derivatives of FAs (SA, OA, LA and LLA) as prospective penetration enhancers for the TDD 
of TNF. Such derivatives have not been reported as CPEs for any route.  
2. Materials and methods
2.1 Materials
TNF was obtained from Sinobright Pharmaceutical Co. Ltd (China). Oleic Acid, Linoleic Acid, 
Linolenic Acid, Stearic Acid, N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDAC.HCl), p-dimethylaminopyridine (DMAP) and precoated Silica-gel 
60F254 plates and hydroxypropyl methyl cellulose (HPMC) was purchased from Sigma-
Aldrich Co. Ltd., (USA). 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and all other reagents and solvents used for synthesis and purification procured from 
Merck Chemicals (Germany) were of analytical grade. Purified water was obtained in our 
laboratories, from the water purification system (Millipore corp., USA). 
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2.2 Methods 
2.2.1 Synthesis and characterization 
Scheme 1. Synthesis of mono-ester fatty acid derivatives 
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Scheme 2. Synthesis of di-ester fatty acid derivatives 
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Scheme 3. Synthesis of tri-ester fatty acid derivatives 
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A two-step synthetic route was employed to synthesize the amino ester derivatives with 
different alkyl chains (Scheme 1-3). Key intermediates, tert-butyl 3-((2-hydroxyethyl) amino) 
propanoate (compound 3; Scheme 1); tert-butyl 3-((1,3-dihydroxypropan-2-yl) amino) 
propanoate (compound 6; Scheme 2); and tert-butyl 3-((1,3-dihydroxy-2-(hydroxymethyl) 
propan-2-yl) amino) propanoate (compound 9; Scheme 3) were obtained quantitatively via 
single Michael addition reaction between amine (1, 5 or 8) and tert-butyl acrylate (2). The 
intermediate (3, 6 or 9) was coupled to stearic acid (SA), oleic acid (OA), Linoleic acid (LA) 
and Linolenic acid (LLA) by Steglich esterification using N,N'-di cyclohexyl carbodiimide 
(DCC) as a coupling reagent to obtain mono- (Scheme 1), di-(Scheme 2) or tri-(Scheme-3)
substituted ester derivatives (4, 7 or 10) with good yield (70-83%) (Supplementary
Information).
2.2.2 Calculation of lipophilicity
In order to determine lipophilicity an online tool (chemicalize) was used to calculate the log P 
values of the derivatives and their respective parent FAs(chemicalize.org, 2016) 
2.2.3 In vitro cytotoxicity 
MTT cytotoxicity evaluation of the fatty acid derivatives were investigated using the human 
breast adenocarcinoma (MCF 7), liver hepatocellular carcinoma (Hep G2), and human lung 
carcinoma (A549) (Supplementary Information).  
2.2.4 In vitro permeation studies 
2.2.4.1 Preparation of gels 
The permeability enhancement properties of the FA esters were evaluated by preparing gels 
that contained 4% w/w HPMC and 2% w/w TNF as the control. The test formulations were 
made up using control gels with the addition of enhancers (FA or FA derivative) at 1% w/w. 
To determine the optimal concentration of most promising enhancer gels containing 0.5, 2, 4, 
6% w/w of the parent FA or the respective FA derivative from the different groups were 
prepared and evaluated. 
2.2.4.2 Harvesting rat skin tissue 
Wistar rats (male) weighing 200-250 g were used in the study. The University of KwaZulu-
Natal (UKZN) Biomedical Research Ethics Committee granted ethical clearance for this study 
in 2014 (054/14/Animal), and was renewed (015/15/Animal). The animals used for 
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experiments were housed at the Biomedical Resource Unit (BRU) of UKZN under controlled 
12-h light/dark cycles, temperature and humidity conditions. The rats were fed and received
water ad libitum on a daily basis. After CO2 euthanasia, the body fur was carefully removed
using standard shaving procedures. The skin located around the abdominal region was
harvested and excised to remove any subcutaneous fat. Skin samples were stored (-20˚C) and
utilized within 3 months (Kalhapure and Akamanchi, 2013; Rambharose et al., 2015). The skin
was thawed using a solution of pH 7.4 PBS at room temperature prior to permeation
experiments.
2.2.4.5 In vitro permeation studies 
The in vitro permeation experiments were performed using a modified vertical Franz type 
diffusion cells system (PermeGear, Inc., Bethlehem, USA) with a diffusional area of 0.786 cm2 
at a temperature of 37 ± 1˚C (Rambharose et al., 2015). The donor compartment of the modified 
vertical Franz diffusion cells contained either control or sample gels and the receptor 
compartment contained 25ml PBS (stirred with a teflon-coated magnetic bar). The central 
diffusional area contained a round section of rat skin tissue mounted directly between the donor 
and receptor cells. The skin section was initially equilibrated with PBS (pH 7.4) at 37 °C for 
30 minutes.  Thereafter samples were removed from the receptor compartments at 
predetermined time intervals and replenished with the equal volume of PBS. Each experiment 
represents a minimum of six replicates. UV spectrophotometry analysis (UV 
Spectrophotometer 1650, Shimadzu, Japan) was used to measure the amount of drug 
permeating through the skin tissues at λmax of 262 nm (Rambharose et al., 2015). After 
establishing the optimal FA derivative enhancer in each series, the concentration effect studies 
were performed using the identified derivative and its respective parent FA gel for each series 
(Ojewole et al., 2014; Rambharose et al., 2015). 
2.2.4.6 Permeability data analysis 
The permeation percentage of drug (TNF) that entered or permeated per unit surface area of 
the skin tissue was plotted against time. The linear part of the permeability curve was used to 
determine the steady state flux (Jss) by linear regression analysis (Microsoft Excel 2010, USA). 
The permeability coefficient (P) was calculated using the following equation (Ojewole et al., 
2014; Rambharose et al., 2015; Rambharose et al., 2014a).
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𝑷𝑷 =
�𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑�
𝐴𝐴
 𝑥𝑥 𝐶𝐶𝑑𝑑 =
𝐽𝐽𝐽𝐽𝐽𝐽
𝐶𝐶𝑑𝑑
 𝑒𝑒𝑒𝑒. (2) 
A, is the diffusion area and Cd is the drug concentration in the donor compartment and dQ/dt 
is the cumulative amount permeated per unit time. The enhancement ratio (ER) was calculated 
as follows (Ojewole et al., 2014; Rambharose et al., 2015). 
𝑬𝑬𝑬𝑬 =
𝑃𝑃 𝑜𝑜𝑜𝑜 𝑡𝑡ℎ𝑒𝑒 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑖𝑖𝑖𝑖 𝑡𝑡ℎ𝑒𝑒 𝑝𝑝𝑑𝑑𝑒𝑒𝐽𝐽𝑒𝑒𝑖𝑖𝑝𝑝𝑒𝑒 𝑜𝑜𝑜𝑜 𝑒𝑒𝑖𝑖ℎ𝑎𝑎𝑖𝑖𝑝𝑝𝑒𝑒𝑑𝑑
𝑃𝑃 𝑜𝑜𝑜𝑜 𝑡𝑡ℎ𝑒𝑒 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑖𝑖𝑖𝑖 𝑡𝑡ℎ𝑒𝑒 𝑎𝑎𝑎𝑎𝐽𝐽𝑒𝑒𝑖𝑖𝑝𝑝𝑒𝑒 𝑜𝑜𝑜𝑜 𝑒𝑒𝑖𝑖ℎ𝑎𝑎𝑖𝑖𝑝𝑝𝑒𝑒𝑑𝑑
 𝑒𝑒𝑒𝑒. (3) 
2.2.5 Transepithelial electrical resistance (TEER) evaluations 
A Millicell ERS meter (Millipore, USA) connected to a pair of chopstick electrodes (STX01) 
was used to establish the integrity of the treated skin tissue sections. TEER values of the skin 
were recorded before and after of the permeation experiment. TEER reading taken before the 
experiment (0 h) was representative of 100% skin integrity i.e. before exposure to the gel 
treatments to the skin. The rebound effect of the skin post drug treatment was measured by 
removing the drug loaded gel from the donor compartment after a period of 6 hours and 
replacing it with fresh PBS for a period of 2 hours followed by subsequent TEER measurements 
(Jones et al., 2013; Rambharose et al., 2015). 
2.2.6 Light Microscopy (LM) 
The control tissues used in this study originated from histological evaluations of freshly 
harvested excised skin tissue sections. After careful tissue removal, the control skin tissue was 
fixed in 10 % buffered formalin, whereas treated tissue samples comprised of skin tissues that 
were exposed to either OA or MOAPE at a concentration of 1% w/w.  The treated skin tissues 
were removed from the Franz diffusion cells at the end of the permeation study, and fixed in 
10 % buffered formalin. The control and enhancer treated skin samples were fixed using 
formalin for seven days at room temperature. Thereafter, an ethanol gradient ranging from 50 
% up to 96 % was used to gradually dehydrate the skin tissue sections. Subsequently, the skin 
tissue sections were embedded within paraffin wax blocks. The tissue samples were sectioned 
using a microtome (Leica RM2235, Leica Biosystems Germany) and skin sections were 
collected on slides, dried and stained with hematoxylin and eosin (H&E). The images from the 
stained slides were captured using a Leica slide scanner (SCN 400, Leica Biosystems 
Germany). All experiments were performed in triplicate (Jones et al., 2013; Rambharose et al., 
2015; Rambharose et al., 2014b). 
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2.2.7 Statistical Analysis 
The data was analysed using GraphPad Prism® (Graph Pad Software Inc., Version 5., USA) 
and presented as mean ± standard deviation (SD). The results were analysed by one-way 
analysis of variance (ANOVA) followed by the non-parametric Kruskal-Wallis test or t tests 
followed by the non-parametric Mann-Whitney test.  p < 0.05 was considered statistically 
significant. 
3. Results and discussion
3.1 Cytotoxicity evaluation
An in vitro cell culture system using MCF-7, Hep G2 and A549 cells with the MTT assay was 
employed to evaluate the biosafety of the synthesized ester derivatives. The MTT assay 
findings displayed non-toxicity for all of the synthesized derivatives against all cell lines 
studied. The cell viability was between 76.55 to 87.39 % for the single chain derivatives, 77.05 
to 90.79 % for the double chain derivatives and 76.76 to 92.17 % for the triple chain derivatives 
(Fig. 1). A one-way ANOVA, with non-parametric Kruskal-Wallis and Dunn’s multiple 
comparison tests showed no statistically significant (p > 0.05) differences between the novel 
ester derivatives and their respective controls in all the cell lines tested. The results indicated 
that these novel mono, di and tri-ester FA derivatives can be safely used for biological studies. 
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Fig. 1 Cytotoxicity assay displaying percentage cell viability after exposure to various 
concentrations of the FA derivatives on (A) MCF – 7, (B) Hep G2 and (C) A549 cells. Results 
are presented as mean ± SD (n = 6).   
Experimental paper 3 Chapter 4 
117 
3.2 In vitro transdermal permeation 
In order to ascertain the permeation enhancement effects of the newly synthesized mono (series 
1), di (series 2) and tri-ester (series 3) derivatives, the transdermal penetration potential of TNF 
in the absence of enhancers was also determined. The results displayed that bare TNF was able 
to penetrate the skin with a cumulative amount of 253.1 ± 23.84 µg/cm2 and steady state flux 
of 40.91 ± 4.93 µg/cm2 h (Table 1). These findings were in good agreement with previous a 
paper on TNF’s transdermal permeation potential (Rambharose et al., 2015). The results 
showed that TNF was able to permeate the skin unaided. However, to ensure that 
therapeutically relevant doses of TNF reach the systemic circulation we explored the 
enhancement potential of the novel single, double and triple chain FA ester derivatives for the 
delivery of TNF.  
Table 1 Effect of the novel groups of FA ester derivatives on the permeability parameters of 
TNF. *Indicates statistically significant difference i.e. p < 0.05 (compared to TNF (control)). 
#indicates statistically significant difference as compared to its respective parent FA. 
Treatment Amount permeated 
(µg.cm -2) 
Jss (flux)  
(µg.cm -2.h-1) 
Permeability (Px10-2) ER 
TNF (Control) 253.10 ± 23.84 40.91 ± 4.93 0.204 ± 0.02 1 
OA 334.75 ± 28.29 54.65 ± 4.22 0.273 ± 0.02 1.33 
MOAPE 1668.75 ± 105.30 240.55 ± 21.06*# 1.20 ± 0.10 5.87 
DOAPE 424.95 ± 59.84 70.07 ± 10.89*# 0.350 ± 0.05 1.71 
TOAPE 342.3 ± 26.94 61.39 ± 4.52* 0.306 ± 0.02 1.5 
SA 296.59 ± 12.31 47.37 ± 2.35 0.236 ± 0.011 1.16 
MSAPE 407.12 ± 66.51 63.48 ± 12.41*# 0.317 ± 0.06 1.55 
DSAPE 336.1 ± 25.67 57.33 ± 5.64*# 0.286 ± 0.02 1.4 
TSAPE 531.70 ± 23.87 85.76 ± 3.69*# 0.428 ± 0.018 2.09 
LA 369.02 ± 25.45 60.46 ± 4.32* 0.302 ± 0.02 1.47 
MLAPE 574.97 ± 74.09 92.07 ± 13.72*# 0.460 ± 0.06 2.25 
DLAPE 1074.62 ± 61.12 161.87 ± 11.32*# 0.809 ± 0.05 3.95 
TLAPE 574.39 ± 88.70 86.47 ± 11.54*# 0.432 ± 0.05 2.11 
LLA 531.96 ± 51.84 90.15 ± 9.39* 0.450 ± 0.04 2.2 
MLLAPE 945.88 ± 44.93 151.58 ± 8.04*# 0.7579 ± 0.04 3.7 
DLLAPE 400.37 ± 18.92 67.58 ± 2.53* 0.337 ± 0.01 1.65 
TLLAPE 453.53 ± 37.43 77.80 ± 8.07* 0.389 ± 0.04 1.9 
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3.2.1 Effects of novel derivatives on TNF permeability 
Table 2 Lipophilicity of novel series 1, 2 and 3 derivatives as represented by their respective 
log P values. 
Group 1 Log P Group 2 Log P Group 3 Log P Group 4 Log P 
Series OA 6.78 SA 7.15 LA 6.42 LLA 6.06 
1 MOAPE 7.48 MSAPE 7.84 MLAPE 7.12 MLLAPE 6.76 
2 DOAPE 14.30 DSAPE   15.02 DLAPE 13.57 DLLAPE 12.85 
3 TOAPE 20.98 TSAPE 22.07 TLAPE 19.89 TLLAPE 18.81 
Fig. 2 The effect of the optimal derivatives from the different ester series on the cumulative 
amount of TNF permeated. Results are presented as mean ± SD (n = 6). 
The results showed that the chemical modification to the parent FAs yielded chemical entities 
with greater lipophilicity characteristics (Table 2). The lipophilicities of the derivatives 
increased as the number of chains were increased from single to double to triple (Table 2). The 
in vitro transdermal permeation studies revealed that all the modified FA derivatives were able 
to significantly enhance the permeation of TNF (p < 0.05), however there was no clear trend 
observed between FA chain number and the ER. Being the only SFA, SA displayed the lowest 
ER of all the FAs investigated (Table 1). Likewise, the SA derivatives also achieved the lowest 
ERs of all the ester derivatives studied with an enhancement range of 1.4 to 2.09–fold, with the 
tri-ester TSAPE displaying the best ER which was 0.93-fold higher than the parent FA (SA) 
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(Table 1). The comparative results between the SFA and the UFAs in this study are reflective 
of literature that reports SFAs being less effective permeation enhancers than their unsaturated 
counterparts (Babu et al., 2015; Oh et al., 2001). In a related report the use of propylene glycol 
(PG) conjugates of SA, OA, LA and LLA in the mono and di-ester form at a concentration of 
1% w/w for the transdermal delivery of lidocaine was investigated (Ben-Shabat et al., 2007). 
The current findings correlate with the trends observed by the Ben-Shabat study (Ben-Shabat 
et al., 2007). Their study showed that the UFA, SA and its mono and di-ester derivative 
displayed the lowest permeability as compared to the UFAs (OA, LA and LLA) and their 
respective mono and di-ester derivatives respectively (Ben-Shabat et al., 2007). That study also 
revealed that neither SA nor its mono and di-ester derivatives at a concentration of 1% w/w 
were able to enhance the permeability of lidocaine. However, both the mono and di-ester SA 
derivatives showed a slightly better efficacy than their parent FA (SA)(Ben-Shabat et al., 
2007). Comparatively, at a similar concentration, our study showed that SA and its ester 
derivatives at were able to enhance the permeability of TNF and the ester derivatives displayed 
a statistically significant increase in permeability as compared to SA (Table 1).   
Literature reports that as the number of unsaturations of a UFA increases, the enhancement 
potential of the UFA also increases (Raut et al., 2014). LLA had the advantage of having the 
highest number of unsaturations of all the UFAs studied and therefore achieved the highest ER 
of the parent FAs studied (Table 1). Conversely, permeation experiments of the LLA group of 
ester derivatives displayed the lowest ER when compared to the other UFA derivative groups. 
The LLA derivatives displayed an ER range of 1.65 to 3.7-fold, with the highest increase being 
only 1.5-fold greater than the parent FA (LLA) (Table 1). Interestingly, with the LLA ester 
group, the greatest ER was achieved by the mono-ester MLLAPE, with decreases in ER 
observed with the di-ester (DLLAPE) and tri-ester (TLLAPE) derivatives to a level below that 
of the parent FA (LLA) (Table 1). The findings of this study are similar to that of Novotny´ et 
al, who reported that single chain dicarboxylic esters were more effective permeation enhancers 
than their double chain counterparts (Novotný et al., 2009). The ERs obtained in our study for 
LLA and its derivatives are superior to those achieved in the Ben-Shabat study for the delivery 
of lidocaine at similar enhancer concentrations (Ben-Shabat et al., 2007). Their study showed 
that although the mono and di-ester derivatives of LLA were able to enhance the permeability 
of lidocaine, the ER achieved by those derivatives were significantly lower than the parent FA 
(Ben-Shabat et al., 2007). These findings of the current study suggest that only single chain 
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LLA offers the optimal capabilities and performance in its group (Table 1). Additional 
conjugations of aliphatic chains do not elicit an increment of the permeation enhancement 
capabilities of this FA, rather a significant decrease is noted (Table 1). As LLA possesses the 
highest number of unsaturations, it will therefore have the most number of “kink” isomers in 
its structure. Additionally, the bent cis-configuration of LLA is anticipated to increase the 
fluidity and create free volumes by interrupting the packing of the intercellular lipids, which 
allows drug molecules to enter the free volumes of the kinks and move across the epithelium 
thereby allowing the drug to transverse the skin (Choi et al., 2012; Harrison et al., 1996; 
Rambharose et al., 2015; Tanojo et al., 1997; Williams and Barry, 2012). The addition of more 
than one aliphatic chain could cause possible hindrances to the bent-cis configuration of LLA 
and therefore decrease its ability to interrupt the lipid matrix of the SC, which could possibly 
decrease its ability to cause membrane fluidisation.  
The permeation results displayed showed that the LA derivatives were able to enhance the 
permeability of TNF within an ER range of 2.11 to 3.95-fold (Table 1). The highest ER 
signifies a statistically significant 2.48-fold increase over the parent FA (LA) (p < 0.05). The 
results also showed that as compared to the parent FA (LA) there was an increase in ER with 
the mono-ester MLAPE and reached a maximum with the di-ester DLAPE, with a subsequent 
decrease with the addition of a third aliphatic chain (TLAPE) (Table 1). Interestingly, DLAPE 
and TLAPE were able to achieve the highest ER of all the di-ester (series 2) and tri-ester (series 
3) derivatives respectively (Table 1, Fig. 2). The results of this LA group display greater
potential than the PG LA mono and di-esters, as the ERs for LLA mono and di-esters in the
present study are superior to the ERs achieved by the PG LA derivatives at similar
concentrations (Ben-Shabat et al., 2007).
The results show that with the exception of di- and tri-ester derivatives from LLA group, all of 
the synthesized derivatives displayed greater ER as compared to their respective parent FAs at 
similar concentrations (Table 1). At a concentration of 1% w/w, LLA displayed a significantly 
greater permeability potential compared to DLLAPE and TLLAPE respectively (Table 1). On 
the other hand, MLLAPE was able to achieve a significantly higher ER than LLA (p < 0.05). 
The ER of MLLAPE was 1.5-fold greater than LA. The findings of the LLA group in this study 
show significantly higher ER when compare to the PG LLA series (Ben-Shabat et al., 2007). 
The ERs of the derivatives and the differences between the derivatives and the parent FA in 
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this study were significantly greater than that achieved by PG mono and di-ester derivatives of 
LLA (Ben-Shabat et al., 2007). 
However, the greatest overall permeation enhancement potential was displayed by OA 
derivatives, which exhibited an ER range between 1.5 to 5.87-fold (Table 1, Fig. 2). The 
superiority of OA as a FA transdermal permeation enhancer is well documented in the literature 
(Babu et al., 2015). OA’s ability to enhance transdermal permeation has been attributed to its 
ability to modify the organisation of the highly ordered lipids in the SC and cause fluidisation 
of this layer (Babu et al., 2015; Neubert et al., 1997). The resultant formation of such pools 
causes permeability defects within the lipid bilayer and therefore promotes the movement of 
drugs across the epidermis. The results show that the chemical modification of OA to produce 
the mono, di and tri esters displayed a greater transdermal permeation enhancement than the 
parent lipid (Table 1). MOAPE was able to achieve the greatest ER (5.87) of the OA derivative 
group. The ER of PG mono and di-ester derivatives of OA did not show improved efficacy 
when compared to its parent OA (Ben-Shabat et al., 2007). However, significantly the mono 
LLA ester in the present report displayed a 4.54-fold increase in the permeation of TNF when 
compared to the efficacy of its respective parent OA. These findings are also similar to a 
previous study where the mono dicarboxylic esters displayed the greatest permeation 
enhancement of theophylline (Novotný et al., 2009). 
Interestingly MOAPE, DLAPE and TLAPE showed the most promise as transdermal 
permeation enhancers (Table 1, Fig. 2) within their respective mono (series 1), di (series 2) or 
tri-ester (series 3) categories. Establishing their concentration effect on the permeability 
parameters of TNF will provide valuable information that will aid in the optimal formulation 
of these enhancers to be incorporated into a future TDD system.  
3.2.2 Concentration effect of optimal permeation enhancer per series 
The concentration effect profile of identified enhancers in each series was evaluated and 
compared against its respective parent FA. The results revealed that MOAPE was able to 
enhance the permeation of TNF from an initial concentration of 0.5 to 1% w/w. A 2% w/w 
increase of the enhancer concentration resulted in a statistically significant (p < 0.05) decrease 
in the ER of TNF (Table 3, Fig. 3). Any further enhancer concentration increases (from 4 to 
6% w/w) did not elicit any significant changes (p > 0.05) in the permeability of TNF as the ER 
remained almost constant for 4% and 6% w/w concentrations. Interestingly, the parent FA 
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(OA) did not display any significant changes in the permeability of TNF across the 
concentration range studied (Table 3, Fig. 3). OA displayed a slight increase in the ER from 
0.5 to 1% w/w, however further increases in the concentration from 2 to 6% failed to 
significantly increase the permeability parameters of TNF (Table 3, Fig. 3). With the exception 
of the sharp decline in ER observed with MOAPE at 2% w/w, the concentration enhancement 
trend for both the parent FA and the novel derivative were very similar (Table 3, Fig. 3). 
Although both the parent FA and derivative displayed a similar concentration enhancement 
profile, the ERs obtained by the derivative were statistically significantly (p < 0.05) different 
from that of the parent FA at all concentrations (Table 3). These observations exhibit the 
superiority of the novel OA ester derivative (MOAPE) over the parent FA (OA). The ester 
derivative ethyl oleate (10%) was only able to enhance the permeability of cyclosporine A by 
1.43-fold (Cui et al., 2013), comparatively MOAPE (1% w/w) in the current study was able to 
achieve a 4.44-fold greater enhancement at a 10 times lower enhancer concentration than ethyl 
oleate. This displays MOAPE’s ability to significantly enhance transdermal drug delivery at 
substantially lower enhancer concentrations. 
Table 3 Concentrations effect of OA and MOAPE on the transdermal permeability parameters 
of TNF. *Indicates a statistically significant difference i.e. p < 0.05 (compared to control), 
#Indicates a statistically significant difference when compared to OA at similar concentration. 
Amount permeated 
(µg.cm -2) 
Jss (flux)  (µg.cm -2.h-1) ER 
Control 253.10 ± 23.84 40.91 ± 4.93 1 
Concentrations 
[% w/w] 
OA MOAPE OA MOAPE OA MOAPE 
0.5 256.92 ± 
35.78 
521.14 ± 
55.22 
41.47 ± 
6.56 
85.05 ± 
11.16*# 
1.01 2.07 
1 334.75 ± 
28.29 
1668.75 ± 
105.30 
54.65 ± 
4.22* 
240.55 ± 
21.06*# 
1.33 5.87 
2 328.38 ± 
45.32 
751.45 ± 
37.82 
54.04 ± 
7.00* 
130.43 ± 
6.13*# 
1.32 3.18 
4 318.06 ± 
37.57 
733.38 ± 
38.50 
52.25 ± 
5.85 
122.87 ± 
6.26*# 
1.27 3 
6 308.06 ± 
36.80 
718.39 ±  
35.87 
50.37 ± 
6.60 
121.34 ±  
7.47*# 
1.23 2.96 
Experimental paper 3 Chapter 4 
123 
0 1 2 3 4 5 6 7
0
50
100
150
200
250
300
MOAPE
OA
Concentrations (% w/w)
Fl
ux
 (J
ss
) (
µg
/c
m
2 h
r)
Fig. 3 Concentration effects of OA and the mono-ester OA derivative (MOAPE) on the flux of 
TNF (n = 6). 
The results for the double chain FA derivatives showed that DLAPE displayed a similar 
enhancement profile to that of MOAPE, where there was an initial increase in ER from 0.5% 
obtaining a maximum ER of 3.95 at 1% w/w (Table 4, Fig. 4). As the enhancer concentration 
increased to 2% w/w there was also a statistically significant (p < 0.05) decrease in the 
permeability of TNF, and further increments in the enhancer concentration from 2 to 6% w/w 
resulted in a decrease in the permeability of the TNF. Comparatively, the parent FA, LA 
displayed an increase in the permeation of TNF from 0.5% to 2% w/w and a subsequent 
decrease in the permeation from 4 to 6% w/w (Table 4, Fig. 4). The differences between the 
derivatives and the parent FA at 0.5 and 1% w/w were statistically significant (p < 0.05). 
Interestingly, at concentrations above 2% w/w the parent FA (LA) displayed a marginally 
higher ER than the di-ester LA derivative (DLAPE). These results reveal that the di-ester LA 
(DLAPE) derivative is only able to display superior permeation than its parent FA at 
concentrations below 2% w/w (Table 4, Fig. 4). 
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Table 4 Concentrations effect of LA and DLAPE on the transdermal permeability parameters 
of TNF. *Indicates a statistically significant difference i.e. p < 0.05 (compared to control), 
#Indicates a statistically significant difference when compared to LA at similar concentration. 
Amount permeated 
(µg.cm -2) 
Jss (flux)  (µg.cm -2.h-1) ER 
Control 253.10 ± 23.84 40.91 ± 4.93 1 
Concentrations 
[% w/w] 
LA DLAPE LA DLAPE LA DLAPE 
0.5 256.69 ± 
28.77 
432.83 ± 
36.18 
41.73 ± 
4.07 
73.36 ± 
5.90*# 
1.02 1.79 
1 369.02 ± 
25.45 
1074.62 ± 
61.12 
60.46 ± 
4.32* 
161.87 ± 
11.32*# 
1.47 3.95 
2 576.20 ± 
50.23 
548.83 ± 
26.30 
94.73 ± 
8.68* 
90.82 ± 4.33* 2.31 2.21 
4 527.02 ± 
39.54 
469.02 ± 
49.20 
81.82 ± 
8.46* 
79.65 ± 9.05* 2 1.94 
6 461.38 ± 
10.59 
405.31 ± 
64.12 
77.08 ± 
1.86* 
67.66 ± 
11.89* 
1.88 1.65 
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Fig. 4 Concentration effects of LA and the di-ester LA derivative (DLAPE) on the flux of TNF 
(n = 6). 
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The concentration range studied was increased to include 0.125 and 0.25% w/w in the case of 
TLAPE as this derivative showed the most promising enhancement potential at the initial 
lowest concentration of 0.5% w/w and therefore warranted further investigation at lower 
concentrations. The extended concentration effect of TLAPE showed that the derivative was 
able to proportionally increase the ER as the enhancer concentration was increased from 0.125 
to 0.5% w/w (Table 5, Fig. 5). At a concentration of 0.5% there was a 4-fold increase in the 
permeation of TNF (Table 5, Fig. 5). The increases in TLAPE concentrations from 1 to 6% 
displayed a decrease in the permeation of TNF (Table 5, Fig. 5). Comparatively, the parent FA 
(LA) displayed an increase in the permeability of TNF from 0.125 to 2% and further increases 
in concentration from 4 to 6% elicited a decrease in its permeation enhancement effects (Table 
5, Fig. 5). Interestingly, from 2 to 6% the ER displayed by the parent FA (LA) was greater than 
the ER obtained with the tri-ester derivative TLAPE (Table 5, Fig. 5). A similar trend was 
observed in the series 2 (di-ester DLAPE) derivatives, which reinforces the notion that LA 
derivatives are only able to display greater permeation enhancement efficacies at lower 
concentrations with the parent FA (LA) surpassing its derivatives enhancement effect at 
concentrations greater than 2%.  
Table 5 Concentrations effect of LA and TLAPE on the transdermal permeability parameters 
of TNF. *Indicates a statistically significant difference i.e. p < 0.05 (compared to control), 
#Indicates a statistically significant difference when compared to LA at similar concentration. 
Amount permeated (µg.cm -2) Jss (flux)  (µg.cm -2.h-1) ER 
Control 253.10 ± 23.84 40.91 ± 4.93 1 
Concentrations 
[% w/w] 
LA TLAPE LA TLAPE LA TLAPE 
0.125 255.14 ± 22.56 279.60 ± 34.31 41.22 ± 2.68 46.88 ± 5.45 1.01 1.14 
0.25 243.58 ± 21.44 401.15 ± 47.53 39.86 ± 3.09 61.39 ± 8.61*# 0.97 1.5 
0.5 256.69 ± 28.77 1024.96 ± 35.20 41.73 ± 4.07 163.77 ± 4.26*# 1.02 4 
1 369.02 ± 25.45 574.39 ± 88.70 60.46 ± 4.32* 86.47 ± 11.54*# 1.47 2.11 
2 576.20 ± 50.23 436.08 ± 48.47 94.73 ± 8.68* 67.56 ± 9.20*# 2.31 1.65 
4 527.02 ± 39.54 350.78 ± 14.15 81.82 ± 8.46* 55.22 ± 2.036*# 2 1.35 
6 461.38 ± 10.59 316.68 ± 33.80 77.08 ± 1.86* 53.11 ± 5.37*# 1.88 1.29 
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Fig. 5 Concentration effects of LA and the tri-ester derivative (TLAPE) on the flux of TNF (n 
= 6). 
The results of the concentration effect study clearly show the mono-ester OA derivative 
(MOAPE) at a concentration of 1% w/w as the superior transdermal permeation enhancer of 
all three series and increased TNF steady state flux to 240.55 ± 21.06 µg/cm2 and cumulative 
amount to 1668.75 ± 105.30µg/cm2 h (Table 3, Fig. 3). Further histomorphological and TEER 
studies were therefore conducted only on MOAPE, the optimal permeation enhancer, and its 
respective parent FA (OA) at a concentration of 1% w/w.     
3.3 TEER studies 
TEER studies were performed to determine the change in the skin’s integrity during the 6 h 
permeation studies. Changes in the TEER measurements are indicative of changes in the barrier 
properties of the skin (Bartosova and Bajgar, 2012; Rambharose et al., 2015; Srinivasan et al., 
2015). TEER values at the end of the experiment are compared to the values recorded prior to 
the addition of the test material to ascertain the change in the barrier property of the skin due 
to the interaction of the drug treatment. A decrease in the TEER values is suggestive of the 
decrease in the barrier properties of the skin, which therefore implies that more transport 
pathways are available through the skin (Rambharose et al., 2015). 
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Fig. 6 TEER measurements (%) recorded after TNF permeation with either 1% w/w of OA or 
MOAPE (n = 6). 
The results showed that the skin samples intended for use in both OA and MOAPE displayed 
similar 0 h TEER values. This confirms that the skin integrity of both test groups were 
equivalent prior to the commencement of the permeation experiment and the results obtained 
from these studies would therefore be able to provide reliable comparisons between the effects 
of both treatments.  The skin samples used for the OA and MOAPE study presented an initial 
resistance of 479.67 ± 42.67 Ω /cm2 and 488.33 ± 32.53 Ω /cm2 respectively. These values 
were used as the respective controls (i.e. 100% TEER value) and compared to the recordings 
taken after the 6 h permeation as well as to the values obtained 2 h post permeation (Fig. 6). At 
the end of the 6 h permeation the skin samples exposed to the 1% w/w OA treatment had a 
TEER value of 472.67 ± 32.65 Ω /cm2 which signified a 3.2% decline in the resistance of the 
skin as compared to its respective 0 h recordings (Fig 6). Comparatively, the 1% w/w MOAPE 
treated skin displayed a TEER value of 390 ± 14.93 Ω /cm2 which is indicative of a 9.63% 
decrease of its 0 h recordings (Fig. 6). These findings indicate that the 1% w/w MOAPE 
treatment is able to decrease the resistance of the skin by 3-fold than the 1% w/w OA treatment. 
These findings correlate well with the findings from the in vitro permeation studies which 
showed that the MOAPE treatment achieves a significantly greater ER than the OA treatment 
at 1% w/w (Table 3, Fig. 3). The 2 h post permeation recordings indicated that the removal of 
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the OA and MOAPE treatments resulted in an increase in the TEER values (Fig. 6). Two hours 
after the removal of the OA treatment the TEER value was recorded at 475.33 ± 32.72 Ω /cm2. 
As compared to the change noted from the differences between the 0 h and 6 h TEER 
recordings, the 2 h post TEER values therefore show a 17.02% recovery in the resistance of 
the skin after removal of the OA treatment (Fig. 6). Similarly, the MOAPE treated skin also 
displayed a recovery in resistance after the 2 h post recordings, however to a greater extent. 
The 2 h post TEER values of the MOAPE skin samples were recorded at 401 ± 32.19 Ω /cm2, 
which indicate a 26.4% recovery in skin resistance (Fig. 6). The results therefore indicate 
neither OA nor MOAPE at a concentration of 1% w/w irreversibly change the integrity of the 
skin, as the TEER evaluations show a return towards the original measured resistance of the 
skin after removal of the enhancer formulations (Fig. 6). These findings confirm that both OA 
and MOAPE at a concentration of 1% w/w were able to display reversible effects on the barrier 
properties of the skin, which is one of the key attributes of ideal permeation enhancers.  
3.4 Light microscopy 
The assessment of skin samples after the permeation study is critical to observe the 
histomorphological changes brought on by the exposure to the drug treatments. Histological 
assessments would enable the evaluation of any adverse effects to the individual epithelial 
layers of the skin by the drug and enhancer treatment (Rambharose et al., 2015). H&E stained 
sections of skin were evaluated using light microscopy (LM) to visualise the effects of the 
various treatments on the skin’s morphology. As the SC is the major hindrance to the 
movement of drugs across the epithelium, histological assessments on this region would 
provide insight to the effects that the enhancers had on this layer to enable larger quantities of 
the drug to pass through the epidermal layer to the blood vessels in the underlying dermis (D). 
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Fig. 7 LM images of H&E stained samples of the control and the treated skin; (A) untreated 
skin (control), (B) samples exposed to TNF gel, (C) skin exposed to 1% w/w OA TNF gel, (D) 
skin samples exposed to 1% w/w MOAPE TNF gel (D: dermis; E: epidermis; SC: stratum 
corneum). 
The control image (Fig. 7A) shows normal thin skin histomorphology, with the SC clearly 
visible and intact. The enhancer free TNF image (Fig. 7B) displayed a very similar 
morphological appearance to that of the control sample. Similar to the control image, the SC 
in this treatment also appeared undamaged and the layers of the epidermis didn’t display any 
indication of changes when compared to the control image. In the OA treated (Fig. 7C) and 
MOAPE treated (Fig. 7D) samples, there were observable changes in the appearance and the 
morphology of the SC layer. The 1% w/w OA treatment resulted in the disruption of the SC 
layer, which is clearly identified by the increase in thickness of this layer which is a result of 
the disruption/fluidisation of the highly ordered lipids found in this layer (Fig. 7C). This 
disruption/fluidisation causes this layer to appear loosely packed (Liu and Chang, 2011) and 
thereby looks thicker than the SC of the control sample. There were also intercellular spaces 
observed in SC of the OA sample which was a further confirmation of the 
disruption/fluidisation of this layer. Interestingly, the MOAPE treated sample also displayed 
these characteristics of a disrupted/ fluidised SC. However, these observations were 
significantly more prominent in the MOAPE treated sample (Fig. 7D). The fluidisation of the 
SC in the MOAPE sample (Fig. 7D) was much greater, and the intercellular spaces were larger 
than that observed in the OA sample (Fig. 7C). These observations are indicative of a greater 
Experimental paper 3  Chapter 4 
130 
degree of disruption/fluidisation of the SC in the MOAPE treated sample. This 
disruption/fluidisation of the SC would decrease the natural barrier property of the skin and 
promote the movement of drugs across the epidermis. As the MOAPE sample displayed 
evidence of more prominent disruptions/fluidisation than the OA image, therefore there would 
be a resultant increase in the amount of drug that would be able to permeate through MOAPE 
treated skin. These observations correlate directly with the findings of the in vitro permeation 
study which showed that MOAPE caused a significantly higher quantity of TNF to permeate 
the skin as compared to OA at 1% w/w (Table 3, Fig. 3). Although there are noticeable changes 
in the uppermost layer (SC) of the epidermis in both the OA and MOAPE treated skin (Fig. 7C 
and 7D), the underlying layers of the epidermis appear unchanged, with normal 
histomorphology comparable to that of the control image. The basal layer of all the treated 
samples (Fig. 7B, 7C and 7D) also appear normal, with characteristics of regular cellular 
arrangement and morphology which are therefore suggestive that this regenerative layer is 
unharmed by the drug or enhancer treatments. These observations therefore suggest that the 
drug and enhancer treatments would not have permanent effects of the epidermal layer of the 
skin.        
4. Conclusions
Our study reports the successful synthesis and characterization of novel mono, di and tri ester
FA derivatives. In vitro biosafety testing revealed their non-toxic effects on human cell lines
which confirm their applicability for biomedical applications. The evaluation of their
permeation enhancement efficacies were successfully performed using the model drug TNF.
The results showed that all the novel ester derivatives were able to enhance the permeability of
TNF at a concentration of 1% w/w; however, there was no direct correlation between FA chain
number and the permeation enhancement efficacy of the derivatives. The results revealed that
all the FA esters displayed greater permeation enhancement activity as compared to their parent
FAs. These findings confirm the superiority of these novel ester derivatives as compared to
their respective parent material. The UFAs and their respective derivatives in this study showed
a greater increase in ER when compared to the SFA (SA) and its derivatives. Within the three
different series MOPE, DLAPE and TLAPE displayed the greatest enhancement potential for
the mono, di and tri-ester derivatives respectively. A concentration affect study on the optimal
enhancer from each series revealed that MOAPE at 1% w/w from the mono ester derivative
series achieved the highest permeation enhancement of TNF with an ER of 5.87. MOAPE
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displayed superior permeation enhancement at all concentrations when compared to OA, a 
parent lipid. Further histomorphological and TEER investigations displayed that 1% w/w 
MOAPE caused no adverse effects to the skin and the skin’s integrity, and that the effects of 
the enhancer treatment were temporary. In conclusion, this study reported novel FA esters 
showing promise as effective permeation enhancers. These findings show that the novel mono 
ester derivative of OA (MOAPE) adds to the pool of CPEs available to formulation scientists 
and can be safely incorporated into TDD systems for several classes of drugs. 
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1. Synthesis and characterisation
General procedure for mono Michael addition I
To a solution of tert-butyl acrylate 2 in alcohol, an amine 1, 5 or 8 was added at room 
temperature and stirred for 4 - 30 h at 25 to 45 °C. Alcohol and excess tert-butyl acrylate were 
evaporated in vacuo and the resulting residue was recrystallized or column purified using 
hexane and ethyl acetate (3:1) to yield the mono Michael addition product (3, 6 and 9).  
General procedure (esterification) for synthesis of amino ester derivatives II 
Fatty acid was added to a stirred mixture of mono Michael adduct (compound 3, 6 or 9), DCC, 
and DMAP in dry DCM under a nitrogen atmosphere at room temperature (RT). The resulting 
reaction mixture was further stirred RT for 18 - 24 h. From the reaction mass, precipitated 
dicyclohexylurea was removed by filtration.  The organic layer (filtrate) was evaporated under 
reduced pressure and the obtained residue was purified by column chromatography (silica gel 
#70-230 and 10-15% ethyl acetate in hexane as an eluent) to yield the ester derivative. 
FT-IR spectra of all the compounds were recorded on a Bruker Alpha-p spectrometer with 
diamond ATR (Germany). 1H NMR and 13C NMR measurements were performed on a Bruker 
NMR spectrometer (United Kingdom) at 400 and 100 MHz respectively. HRMS was 
performed on a Waters Micromass LCT Premier TOF-MS (United Kingdom). 
Synthesis of tert-butyl 3-((2-hydroxyethyl) amino) propanoate (compound 3) 
To a solution of tert-butyl acrylate 2 (135.0 g, 1.05 mol) in methanol (500 ml), 2-aminoethanol 
1 (61.0 g, 1.0 mol) was added at room temperature and stirred for 24 h at the same temperature. 
Methanol and excess tert-butyl acrylate were evaporated in vacuo and the resulting residue was 
purified by column chromatography using hexane and ethyl acetate (3:1) to yield compound 3 
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as a thick oil (151.0 g, 80%). 1H NMR (CDCl3) δ (ppm): 1.38 (s; 9H; -C(CH3)3), 2.30 (t; 2H; -
NHCH2CH2- ), 2.39-2.43 (m; 4H; –CH2NHCH2-), 3.59 (m; 2H; -CH2OH). 13C NMR (CDCl3) 
δ (ppm): 28.08, 35.46, 44.65, 50.90, 60.43, 80.73, 172.01.  
Synthesis of tert-butyl 3-((1,3-dihydroxypropan-2-yl) amino) propanoate (compound 6) 
To a solution of tert-butyl acrylate 2 (141.0 g, 1.10 mol) in ethanol (300 ml), 2-amino-1,3-
propanediol 5 (91.11 g, 1.0 mol) was added at room temperature and stirred for 4 h at the same 
temperature. Ethanol and excess tert-butyl acrylate were evaporated in vacuo and the resulting 
residue was recrystallized using hexane and ethyl acetate (3:1) to yield compound 6 as a white 
solid (201.74 g, 92%). M.p. 69 °C. 1H NMR (CDCl3) δ (ppm): 1.39 (s; 9H; -C(CH3)3), 2.30 (t; 
2H; -NHCH2CH2-), 2.47 (m; 1H; –NHCH(CH2-)2), 2.74 (t; 2H; -NHCH2CH2;), 3.25 -  3.38 
(m; 4H; -CH2OH). 13C NMR (CDCl3) δ (ppm): 28.09, 35.84, 36.41, 60.18, 62.83, 81.40, 
172.84. ESI-TOF MS m/z: [M + Na]+ - calculated 242.1367 found 242.1368. 
Synthesis of tert-butyl 3-((1, 3-dihydroxy-2-(hydroxymethyl) propan-2-yl) amino) propanoate 
(compound 9) 
To a solution of tert-butyl acrylate 2 (128.17 g, 1.0 mol) in ethanol (250 ml), Trizma 8 (60.57 
g, 0.5 mol) was added at 45 °C and stirred for 30 h at the same temperature. Ethanol and excess 
tert-butyl acrylate were evaporated in vacuo and the resulting residue was recrystallized using 
hexane and ethyl acetate (3:1) to yield compound 9 as a white solid (112.19 g, 90%). M.p. 69 
°C; Rf = 0.55 (CHCl3: MeOH; 9:1); FTIR: 3322.08, 3285.98, 2872.02, 1707.18, 1171.35, 
1020.30 cm-1.  1H NMR (CDCl3) δ (ppm): 1.46 (s; 9H; -C(CH3)3), 2.44 (t; 2H; -NHCH2CH2- ), 
2.83 (t; 2H; -NHCH2CH2;), 3.18 (bs; 3H; -OH), 3.56 (s; 6H; -CH2OH). 13C NMR (CDCl3) δ 
(ppm): 28.09, 35.84, 36.41, 60.18, 62.83, 81.40, 172.84. ESI-TOF MS m/z: [M + Na]+ - 
calculated 272.15 found 272.10. 
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2-((3-(tert-butoxy)-3-oxopropyl) amino) ethyl stearate (MSAPE) 4 (I) 
Stearic acid (14.51g, 0.051 mol) in DCM (50 ml) was added to a solution of compound 3 (9.50 
g, 0.05 mol), DCC (10.52 g, 0.051 mol) and DMAP (1.22g, 0.01 mol) in DCM (50 ml) under 
stirring. The reaction mixture was stirred at room temperature for 18 h and worked up as per 
the given general procedure II to obtain MSAPE 4 (I) as thick liquid (20.280 g, 89% yield) 
after column chromatographic purification. FTIR: 2915.37, 2847.87, 1727.59, 1642.58, 
1461.33, 1155.84 cm-1.  1H NMR (CDCl3) δ (ppm): 0.81 (t; 3H; -CH3), 1.18 (m; 28H; -CH2-), 
1.38 (s; 9H; -C(CH3)3), 1.55 (m; 2H; -CH2CH2COO-), 2.29 (t; 2H; -CH2COO-), 2.45 (t; 2H; -
NHCH2CH2-), 3.51-3.57 (m; 4H; –CH2NHCH2-), 4.12 (m; 2H; -CH2OOC-). 13C NMR (CDCl3) 
δ (ppm): 14.11, 22.69, 24.83, 25.43, 29.66, 31.93, 33.91, 34.12, 34.23, 35.18, 42.87, 44.70, 
45.06, 47.27, 61.94, 81.46, 170.21, 173.50. ESI-TOF MS m/z: [M + Na]+ - calculated 478.3872 
found 478.3870. 
2-((3-(tert-butoxy)-3-oxopropyl) amino) ethyl oleate, (MOAPE) 4 (II) 
A solution of oleic acid (14.41g, 0.051 mol) in DCM (50 ml) was added to a mixture of 
compound 3 (9.50 g, 0.05 mol), DCC (10.52g, 0.051 mol) and DMAP (1.22g, 0.01 mol) in 
DCM (50 ml) under stirring. The reaction mixture was stirred at room temperature for 18 h and 
worked up as per the general procedure II to obtain MOAPE 4 (II) as thick liquid (20.73g, 91% 
yield) after column chromatographic purification. FTIR: 2922.54, 2852.98, 1730.35, 1653.61, 
1457.99, 1151.46 cm-1.  1H NMR (CDCl3) δ (ppm): 0.81 (t; 3H; -CH3), 1.19 (m; 20H; -CH2-), 
1.36 (s; 9H; -C(CH3)3), 1.55 (m; 2H; -CH2CH2COO-), 1.98 (m; 4H; -CH2CH=CHCH2-), 2.22 
(t; 2H; -CH2COO-), 2.45 (t; 2H; -NHCH2CH2-), 3.49-3.54 (m; 4H; –CH2NHCH2-), 4.12 (m; 
2H; -CH2OOC-), 5.28 (m; 4H; -CH=CH-).  13C NMR (CDCl3) δ (ppm): 14.10, 22.68, 25.29, 
27.22, 28.05, 28.06, 29.76, 33.09, 33.98, 34.09, 34.20, 35.23, 42.71, 44.60, 44.90, 47.08, 61.73, 
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62.05, 81.36, 129.96, 129.99, 170.28, 171.48, 173.35, 173.45. ESI-TOF MS m/z: [M + Na]+ - 
calculated 476.3716 found 476.3728. 
2-((3-(tert-butoxy)-3-oxopropyl) amino) ethyl (9Z,12Z)-octadeca-9,12-dienoate, (MLAPE) 4 
(III)  
A solution of linoleic acid (12.0 g, 0.043 mol) in DCM (25 ml) was added to a mixture of 
compound 3 (7.94 g, 0.042 mol), DCC (8.83 g, 0.043 mol) and DMAP (1.22 g, 0.01 mol) in 
DCM (25 ml) under stirring. The reaction mixture was stirred at room temperature for 22 h and 
worked up as per the given general procedure II to obtain MLAPE 4 (III) as thick liquid (17.05 
g, 90% yield) after purification. FTIR: 2923.36, 2853.52, 1730.13, 1653.24, 1457.99, 1151.44 
cm-1.  1H NMR (CDCl3) δ (ppm): 0.82 (t; 3H; -CH3), 1.23 (m; 16H; -CH2-), 1.38 (s; 9H; -
C(CH3)3), 1.55 (m; 2H; -CH2CH2COO-), 1.98 (m; 4H; -CH2CH=CHCH2-), 2.25 (t; 2H; -
CH2COO-), 2.45 (t; 2H; -NHCH2CH2-), 3.49-3.54 (m; 4H; –CH2NHCH2-), 4.12 (m; 2H; -
CH2OOC-), 5.28 (m; 4H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 14.05, 22.55, 24.84, 25.28, 
27.18, 28.04, 29.09-29.75, 31.50, 31.88, 33.072, 33.12, 34.08, 35.21, 47.08, 61.71, 62.03, 
80.64.05, 81.35, 127.88, 130.18, 170.27, 171.47, 173.36, 173.43. ESI-TOF MS m/z: [M + Na]+ 
- calculated 474.3559 found 474.3557.
2-((3-(tert-butoxy)-3-oxopropyl) amino) ethyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate 
(MLLAPE) 4 (IV) 
A solution of linolenic acid (7.50 g, 0.0269 mol) in DCM (25 ml) was added to a mixture of 
compound 3 (5.0 g, 0.0264 mol), DCC (5.45 g, 0.0269 mol) and DMAP (1.22g, 0.01mol) in 
DCM (25 ml) under stirring. The reaction mixture was stirred at room temperature for 24 h and 
worked up as per the given general procedure II to obtain MLLAPE 4 (IV) as thick liquid 
(10.095 g, 85% yield) after column chromatographic purification. FTIR: 2928.52, 2856.01, 
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1727.82, 1629.20, 1457.72, 1152.66 cm-1.  1H NMR (CDCl3) δ (ppm): 0.89 (t; 3H; -CH3), 1.23 
(m; 12H; -CH2-), 1.36 (s; 9H; -C(CH3)3), 1.53 (m; 2H; -CH2CH2COO-), 1.98 (m; 4H; -
CH2CH=CHCH2-), 2.24 (t; 2H; -CH2COO-), 2.44 (t; 2H; -NHCH2CH2-), 3.49-3.53 (m; 4H; –
CH2NHCH2-), 4.10 (m; 2H; -CH2OOC-), 5.29 (m; 4H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 
14.26, 20.53, 22.55, 25.28, 25.60, 31.50, 33.08, 33.12, 33.97, 34.08, 34.19, 42.71, 44.91, 47.78, 
61.73, 62.04, 81.37, 127.09, 128.22, 130.20, 131.92, 170.28, 171.48, 173.37.  
2-((3-(tert-butoxy)-3-oxopropyl) amino) propane-1,3-diyl distearate (DSAPE) 7 (I) 
Stearic acid (13.10 g, 0.0461 mol) in DCM (50 ml) was added to a solution of compound 3 (5.0 
g, 0.0228 mol), DCC (9.50 g, 0.0461 mol) and DMAP (2.44 g, 0.02 mol) in DCM (50 ml) 
under stirring. The reaction mixture was stirred at room temperature for 22 h and worked up 
following general procedure II to obtain DSAPE 7 (I) as thick liquid (15.78g, 92% yield) after 
purification by using column chromatography. FTIR: 2914.26, 2849.09, 1732.04, 1470.43, 
1152.05 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 81 (t; 6H; -CH3), 1.19-1.23 (m; 56H; -CH2-), 1.38 
(s; 9H; -C(CH3)3), 1.55 (q; 4H; -CH2CH2COO-), 1.95 (m; 8H; -CH2CH=CHCH2-), 2.25 (t; 4H; 
-CH2COO-), 2.34 (t; 2H; -NHCH2CH2-), 2.83 (t; 2H; -NHCH2CH2-), 2.96 (m; 1H –
NHCH(CH2-)2), 4.03 (s; 4H; -CH2OOC-). 13C NMR (CDCl3) δ (ppm): 14.10, 22.67, 24.87, 
27.16, 27.21, 28.10, 29.11 - 29.76, 31.90, 34.16, 43.02, 55.38, 63.38, 80.58, 171.84, 173.57. 
ESI-TOF MS, m/z: [M + Na]+ - calculated 774.6588, found 774.6595. 
2-((3-(tert-butoxy)-3-oxopropyl) amino) propane-1,3-diyl dioleate (DOAPE) 7 (II) 
A solution of oleic acid (13.0 g, 0.0461 mol) in DCM (50 ml) was added to a solution of 
compound 3 (5.0 g, 0.0228 mol), DCC (9.50 g, 0.0461 mol) and DMAP (2.44 g, 0.02 mol) in 
DCM (50 ml) under stirring. The reaction mixture was stirred at room temperature for 22 h and 
worked up as per the given general procedure II to obtain DOAPE 7 (II) as thick liquid (15.87g, 
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93% yield) after column purification. FTIR: 2923.54, 2853.64, 1734.07, 1662.78, 1459.33, 
1367.17, 1156.55 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 81 (t; 6H; -CH3), 1.19-1.23 (m; 40H; -
CH2-), 1.38 (s; 9H; -C(CH3)3), 1.55 (q; 4H; -CH2CH2COO-), 1.95 (m; 8H; -CH2CH=CHCH2-
), 2.25 (t; 4H; -CH2COO-), 2.34 (t; 2H; -NHCH2CH2-), 2.83 (t; 2H; -NHCH2CH2-), 2.96 (m; 
1H –NHCH(CH2-)2), 4.03 (s; 4H; -CH2OOC-), 5.27 (m; 4H; -CH=CH-). 13C NMR (CDCl3) δ 
(ppm): 14.10, 22.67, 24.87, 27.16, 27.21, 28.10, 29.11 - 29.76, 31.90, 34.16, 43.02, 55.38, 
63.38, 80.58, 129.72, 129.98, 171.84, 173.57. ESI-TOF MS, m/z: [M + Na]+ - calculated 
770.6275, found 770.6281. 
2-((3-(tert-butoxy)-3-oxopropyl) amino) propane-1,3-diyl (9Z,9'Z,12Z,12'Z)-bis(octadeca-
9,12-dienoate) (DLAPE) 7 (III) 
A solution of linoleic acid (6.46g, 0.023mol) in DCM (25ml) was added to a mixture of 
compound 6 (2.5 g, 0.0114 mol), DCC (4.75g, 0.023 mol) and DMAP (1.22 g, 0.01 mol) in 
DCM (25 ml) under stirring. The reaction mass was stirred at room temperature for 24 h and 
worked up following general procedure II to obtain DLAPE 7 (III) as thick liquid (7.64 g, 90% 
yield) after column chromatographic purification. FTIR: 2925.68, 2854.28, 1735.04, 1454.93, 
1156.54 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 82 (t; 6H; -CH3), 1.23 (m; 32H; -CH2-), 1.38 (s; 
9H; -C(CH3)3), 1.55 (q; 4H; -CH2CH2COO-), 1.98 (m; 8H; -CH2CH=CHCH2-), 2.25 (t; 4H; -
CH2COO-), 2.33 (t; 2H; -NHCH2CH2-), 2.70 (t; 2H; -NHCH2CH2-), 2.83 (m; 1H –
NHCH(CH2-)2), 4.03 (s; 4H; -CH2OOC-), 5.28 (m; 8H; -CH=CH-). 13C NMR (CDCl3) δ 
(ppm): 14.10, 22.57, 24.88, 25.45, 25.62, 27.19, 28.11, 29.12 - 29.61, 31.52, 34.16, 34.92, 
36.10, 43.05, 55.36, 63.46, 80.54, 127.90, 128.04, 130.02, 130.20, 171.84, 173.59. ESI-TOF 
MS, m/z: [M + Na]+ - calculated 766.5962, found 766.5976. 
2-((3-(tert-butoxy)-3-oxopropyl) amino) propane-1,3-diyl (9Z,9'Z,12Z,12'Z,15Z,15'Z)-
bis(octadeca-9,12,15-trienoate) (DLLAPE) 7 (IV) 
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A solution of linolenic acid (6.41 g, 0.023 mol) in DCM (25 ml) was added to a mixture of 
compound 6 (2.5 g, 0.011 mol), DCC (4.75g, 0.023 mol) and DMAP (1.22 g, 0.01 mol) in 
DCM (25 ml) under stirring. The reaction mixture was stirred at room temperature for 24 h and 
worked up as per the given general procedure II to give DLLAPE 7 (IV) as thick liquid (7.26g, 
86% yield) after purification. FTIR: 2926.91, 2854.49, 1734.86, 1456.85, 1154.96 cm-1. 1H 
NMR (CDCl3) δ (ppm): 0. 90 (t; 6H; -CH3), 1.24 (m; 24H; -CH2-), 1.38 (s; 9H; -C(CH3)3), 
1.55 (q; 4H; -CH2CH2COO-), 1.98 (m; 8H; -CH2CH=CHCH2-), 2.25 (t; 4H; -CH2COO-), 2.33 
(t; 2H; -NHCH2CH2-), 2.73 (t; 2H; -NHCH2CH2-), 2.84 (m; 1H –NHCH(CH2-)2), 4.03 (s; 4H; 
-CH2OOC-), 5.29 (m; 12H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 14.27, 20.54, 22.57, 24.86,
25.52, 25.61, 27.20, 28.10, 29.11 - 29.58, 31.52, 34.15, 43.00, 55.39, 63.33, 80.64, 127.11, 
127.73, 128.24, 128.28, 130.20, 130.24, 131.94, 171.85, 173.56. ESI-TOF MS, m/z: [M + Na]+ 
- calculated 762.5649, found 762.5663.
2-((3-(tert-butoxy)-3-oxopropyl) amino)-2-((stearoyloxy)methyl) propane-1,3-diyl distearate, 
(TSAPE) 10 (I) 
A solution of stearic acid (14.37 g, 0.051 mol) in DCM (50 ml) was added to a mixture of 
compound 9 (2.0 g, 0.016 mol), DCC (10.42 g, 0.051 mol) and DMAP (2.44 g, 0.02 mol) in 
DCM (50 ml) under stirring. The reaction mixture was stirred at room temperature for 24 h and 
worked up as per the given general procedure II to obtain TSAPE 10 (I) as thick liquid (15.22 
g, 88% yield) after column chromatographic purification. M.p. 58 °C; FTIR: 2916.07, 2849.18, 
1752.83, 1718.20, 1609.02, 1468.45, 1195.72, 1154.03 - 1020.30 cm-1.   1H NMR (CDCl3) δ 
(ppm): 0. 81 (t; 9H; -CH3), 1.19 (m; 84H; -CH2-), 1.39 (s; 9H; -C(CH3)3), 1.54 (q; 6H; -
CH2CH2COO-), 2.25 (t; 6H; -CH2COO-), 2.32 (t; 2H; -NHCH2CH2-), 2.77 (t; 2H; -
NHCH2CH2-), 4.03 (s; 6H; -CH2OOC-). 13C NMR (CDCl3) δ (ppm): 14.11, 22.67, 24.90, 
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28.11, 29.16, 29.26, 29.35, 29.69, 29.70, 31.92, 34.20, 36.10, 36.76, 60.51, 63.07, 81.06, 
172.22, 173.45; ESI-TOF MS m/z: [M + Na]+  - calculated 1070.93, found 1070.79. 
2-((3-(tert-butoxy)-3-oxopropyl) amino)-2-((((Z)-octadec-9-enoyl) oxy) methyl) propane-1,3-
diyl(9Z,9'Z)-bis(octadec-9-enoate) (TOAPE) 10 (II)  
A solution of oleic acid (17.84 g, 0.063 mol) in DCM (50 ml) was added to a mixture of 
compound 9 (2.5 g, 0.021 mol), DCC (13.03 g, 0.063 mol) and DMAP (2.44 g, 0.02 mol) in 
DCM (25 ml) under stirring. The reaction mixture was stirred at room temperature for 24 h and 
general procedure II was followed for work up to obtain TOAPE 10 (II) as thick liquid (19.37 
g, 90% yield) after column chromatographic purification. FTIR: 2923.46, 2855, 1746.15, 
1662.78, 1459.29, 1379.17, 1157.32 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 81 (t; 9H; -CH3), 1.19-
1.23 (m; 60H; -CH2-), 1.37 (s; 9H; -C(CH3)3), 1.54 (q; 6H; -CH2CH2COO-), 1.93 (m; 12H; -
CH2CH=CHCH2-), 2.25 (t; 6H; -CH2COO-), 2.28 (t; 2H; -NHCH2CH2-), 2.75 (t; 2H; -NHCH2-
CH2-), 4.04 (s; 6H; -CH2OOC-), 5.27 (m; 6H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 14.11, 
22.67, 24.86, 27.18, 27.22, 28.10, 29.14 - 29.77, 31.90, 34.16, 37.71, 57.27, 63.22, 80.57, 
129.71, 129.98, 171.79, 173.26. ESI-TOF MS, m/z: [M + Na]+ - calculated 1064.88, found 
1064.76. 
2-((3-(tert-butoxy)-3-oxopropyl) amino)-2-((((9Z,12Z)-octadeca-9,12-dienoyl) oxy) methyl) 
propane-1,3-diyl (9Z,9'Z,12Z,12'Z)-bis(octadeca-9,12-dienoate) (TLAPE) 10 (III) 
Linoleic acid (7.08 g, 0.025 mol) in DCM (25 ml) was added to a mixture of compound 9 (1.0 
g, 0.008 mol), DCC (5.12 g, 0.025 mol) and DMAP (1.22 g, 0.01 mol) in DCM (25 ml) under 
stirring. The reaction mass was stirred at room temperature for 24 h and worked up as per the 
given general procedure II to obtain TLAPE 10 (III) as thick liquid (7.36g, 86% yield) after 
column chromatographic purification. FTIR: 2922.84, 2854.77, 1744.70, 1666.39, 1457.92, 
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1378.45, 1150.55 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 90 (t; 9H; -CH3), 1.31 (m; 48H; -CH2-), 
1.45 (s; 9H; -C(CH3)3), 1.62 (m; 6H; -CH2CH2COO-), 2.04 (m; 12H; -CH2CH=CHCH2-), 2.33 
(t; 6H; -CH2COO-), 2.37 (t; 2H; -NHCH2CH2-), 2.83 (t; 2H; -NHCH2-), 4.12 (s; 6H; -
CH2OOC-), 5.38 (m; 12H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 14.10, 22.57, 24.84, 25.53, 
27.19, 27.52, 28.11, 29.14 - 29.62, 31.52, 34.15, 57.27, 63.21, 80.57, 127.90, 128.04, 130.21, 
171.80, 173.27. ESI-TOF MS, m/z: [M+Na]+ - calculated 1058.84, found 1058.77. 
2-((3-(tert-butoxy)-3-oxopropyl) amino)-2-((((9Z,12Z,15Z)-octa -dec-9,12,15-trienoyl) oxy) 
methyl) propane-1,3-diyl (9Z,9'Z,12Z,12'Z,15Z, 15'Z) -bis(octadeca-9,12,15-trienoate) 
(TLLAPE) 10 (IV) 
Linolenic acid (7.03 g, 0.025 mol) in DCM (25 ml) was added to a mixture of compound 9 (1.0 
g, 0.008 mol), DCC (5.12 g, 0.025 mol) and DMAP (1.22 g, 0.01 mol) in DCM (25 ml) under 
stirring. The reaction mixture was stirred at room temperature for 24 h and worked up as per 
the given general procedure II to obtain TLLAPE 10 (IV) as thick liquid (7.15 g, 84% yield) 
after column chromatographic purification. FTIR: 2927.36, 2858.37, 1746.03, 1663.52, 
1458.04, 1388.94, 1157.18 cm-1. 1H NMR (CDCl3) δ (ppm): 0. 90 (t; 9H; -CH3), 1.23 (m; 36H; 
-CH2-), 1.37 (s; 9H; -C(CH3)3), 1.54 (m; 6H; -CH2CH2COO-), 1.99 (m; 12H; -
CH2CH=CHCH2-), 2.25 (t; 6H; (-CH2COO-), 2.29 (t; 2H; -NHCH2CH2-), 2.75 (t; 2H; -
NHCH2), 4.04 (s; 6H; -CH2OOC-), 5.29 (m; 18H; -CH=CH-). 13C NMR (CDCl3) δ (ppm): 
14.27, 22.58, 24.84, 25.60, 27.20, 28.10, 29.13, 29.33, 29.59, 31.52, 34.14, 37.69, 57.25, 63.21, 
80.55, 127.11, 127.73, 128.23, 128.27, 130.22, 131.93, 171.79, 173.25. ESI-TOF MS, m/z:  [M 
+ Na]+ - calculated 1052.79, found 1052.68.
2. In vitro cytotoxicity
Cell culture 
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Complete growth medium was prepared by supplementing EMEM cell culture media with 
streptomycin (100 mg/ml), 10 % bovine calf serum (10 %) and penicillin (100 units/ml). The 
resultant complete growth medium was used to sustain the growth of human breast 
adenocarcinoma (MCF 7), liver hepatocellular carcinoma (Hep G2), and human lung 
carcinoma (A549) cells using standard aseptic cell culture protocols. The cells were incubated 
at the following conditions (a temperature of 37 °C and humidified atmosphere of 5 % CO2).  
Solutions 
Stock solutions of the different series were prepared by dissolving in appropriate volumes of 
DMSO and purified water. These stock solutions were further diluted in the growth media to 
attain the final concentrations of 20, 40, 60, 80 and 100 µg/ml (Rambharose et al., 2015). 
MTT assay 
MCF 7, A549 and Hep G2 cells were seeded in 96 well plates at an equivalent cell density of 
4.4 x103 cells per well. Following 24 h incubation the initial culture medium was removed and 
each well was replaced with 100 µL of fresh growth medium containing the ester derivatives 
with final concentrations of 20, 40, 60, 80 and 100 µg/ml. The control consisted of cells and 
culture medium only, whilst wells containing medium only was used as the blank control. The 
treatments were incubated with the cells for 48 h. Subsequent to the 48 h incubation with the 
derivatives, the treatment mediums were removed and each well was supplemented with MTT 
reagent (100 µL of 5 mg/ml in PBS) and 100 µL of complete medium, then incubated for a 
further 4 h. Afterwards the media and MTT solution was removed and 100 µL of DMSO was 
added to each well, allowing the solubilisation the MTT formazan crystals. A microplate 
spectrophotometer (Spectrostar Nano) at a wavelength of 540 nm was used to detect the optical 
density of each well (Rambharose et al., 2015). All the cytotoxicity experiments were carried 
out with n = 6. The quantity of viable cells was calculated with the following equation: 
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% 𝐶𝐶𝑒𝑒𝐶𝐶𝐶𝐶 𝑉𝑉𝑖𝑖𝑎𝑎𝑎𝑎𝑖𝑖𝐶𝐶𝑖𝑖𝑡𝑡𝑉𝑉 =
𝐴𝐴540 𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐
𝐴𝐴540 𝑛𝑛𝑛𝑛 𝑢𝑢𝑛𝑛𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑐𝑐𝑡𝑡𝑐𝑐𝑐𝑐𝑐𝑐
 𝑥𝑥100  𝑒𝑒𝑒𝑒. (1) 
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CHAPTER 5 
EXPERIMENTAL PAPER 4 
5.1 Introduction 
This chapter addresses aim 1.4.4 and is a first authored experimental article published in 
Colloids and Surfaces B: Biointerfaces (Impact Factor = 3.902) which is an ISI 
international journal. This article reports the use of a novel linolenic acid based heterolipid, 
LLA1E (a novel transdermal permeation enhancer), as an oily phase in the development 
of a nanoemulgel for the transdermal drug delivery of tenofovir. LLA1E was selected as 
the oily phase for the formulation of the TNF nanoemulgel, as it exhibited the highest 
enhancement ratio (ER = 6.11) of all the novel FA derivatives synthesized in this PhD study. 
Mr. S. Rambharose contributed to the design of the project, modification and optimisation of 
methods as well as synthesis of the linolenic acid ester dendritic derivative (LLA1E). Mr. S. 
Rambharose also conducted the experiments for the construction of the pseudo-ternary phase 
diagrams and prepared and characterized all NE and NEG formulations in terms of mean 
globule diameter, polydispersity index, zeta potential, rheology, morphology and stability. Mr. 
S. Rambharose conducted the incorporation efficiency studies and all transdermal permeation 
experimental work including, rat skin tissue harvesting, in vitro permeation experiments, TEER 
experiments and light microscopy evaluations. Mr. S. Rambharose also wrote the paper.  Dr. 
R.S. Kalhapure assisted with the overall design of the project and the methods of preparation 
and characterisation as well as editing of the paper. Prof. T. Govender served as supervisor and 
was responsible for project conceptualisation, editing of paper and abstract and general 
supervision of the study.
Experimental paper 4 Chapter 5 
151 
5.2 Graphical abstract 
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Abstract 
Improvement in permeation enhancement strategies such as nanoemulsions (NEs) and 
nanoemulgels (NEGs) has led to a renewed interest in transdermal drug delivery (TDD). This study 
aimed to investigate the potential of LLA1E, a novel dendritic permeation enhancer, as an oily 
phase in the development of a NEG for the TDD of tenofovir (TNF). TNF loaded NEs (TNEs) 
were first prepared and analysed for mean globule diameter (MGD), polydispersity index (PDI), 
zeta potential (ZP) and morphology.  NEGs of the TNEs (TNEGs) were prepared and evaluated 
for ex vivo transdermal permeation efficacy. The skin integrity before and after experiments was 
assessed using histology and transepithelial electrical resistance (TEER).  TNEs had a MGD of 
129.06 ± 3.35 nm, PDI of 0.192 ± 0.038 and ZP of 20.9 ± 2.02 mV with an incorporation efficiency 
of 91.94 ± 0.84%. There was no significant change is these properties after incorporation of TNEs 
into hydrogel as MGD, PDI and ZP of TNEGs were found to be 136.13 ± 5.21 nm, 0.182 ± 0.020 
and -20.9 ± 2.08 mV respectively. Ex vivo permeation studies showed that the TNEG significantly 
enhanced the TNF permeation by 39.65-fold, with a cumulative amount of 1866.54 ± 108.62 
µg.cm -2.  Histological and TEER assessments showed no permanent effects on the skin by TNEG. 
Therefore, this novel TNEG nanosystem has the potential of further translation into clinical trials 
for optimal treatment alternatives for HIV/AIDs patients.  
Keywords: nanoemulsion; nanoemulgel; linolenic acid; heterolipid; transdermal permeation 
enhancer; tenofovir 
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1. Introduction
The global burden of HIV/AIDS shows a drastic increase in the spread of this disease each year,
with a large number of HIV infected patients relying mainly on the use of antiretroviral drugs to
help control the progression of this virus [1]. Although the World Health Organisation (WHO) has
recommended the use of tenofovir (TNF) as an essential medicine for the treatment of HIV [2-4],
its current oral dosing presents several undesired gastrointestinal tract (GIT) associated side effects
[5]. Therefore, strategies to formulate TNF for alternative delivery routes which can bypass the
GIT have shown promising outcomes. Various alternative routes such as vaginal, buccal, rectal
and more recently the transdermal route [6-10] have been explored for the administration of TNF.
Transdermal drug delivery (TDD) is well reported as a promising alternative route for the
administration of drugs which create GIT discomfort in patients such as diclofenac sodium,
peroxicam, ketoprofen and donepezil [11-14].
TDD systems offer numerous advantages over conventional oral drug therapy such as higher 
bioavailability, evasion of metabolic degradation pathways and avoidance of  GIT associated side 
[15]. However, a key limitation in TDD applications is the protective barrier properties of the 
stratum corneum (SC) layer of the skin [16]. TDD systems are therefore carefully designed to 
reversibly interact with and alter the barrier properties of the SC layer [16] via mechanisms such 
as reversible disruption and fluidisation which results in an increase in the dermal uptake of the 
drug. [17-19]. Fatty acids (FAs) and their esters have evolved as the most attractive class of 
chemical permeation enhancers (CPEs) for the effective transdermal delivery of drugs [20, 19, 21, 
10]. More recently scientists have developed strategies to enhance TDD through the use of 
nanomaterials, specifically lipid based nanoparticle formulations such as nano or microemulsions 
and nanoemulgels that could enhance the delivery of drugs across skin [22-26]. 
Nanoemulsions (NEs) have a size range of 20-500 nm and have been reported for the delivery of 
drugs via the transdermal route [27]. NE are composed an oil and water phase stabilized by an 
interfacial film of surfactants usually in combination with a co-surfactant [28, 29]. NEs offer 
numerous advantages such as lower formulation costs, thermodynamic stability, higher storage 
stability and the absence of organic solvents [30]. NEs have been advocated for the efficient 
delivery of drugs through the skin as the nano sized emulsion with large surface areas allows rapid 
penetration through the pores of the skin to reach the systemic circulation [28, 31]. Oil in water 
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(o/w) NEs have an oil core, with the interface stabilized by an appropriate combination of 
surfactants/co-surfactants [28, 29]. The oil phase of an o/w NE is a critically important due to its 
ability to solubilize lipophilic drug molecules and increase absorption through lipid membranes 
[31]. It has been reported that conventional transdermal formulations such as gels and emulsions 
have lower drug permeation than transdermal nanoemulsions [30, 28]. However, due to the 
inconvenience of its low viscosity, the clinical application of NE is restricted [32]. Literature 
reports that hydrogel thickened NEs serve as effective TDD systems, with improved rheological 
characteristics as well as enhanced permeability and long term stability [32]. When NEs are 
incorporated into a hydrogel matrix, it is termed nanoemulgels (NEGs). NEGs have further 
improved the transdermal applicability as they have the advantages of both NEs and gels and have 
therefore shown the ability to achieve superior permeation enhancement across the skin [33, 34]. 
Although these advantages have resulted in the recent development of NEGs for TDD of drugs 
from several classes [35-38, 34, 39, 40], there have been no reports on the investigation of TNF 
NEs or NEGs for transdermal application.  
Although the literature is replete with preliminary studies on novel materials that improve the 
permeation of drug solutions via the transdermal route [41, 42, 18, 19, 43, 17], there is limited data 
on their translation into a dosage form or delivery systems for TDD, which is essential to realise 
their pharmaceutical applications. The identification of newly reported materials that can act as 
efficient oily cores of NEs can contribute to optimizing TDD via NEG systems. In a recent report, 
we synthesized and characterized a novel series of FA ester derivatives, dendritic heterolipids, that 
functioned as effective transdermal permeation enhancers of TNF drug solution and displayed 
greater permeation enhancement efficacies when compared to their respective parent FAs [10]. 
The optimal enhancer identified in that reported series was 2% w/w LLA1E, which displayed the 
greatest promise to be incorporated into a future TDD system [10]. Its applicability in an actual 
TDD formulation for drugs, which is essential for eventual patient administration, remain to be 
explored. In this study we now propose the use of LLA1E as the oily phase in the development of 
a NE for the TDD of TNF. In addition to this study reporting for the first time, the use of this novel 
heterolipid as an excipient in a nano delivery system, it also reports for the first time a NE and 
NEG system of TNF. Therefore, the aim of the present investigation was to identify the potential 
of LLA1E as an oily phase excipient in the preparation of an efficient TNF NEG in order to provide 
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a future TDD formulation for effective management of HIV/AIDS without compromising patient 
compliance. 
2. Materials and methods
2.1 Materials
TNF was procured from Sinobright Pharmaceutical Co. Ltd., (China). Solutol HS 15®, PEG 400, 
triethylamine and hydroxypropyl methyl cellulose (HPMC) were purchased from Sigma-Aldrich 
Co. Ltd., (USA). Milli-Q water purification system (Millipore corp., USA) was used to obtain 
purified water for the preparation of formulations. The materials, methods and procedure for the 
synthesis of LLA1E are provided in the supporting information.  
2.2 Methods 
2.2.1 Construction of pseudo-ternary phase diagram 
Pseudo-ternary phase diagrams were constructed by titrating homogenous mixtures of LLA1E as 
the oily phase, Solutol HS 15® and PEG 400 as the surfactant/co-surfactant mixture (Smix) with 
water at room temperature. The phase diagrams were constructed for 1:1 (Km = 1) and 2:1 (Km = 
2) ratio of surfactant: co-surfactant. For each phase diagram mixtures of LLA1E, surfactant and
co-surfactant were prepared from weight ratios of 9:1 to 1:9. The LLA1E and Smix mixtures were
titrated drop-wise with water under vortex. After equilibration for 30 min at the room temperature,
the systems were visually characterized. Single-phase, transparent mixtures were chosen as
nanoemulsions with no attempts to completely identify the other regions of the phase diagram.
Based on the findings of the phase diagrams, appropriate quantities of LLA1E and Smix was
selected and used for the preparation of NEs [44].
2.2.2 Formulation of NEs 
NEs were prepared by an ultra-sonication method [45]. In short, the oily phase (LLA1E) and the 
Smix were mixed, the required quantity of milli-Q water was added and sonicated [probeOmni 
Sonic Ruptor 400 Ultrasonic Homogenizer (Kennesaw, USA)] at 30% amplitude for 10 min (20 
°C) to form the blank NE. The emulsification was conducted in a temperature controlled ice bath 
to regulate the heat generated in this high energy process. The drug loaded NE was prepared 
following the above mentioned method, with the exception of the addition of 0.25% TNF to the 
Experimental paper 4 Chapter 5 
157 
oily phase prior to mixing with the Smix. No phase change was noted after addition of the drug or 
after equilibration. 
2.2.3 Incorporation efficiency 
The TNEs were centrifuged at 4500 rpm and 4 °C for 40 min using a Hermle Z326k centrifuge 
(Germany) in order to separate the un-incorporated drug. The supernatant was analyzed at a λmax 
of 262 nm using UV Spectrophotometer 1650 (Shimadzu, Japan) to determine the amount of un-
incorporated drug (W1) from total amount of drug used (W2). Total drug content was estimated by 
dissolving the lipid emulsion in methanol. The percentage incorporation efficiency (% IE) was 
calculated using the following equation [46]: 
% 𝐼𝐼𝐼𝐼 =
W2 −𝑊𝑊1
𝑊𝑊2
 𝑋𝑋 100 
2.2.4 Formulation of TNF nanoemulgel (TNEG) 
To prepare the TNEG, 400mg (4% w/w) HPMC was added to the prepared TNF loaded NE under 
magnetic stirring for 24 h. The pH was adjusted to 7.4 using triethylamine. The physico-chemical 
characterization of the TNF NE and the TNEG was characterized as follows: 
2.2.5 Characterization of TNF NE (TNE) and TNEG 
The TNE and TNEG were characterized for mean globule diameter (MGD), polydispersity index 
(PDI) and zeta potential (ZP) using a Zetasizer Nano ZS90 (Malvern Instruments Ltd., 
Worcestershire, UK) after suitably diluting with milli-Q water.  All measurements were performed 
in triplicate at 25 °C.  
2.2.6 Rheology 
A MCR 302 Rheometer® (Anton Parr, Graz, Austria) with a parallel plate (PP50) applying the 
shear rate in a linear manner from 0 to 100 s-1 at 25 °C was used to measure the viscosity of the 
prepared TNE and TNEG. The apparent viscosity was calculated at a shear rate 100 s-1. n = 3 [45]. 
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2.2.7 Morphology 
Surface morphology of TNE was evaluated using a transmission electron microscope (TEM) (Jeol, 
JEM-1010, Tokyo, Japan). TEM images were obtained by diluting a drop of TNE and positioned 
on 3 mM forman coated copper grid and allowed to dry, it was subsequently stained with 1% w/v 
phosphotungstic acid and captured. 
2.2.8 Ex vivo transdermal permeation studies 
Ethical clearance was obtained from the University of KwaZulu-Natal (UKZN) Animal Research 
Ethics Committee in 2014 (AREC/054/14/Animal), and renewed (AREC/015/15/Animal). Wistar 
rats (Male) were acquired from the Biomedical Resource Unit (BRU), (UKZN).  The experimental 
animals received water and food ad libitum and were maintained under controlled light, 
temperature and humidity in the animal housing facility at the BRU of UKZN. The euthanized 
animals were shaved and the abdominal skin was removed with surgical scissors. The skin was 
stored (-20 ˚C) and utilised within three months [12, 10].  
Ex vivo permeation studies were conducted using vertical Franz diffusion cells (PermeGear, Inc., 
Bethlehem, USA) at 37 ± 1 oC [47, 10]. Prior to the experiments, skin samples were defrosted in 
PBS (pH 7.4) at room temperature.  The receptor compartment was filled with PBS of pH 7.4 (25 
ml) andthe skin was mounted on Franz diffusion cells with the SC facing the donor compartment.
The skin samples were equilibrated with PBS (pH 7.4) at 37 °C for 30 minutes before conducting
the permeation experiments.
 The TNF gel or the TNEG (2 ml) was applied on the SC and receptor compartment was stirred 
with a teflon-coated magnetic stirrer bar at 37 oC. The receptor compartment was sampled and 
replenished with equal volumes of fresh PBS at predetermined intervals during the 6 h permeation 
study. The drug was quantified at a λmax of 262 nm using UV Spectrophotometer 1650 (Shimadzu, 
Japan). The experiments were performed with a minimum of n = 6 [48, 10]. The gel prepared using 
only TNF and HPMC served as a control.  
The cumulative amount of TNF permeated per unit surface area was plotted against time. Linear 
regression analysis was used to determine the steady state flux (Jss) from the linear part of the 
permeability curve (Microsoft Excel 2010, USA). The permeability coefficient (P) was calculated 
as follows [10, 49]: 
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P = (dQ/dT)/A x Cd = Jss/Cd      
Where dQ/dt is the cumulative amount permeated per unit time, A is the diffusion area and Cd is 
the drug concentration in the donor compartment. The enhancement ratio (ER) was calculated 
using the following equation [10]: 
ER = P of the drug in the presence of enhancer/P of the drug in the absence of enhancer 
2.2.9 Transepithelial electrical resistance (TEER) studies  
A millicell ERS meter (Millipore USA) connected to a pair of chopstick electrodes (STX01) was 
used to measure changes in the integrity of skin during the permeation study. The TEER recordings 
before the addition of the formulation served as the original integrity values. TEER recordings at 
the end of the 6 h permeation would establish if the values changed from the original measured 
skin integrity during the permeation study. Two hours after removal of the formulation, further 
TEER measurements were taken to determine whether there was any rebound by the skin’s barrier 
properties [50, 10]. 
2.2.10 Histological evaluation 
Control and treated skin samples were assessed histologically to assess any tissue damage or 
morphological changes due to exposure to the formulations. Freshly excised skin was fixed in 10% 
buffered formalin and served as the control. The treated skin (TNF gel or TNEG) were removed 
from the Franz diffusion cells and fixed in 10% buffered formalin directly after the 6 h permeation 
study. After 7 days, skin samples were removed from the fixative and dehydrated in a 50 to 96% 
ethanol gradient. The samples were then embedded in paraffin wax and sectioned using a 
microtome (Leica RM2235, Leica Biosystems Germany). The skin sections were collected on 
slides, dried and stained with hematoxylin and eosin (H&E) for light microscopy (LM) 
evaluations. Sections were examined with Leica slide scanner (SCN 400, Leica Biosystems 
Germany). All experiments were performed in triplicate [50, 49, 51, 10]. 
2.2.11 Stability 
The stability of the TNEG was evaluated at room temperature (RT) and at 4 °C over a period of 3 
months. Physical appearance, MGD, PDI and ZP were used as assessment parameters for stability. 
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2.2.12 Statistical Analysis 
The results are expressed as mean ± standard deviation (SD). Data was statistically analysed using 
GraphPad Prism® (Graph Pad Software Inc., Version 5., USA) by either one-way analysis of 
variance (ANOVA) followed by the non-parametric Kruskal-Wallis test or Dunn’s multiple 
comparison test or t tests were performed followed by the non-parametric Mann-Whitney test. A 
p value of less than 0.05 was considered statistically significant. 
3. Results and Discussion
3.1 Pseudo-ternary phase diagrams
Fig. 1 Pseudoternary phase diagrams depicting the area of nanoemulsion existence. (a) Km = 1, (b) 
Km = 2. Oily phase = LLA1E, surfactant = Solutol HS 15®, co-surfactant = PEG 400, aqueous 
phase = milli-Q water. 
Solutol HS 15® was chosen as a surfactant due its physiological compatibility and ability to 
decrease globule size of o/w NEs [52, 44]. PEG 400 was selected as a co-surfactant considering 
its low toxicity, miscibility with aqueous fluids at all concentrations and ability to dissolve several 
poorly aqueous soluble compounds [53]. In order to determine the nanoemulsion regions pseudo-
ternary phase diagrams were constructed [44]. The shaded area of the graph represents the area of 
nanoemulsion existence (Fig. 1). The results showed that the 1:1 (Km = 1) Smix displayed a larger 
region of nanoemulsion existence as compared to the 2:1 (Km = 2) Smix. This demonstrated that 
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Solutol HS 15®/PEG 400 at 1:1 ratio was able to nanoemulsify LLA1E to a greater extent and was 
therefore selected for use in the NE formulation.  
3.2 Formulation of NEs 
In the previous report on LLA1E’s transdermal permeation enhancement abilities, a concentration 
effect study revealed that LLA1E at a concentration of 2% w/w displayed the highest ER of TNF 
[10]. It was hypothesized that the incorporation of LLA1E at the same concentration would ensure 
that besides functioning as an oily phase of the NE it may also function as an effective transdermal 
permeation enhancer. Therefore, to maintain the ideal concentration of LLA1E (2% w/w) in the 
nano formulation, NEs were prepared with 2% w/w LLA1E as the oily phase. In order to establish 
the optimal concentration of Smix (Km = 1) to form NEs with low MGD, PDI and sufficient stearic 
stability different concentrations of Smix with 2 % w/w LLA1E were screened (Table 1).  
Table 1. MGD, PDI and ZP achieved using different ratios of LLA1E: Smix 
LLA1E:Smix (Km = 1) MGD (nm) PDI ZP (mV) 
1:1 131.5 ± 2.00 0.237 ± 0.02 -8.43 ± 0.52
1:2 116.5 ± 0.47 0.158 ± 0.009 -7.49 ± 1.59
1:3 106.83 ± 1.56 0.335 ± 0.029 -1.33 ± 0.16
The results displayed that all the ratios of LLA1E: Smix (Km = 1) formed NEs after sonication for 
10 min at 30% amplitude (Table 1). The results showed that as the concentration of Smix (Km = 1) 
was increased there was a decrease in the MGD and an increase in the ZP (Table 1). Although the 
NEs at 1:3 ratio had a lower MGD, its PDI was more than 2-fold higher than the NEs at 1:2 ratio 
(Table 1). Therefore, NEs with 1:2 LLA1E to Smix (Km = 1) ratio which exhibited MGD close to 
the 100 nm range, with a good PDI and acceptable ZP (Table 1) were used in further studies [31]. 
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Table 2. MGD, PDI and ZP of the prepared nano formulations (n = 3). *Indicates statistically 
significant difference i.e. p < 0.05 (compared to blank NE). 
Formulation MGD (nm) PDI ZP (mV) 
Blank NE 116.5 ± 0.47 0.158 ± 0.009 -7.49 ± 1.59
TNE 129.06 ± 3.35 0.192 ± 0.038 *20.9 ± 2.02
TNEG 136.13 ± 5.21 0.182 ± 0.020 -20.9 ± 2.08
After studying effect of drug loading on the characteristics of NEs, 0.25% w/w TNF was selected 
as an optimum concentration. The addition of 0.25% w/w TNF to the NE formulation resulted in 
a slight increase in the MGD and PDI whereas ZP value changed significantly (Table 2). The 
change in ZP could be attributed to un-entrapped TNF which bears 4-herocyclic and one primary 
nitrogen in its structure. The results indicated that the increase in MGD after the addition of 0.25% 
w/w TNF was not statistically significant (p > 0.05) (Table 2). The TNF loaded particle size 
(MGD) obtained in this study is similar to or better than particle sizes achieved by other studies 
that incorporated TNF in liposomes and polymeric nanoparticles respectively [54, 55]. The % IE 
of TNF in the TNE was calculated at 91.94 ± 0.84 % which is similar to other reports for % IE in 
NEs, as well as for the % IE of TNF in other nano formulations [54, 56, 57]. The ability of LLA1E 
to form NEs with good MGD, PDI and acceptable ZP in combination with the high drug loading 
of this o/w NE system is evidence of its potential to function as an effective oily phase. The 
characteristics of the formulated TNEs in this study are within the range of literature reported NEs 
for TDD of several classes of drugs [58, 57, 59, 60]. In order to thicken the TNE formulation to 
allow ease of topical application for transdermal permeation studies, the TNE formulation was 
converted into a hydrogel. The addition of 4% w/w HPMC to the TNE resulted in the formation 
of a hydrogel (TNEG) that contained TNE with a MGD of 136.13 ± 5.21 nm (Table 2). The shift 
in ZP value from positive to negative in TNEG could be attributed to the addition of HPMC to 
form the TNEG. 
3.3 Rheology 
Both the TNE and the TNEG exhibited Newtonian flow characteristics as the viscosity of the TNE 
and the TNEG remained constant with an increase in the rate of shear. The viscosity of the TNE 
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and the TNEG was calculated at 1.24 ± 0.01 and 147.67 ± 32.64 respectively, at the shear rate 100 
s-1. This shows that there was a 119-fold increase in the viscosity when TNE was converted to
TNEG. The viscosity of the TNEG achieved in this study is suitable for a hydrogel thickened NEs
intended for transdermal application [32].
3.4 Morphology 
TEM images revealed that the TNE droplets were spherical in shape with MGD in the range of 
86.51 to 137.83 nm (Fig. 2). The size range of TNE globules obtained by TEM analysis correlate 
with the MGD obtained using a dynamic light scattering with the zetasizer. 
Fig. 2 TEM images of the optimized TNEs. A – Population of lipid globules; B – individual 
globule measuring 131.55 nm 
3.5 Ex vivo permeation 
Table 3. TNEG permeability parameters across rat skin. *Indicates statistically significant 
difference i.e. p < 0.05 [compared to TNF gel (control)]. 
Treatment Amount permeated 
(µg.cm -2) 
Jss (flux) 
(µg.cm -2.h-1) 
Permeability 
(Px10-2) 
ER 
TNF gel (Control) 50.88 ± 7.18 8.41 ± 1.17 0.336 ± 0.04 1 
TNEG 1866.54 ± 108.62 *333.49 ± 18.25 13.33 ± 0.73 39.65 
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The ex vivo permeation studies revealed that the control gel was able to permeate TNF through the 
skin. TNF from control gel permeated the skin with a cumulative amount of 50.88 ± 7.18 µg/cm2
and steady state flux of 8.41 ± 1.17 µg/cm2 h (Table 3). The reported IC50 value for TNF is between 
0.55–2.2 µM (158–632 µg) [61, 10]. Therefore, the quantity of TNF permeated from TNF control 
gel was significantly lower than the required therapeutic dose of TNF.  Comparatively, the TNEG 
was able to significantly (p < 0.05) enhance the permeability of TNF by 39.65-fold and deliver 
therapeutically relevant doses of TNF via the skin (Table 3). The TNEG displayed a permeated 
cumulative amount of 1866.54 ± 108.62 µg/cm2 and steady state flux of 333.49 ± 18.25 µg/cm2 h 
(Table 3). These permeation enhancement values are significantly higher than that achieved by 2% 
w/w LLA1E in the previous report [10]. In that study 2% LLA1E was able to achieve a cumulative 
amount of 1214.88 ± 87.33 µg/cm2 and steady state flux of 192.37 ± 17.58 µg/cm2 h with an ER 
of 6.11 [10]. Interestingly, the loading dose of TNF in that study was 2% w/w; however, in the 
present report TNF loading was 0.25% w/w which signifies an 8-fold lower TNF loading dose in 
the current study. These findings therefore display the superiority of the 0.25 % TNEG as it was 
able to achieve a significantly higher cumulative amount than the LLA1E TNF gel, however at a 
considerably lower loading dose. The use of NEs is proposed as a promising strategy for enhancing 
TDD without the use of CPEs, as the constituents such as the oily phase of the NEs can act as 
permeation enhancers themselves [39, 62].  Therefore, in addition to the permeation enhancement 
advantages that are characteristic of the NEG, the use of the reported superior transdermal 
permeation enhancer LLA1E as the oily phase could have added to the significantly higher ER 
obtained by the TNEG.  
3.6 TEER 
A change in the skin’s integrity after exposure to the TNEG can be determined using TEER studies. 
The changes in the TEER recordings are suggestive of associated changes in the barrier properties 
of the skin [10]. In order to assess the influence of drug formulations on the skins integrity TEER 
measurements are recorded prior to, and after permeation experiments. The differences in these 
recorded values enable the quantification of the change in skin integrity after exposure to the drug 
formulation [10, 47, 63]. A reduction in the TEER values can be correlated to a decline in the 
barrier properties of the skin [10].   
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Fig. 3 TEER measurements (%) recorded after permeation studies with either TNF gel or TNEG 
(n = 6). 
TEER recordings confirmed that the integrities of skin samples used in both experiments (TNF gel 
and TNEG) were similar in terms of their 0 h TEER measurements. The skin intended for use in 
the TNF gel and TNEG studies presented a 0 h recording of 444.00 ± 46.18 Ω /cm2 and 423.33 ± 
35.50 Ω /cm2 respectively (Fig. 3). These 0 h values were used as the 100% TEER values for the 
respective experiments and were compared to the 6 h TEER recordings measured at the end of the 
permeation experiment to establish the change brought on by the drug formulation. The 2 h post 
permeation TEER measurements were also compared to the 0 h recordings to determine if there 
was any return towards the original recorded skin integrity. The TEER values recorded at the end 
of the permeation studies for the TNF gel and TNEG were 433.67 ± 47.72 Ω /cm2 and 381.67 ± 
34.56 Ω /cm2 respectively (Fig. 3). This signified a 2.32% and 9.84 % decrease in the original 
measured (0 h) TEER values of the TNF gel and TNEG skin samples respectively (Fig. 3) after 6 
h. Comparatively, 2% w/w LLA1E in the previous report was able to reduce the TEER values by
8.3 % when it was incorporated in a gel for transdermal delivery of TNF [10]. The assessments in
the present study showed that the TNEG decreases the skins integrity 4.24-fold more than the TNF
gel. The present study revealed that 2% w/w LLA1E incorporated as the oily phase in the TNEG
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displays a greater decrease in the skins integrity. These findings correlate with the ex vivo 
transdermal permeation studies, which showed that the TNEG is able to achieve a significantly 
higher permeation of TNF compared to the TNF gel (Table 3). Interestingly, 2 h after the removal 
of the drug formulations there was increase in the TEER recordings from both experiments (Fig. 
3). The 2 h post permeation TEER value of the TNF gel and TNEG were recorded as 435.33 ± 
47.88 Ω /cm2 and 397.67 ± 45.08 Ω /cm2 respectively. When compared to the differences between 
the 0 h and 6 h TEER measurements, the 2 h post permeation TEER values showed a 16.12 % and 
38.4 % recovery in the resistance values of the skin after removal of the TNF gel and TNEG 
respectively (Fig. 3). This indicates a return towards the original measured resistance of the skin 
(Fig. 3). These observations show that both drug formulations have reversible effects on the 
integrity of the skin, which is one of the key attributes of ideal permeation enhancers.  
3.7 Histology 
Histomorphological investigations allow for the assessment of morphological changes due to the 
exposure of the skin to the drug formulations. Observations made in the individual epithelial layers 
would enable evaluations of any harmful effects of the drug formulations on the treated skin 
samples. Histomorphological evaluation of the SC in particular would provide valuable 
information in determining the drug formulation’s ability to decrease the integrity of the epidermis, 
as this layer provides the major barrier to the movement of drugs across the epithelium of skin [64, 
19, 17].  
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Fig. 4 LM images of H&E stained samples of the control and the treated skin; (A) untreated skin 
(control), (B) samples exposed to TNF gel, (C) skin exposed to TNEG (D: dermis; E: epidermis; 
SC: stratum corneum). 
The control skin sample (Fig. 4A) displayed normal thin skin morphology which is characteristic 
of skin from this region [64] and clearly showed complete and undamaged SC. The skin treated 
with TNF gel (Fig. 4B) showed histomorphological similarities to that of the control skin (Fig. 
4A) as the SC layer in the TNF gel treated skin (Fig. 4B) also appeared intact and the underlying 
layers of the epidermis didn’t present any observable signs of morphological changes. The TNEG 
treated sample (Fig 4C) displayed clearly evident changes in the appearance and the morphology 
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of the SC layer. The TNEG treatment showed an increase in the thickness of the SC layer which 
could be a result of the disruption/fluidisation of lipids found in this layer (Fig. 7C). This 
disruption/fluidisation causes the SC to appear loosely packed [65] and therefore appears thicker 
than the SC layer of the control skin (Fig. 4A). There were large intercellular spaces in SC layer 
of the TNEG treated samples (Fig. 4C). The disruption/fluidisation caused by the exposure of the 
TNEG in the SC layer would lead to a consequent decline in the barrier function presented by 
normal skin, which would encourage the transport of drugs across the epidermis into the dermal 
layers of the skin. The histomorphological observations made in the TNEG treated skin correlate 
directly with the findings of the ex vivo permeation study which displayed a significantly higher 
permeation of TNF from the TNEG (Table 3). While there were significant morphological changes 
in the SC of the TNEG treated skin (Fig. 4C), the underlying epidermal layers showed no signs of 
damage or change from the normal morphology of the control image (Fig 4A). The regenerative 
basal layer of the TNEG treated samples (Fig. 4C) appeared normal and unharmed by the drug 
formulation. This study indicated that the TNEG exposure would only have temporary effects on 
the epidermal layer of the skin.      
3.8 Stability 
The stability of the TNEG was assessed over a 90-day period at room temperature and 4 °C. 
Student t-tests, followed by Mann-Whitney tests revealed that over the 90-day period there were 
no statistically significant changes in the characteristics (MGD, PDI and ZP) of the NE at both the 
storage conditions as compared to their respective controls (Table 4). The TNEGs showed no signs 
of phase separation for the duration of the stability studies.  
Table 4. Effect of storage conditions and time on MGD, PDI and ZP of TNEG (n=3). 
Time 
(Days) 
MGD (nm) PDI ZP 
4º C R.T 4º C R.T 4º C R.T
0 136.13 ± 
5.21 
136.13 ± 
5.21 
0.182 ± 
0.02 
0.182 ± 
0.02 
-20.9 ±
2.08
-20.9 ±
2.08
30 141.60 ± 
3.48 
148.93 ± 
6.01 
0.210 ± 
0.015 
0.221 ± 
0.013 
-23.53 ±
2.68
-25.7 ±
0.50
60 145.30 ± 
2.45 
155.03 ± 
2.77 
0.222 ± 
0.022 
0.231 ± 
0.016 
-24.77 ±
1.36
-26.77 ±
0.42
90 146.67 ± 
2.61 
161.53 ± 
2.31 
0.241 ± 
0.041 
0.242 ± 
0.014 
-24.97 ±
2.44
-27.67 ±
1.66
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3.9 Conclusions 
Transdermal drug delivery is hampered by the barrier properties of the skin. Innovative strategies 
are required to optimize the applicability of this route and increase the range of drugs that can be 
effectively delivered through the skin.  In this study, LLA1E which is a recently reported novel 
transdermal permeation enhancer was successfully employed as an oily phase excipient, in the 
formulation of TNEGs.  The formulated TNEG with a low drug loading of 0.25% w/w displayed 
high incorporation efficiency and superior ex vivo transdermal permeation enhancement of TNF. 
This is the first study to report the formulation of a TNF NE and NEG system, as well as to 
successfully deliver therapeutically relevant amounts of TNF via the transdermal route using a 
nano drug delivery system. The TEER and histological studies revealed that the effects of the 
TNEG on the skin were temporary. It can therefore be concluded that LLA1E is a promising oily 
phase excipient in the formulation development of lipid based transdermal nano formulations and 
the proposed TNEG in this paper has the potential to revolutionize HIV/AIDS treatment. 
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Materials and Method for the synthesis of LLA1E 
Materials 
Linolenic Acid, N-(3-dimethylaminopropyl) - N-ethylcarbodiimide hydrochloride (EDAC.HCl) 
and p-dimethylaminopyridine (DMAP) was obtained from Sigma (St. Louis, MO). 3-Amino-1-
propanol and tert-butyl acrylate were purchased from Alfa-Aesar (Karlsruhe, Germany). Acetyl 
chloride (AcCl) and dichloromethane (DCM) were from Merck Chemicals (Hohenbrunn, 
Germany). Merck precoated Silica-gel 60F254 plates were used for thin layer chromatography was 
purchased from Sigma-Aldrich (Steinheim, Germany). All other reagents and solvents used were 
of analytical grade and were procured from Merck Chemicals. 
Method 
Synthesis of dendritic ester of linolenic acid (LLA) (Scheme 1) 
To a stirred mixture of dendron 1 (1.2 equiv.), synthesized using a previously reported method [1] 
and DMAP (0.75 equiv.) in DCM was added EDAC.HCl (1.5 equiv.) followed by LLA (1 equiv.). 
The resulting reaction mixture was magnetically stirred at room temperature for a 48 h period. The 
organic layer was washed with brine solution and concentrated in vacuo. The crude product 
obtained was purified by column chromatography (silica gel # 60–100 mesh, hexane/EtOAc; 9: 1) 
[2]. 
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CHAPTER 6  
CONCLUSION 
6.1 General conclusions 
Due to its increasing prevalence, HIV and AIDS is one of the most serious public health diseases 
worldwide. Although TNF is considered the most successful ARV to treat and prevent HIV and 
AIDS, its current oral administration has numerous limitations which negatively impact on the 
effective treatment/management of the disease. The current HIV and AIDS crisis coupled with 
limitations of oral TNF therapy therefore drive the need for identifying innovative drug delivery 
approaches. Drug delivery scientists have thus explored the use of novel drug delivery systems 
and alternate routes of drug administration for TNF. Although TDD offers an attractive 
alternative for the systemic delivery of drugs, this route has not been explored for the delivery of 
TNF. Despite the advantages of TDD, the barrier properties of the skin limit the applicability of 
this route. The use of FAs as transdermal CPEs has been advocated to efficiently decrease the 
barrier properties of the skin. FA esters have shown greater promise as transdermal permeation 
enhancers than their respective parent material. Therefore, the modification of existing FA CPEs 
to produce novel FA derivatives that display superior performance is highly desirable. Another 
strategy that has emerged as an effective means of promoting TDD is the use of biocompatible 
nanomaterials. NEGs have unique characteristics that promote enhanced drug permeation via the 
transdermal route and have therefore been used for the TDD of various classes of drugs. 
However, to date there is no report on the formulation of NEG for transdermal delivery of TNF.   
The broad aim of this study was to explore the potential of lipid-based strategies for enhancing 
transdermal permeation of TNF. The specific research aims of this study were therefore: (1) to 
synthesize and characterize novel biocompatible dendritic ester derivatives of UFAs and explore 
their potential as promising permeation enhancers for the transdermal delivery of TNF. (2) To 
evaluate the novel application of UFA esters of cholesterol as promising transdermal permeation 
enhancers using TNF as a model drug. (3) To synthesize and characterize novel biocompatible 
mono, di and tri-ester derivatives of FAs and explore their potential as promising transdermal 
permeation enhancers using TNF as a model drug. (4) To explore the potential of novel linolenic 
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acid based heterolipid, LLA1E (a novel transdermal permeation enhancer), as an oily phase in 
the development of a nanoemulgel for the transdermal drug delivery of TNF. 
In order to achieve aim 1, the objectives were to: 
i) Synthesize novel ester dendritic derivatives of palmitoleic (PA), linoleic (LA), linolenic
(LLA) and arachidonic acid (AA) and characterize the derivatives using FTIR, NMR (1H
and 13C) and HRMS techniques.
ii) Determine the lipophilicity and pH responsiveness as well as the in vitro biosafety of the
novel ester derivatives.
iii) Explore the in vitro potential of the novel UFA ester derivatives as transdermal
permeation enhancers for TNF and assess the effects of the enhancer treatment on the
skin using transepithelial electrical resistance as well as light and transmission electron
microscopy.
To achieve aim 2, the objectives were to: 
i) Synthesize cholesterol ester derivatives of oleic (OA), linoleic (LA), linolenic (LLA),
Lauric (LuA), Palmitic (PA) and stearic acid (SA) and characterize the derivatives using
FTIR, NMR (1H and 13C) techniques as well as determining their lipophilicity.
ii) Explore the in vitro potential of the cholesterol ester derivatives as transdermal
permeation enhancers for TNF and assess the effects of the enhancer treatment on the
skin using transepithelial electrical resistance and light microscopy.
To achieve aim 3, the objectives were to: 
i) Synthesize novel mono, di and tri-ester derivatives of FAs bearing β-alanine t-butyl ester
head group using oleic (OA), linoleic (LA), linolenic (LLA) and stearic acid (SA) and
characterize the derivatives using FTIR, NMR (1H and 13C) and HRMS techniques.
ii) Determine the lipophilicity and the in vitro biosafety of the novel ester derivatives.
iii) Explore the in vitro potential of the novel ester derivatives as transdermal permeation
enhancers for TNF and assess the effects of the enhancer treatment on the skin using
transepithelial electrical resistance and light microscopy.
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To achieve aim 4, the objectives were to: 
i) To determine the optimal ratio of surfactant and co-surfactant (Smix) to oil (LLA1E) by
constructing pseudo-ternary phase diagrams.
ii) Evaluate the TNF NE and TNF NEG in terms of mean globule diameter, polydispersity
index, zeta potential, viscosity, morphology and stability.
iii) Explore the ex vivo potential of the novel TNF nanoemulgel to enhance the transdermal
delivery of TNF and assess the effects of the nano formulation on the skin using
transepithelial electrical resistance and light microscopy.
The main conclusions generated from the research data are summarised below: 
1. Aim 1:
• Novel ester dendritic derivatives of palmitoleic (PA), linoleic (LA), linolenic (LLA) and
arachidonic acid (AA) were successfully synthesized and their physical characteristics
were confirmed using FTIR, NMR (1H and 13C) and HRMS techniques.
• All the derivatives synthesized in this study had a higher lipophilicity as compared to
their respective parent UFA. This is a desirable property as the greater the lipophilic
nature of an enhancer, the greater the permeability across the skin. The MTT assay results
showed that none of the synthesized UFA ester dendritic derivatives were toxic against
the HeLa cell line. The percentage cell viability between 85 to 95% for all derivatives
across the concentration ranges studied with no dose dependent trends observed. These
findings therefore suggest that the use of the synthesized UFA ester dendritic derivatives
in biological studies would be safe. Further, all the synthesized UFA ester dendritic
derivatives consist of tertiary nitrogen in their structure and their potential to show pH
dependency were proven experimentally. This pH dependent property may attract
attention, especially in pH based drug targeting.  It therefore contributes to widening the
pool of novel biocompatible excipients for drug delivery applications in addition to their
use as transdermal chemical permeation enhancers.
• All synthesized UFA ester dendritic derivatives at 1% w/w were found to be more
effective enhancers as compared to their parent UFAs, with LLA1E being identified as
the most superior (ER = 5.31). Further, the concentration effect study revealed that at 2%
w/w LLA1E had a greater ER (6.11) as compared to its parent (ER = 3.85). The
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permeability data correlated with the observations made in the histomorphological and 
TEER evaluations. Histomorphological evaluations suggested that TNF used the 
transcellular and intercellular route of transport across the epidermis. There was no 
significant loss in the integrity of the epidermis with drug and enhancer treatment having 
no permanent damage on the epidermis. The novel dendritic ester derivatives of the 
UFAs therefore can be considered as effective transdermal permeation enhancers. 
2. Aim 2:
• Cholesterol ester derivatives of oleic (OA), linoleic (LA), linolenic (LLA), Lauric (LuA),
Palmitic (PA) and stearic acid (SA) were successfully synthesized and their physical
characteristics were confirmed using FTIR, NMR (1H and 13C) techniques. All the
cholesterol ester derivatives synthesized in this study had a higher lipophilicity as
compared to their respective parent FA. The greater the lipophilic nature of the
derivatives suggests their ability to encourage greater permeability across the skin.
• All cholesterol UFA esters at 1% w/w were found to be more effective enhancers when
compared to their respective parent FAs and saturated FA counterparts. Cholesteryl
linolenate (Chol-LLA) showed the most superior performance (ER = 3.71). Attributes
such as increased lipophilicity, optimal carbon chain length and the optimum number of
double bonds favor Chol-LLA as the superior permeation enhancer. Additionally, the
concentration dependent study showed that the greatest ER for Chol-LLA (5.93) was
achieved at a concentration of 2% w/w. The histomorphological and TEER evaluations
supported the results of the permeability studies. The histomorphological studies revealed
that the disruption and fluidization of lipids in the SC was responsible for the
permeability enhancement of TNF by Chol-LLA (2% w/w). These findings showed no
significant loss in the integrity of the epidermis, with drug and enhancer treatment having
temporary effects on the barrier property of the epidermis. Cholesterol UFA esters can
therefore be considered as new CPEs for exploitation in topical formulations for various
classes of drugs.
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3. Aim 3:
• Novel mono, di and tri-ester derivatives of FAs bearing β-alanine t-butyl ester head group
using oleic (OA), linoleic (LA), linolenic (LLA) and stearic acid (SA) were successfully
synthesized and their physical characteristics were confirmed using FTIR, NMR (1H and
13C) and HRMS techniques.
• All the derivatives synthesized in this study had a higher lipophilicity as compared to
their respective parent FA and the lipophilicity increased as the number of FA chains
increased. The MTT assay findings displayed non-toxicity for all of the synthesized
derivatives against MCF-7, Hep G2 and A549 cell lines. The percentage cell viability
was between 76.55 to 92.17 % for all derivatives across the concentration ranges studied
with no dose dependent trends observed.
• The results showed that all the novel ester derivatives were able to enhance the
permeability of TNF at a concentration of 1% w/w; however, there was no direct
correlation between FA chain number and the permeation enhancement efficacy of the
derivatives. The results revealed that all the FA esters displayed greater permeation
enhancement activity as compared to their parent FAs. These findings confirm the
superiority of these novel ester derivatives as compared to their respective parent
material. The UFAs and their respective derivatives in this study showed a greater
increase in ER when compared to the SFA (SA) and its derivatives. A concentration
affect study on the optimal enhancer from each series revealed that MOAPE at 1% w/w
from the mono ester derivative series achieved the highest permeation enhancement of
TNF with an ER of 5.87. MOAPE displayed superior permeation enhancement at all
concentrations when compared to OA its parent lipid. Further histomorphological and
TEER investigations displayed that 1% w/w MOAPE caused no adverse effects to the
skin and the skin’s integrity, and that the effects of the enhancer treatment were
temporary. These findings show that the reported novel FA esters showing promise as
effective permeation enhancers and the novel mono ester derivative of OA (MOAPE)
adds to the pool of CPEs available to formulation scientists and can be safely
incorporated into TDD systems for several classes of drugs.
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4. Aim 4:
• The results showed that the 1:1 (Km = 1) Smix displayed a larger region of nanoemulsion
existence as compared to the 2:1 (Km = 2) Smix. This demonstrated that Solutol HS
15®/PEG 400 at 1:1 ratio was able to nanoemulsify LLA1E to a greater extent and was
therefore selected for use in the NE formulation.
• TNEs had a MGD of 129.06 ± 3.35 nm, PDI of 0.192 ± 0.038 and ZP of 20.9 ± 2.02 mV
with an incorporation efficiency of 91.94 ± 0.84%. There was no significant change is
these properties after incorporation of TNEs into hydrogel as MGD, PDI and ZP of
TNEGs were found to be 136.13 ± 5.21 nm, 0.182 ± 0.020 and -20.9 ± 2.08 mV
respectively. The viscosity of the TNE and the TNEG was calculated at 1.24 ± 0.01 and
147.67 ± 32.64 respectively. This shows that there was a 119-fold increase in the
viscosity when TNE was converted to TNEG. The viscosity of the TNEG achieved in this
study is suitable for a hydrogel thickened NEs intended for transdermal application. The
surface morphology of the TNE displayed the spherical shaped NE droplets and short-
term stability investigations of the TNEGs performed at 4 °C and room temperature for 3
months confirmed its stability.
• Ex vivo permeation studies showed that the TNEG significantly enhanced the TNF
permeation by 39.65-fold, with a cumulative amount of 1866.54 ± 108.62 µg.cm -2.
Histological and TEER assessments showed no permanent effects on the skin by TNEG.
Therefore, this novel TNEG nanosystem has the potential of further translation into
clinical trials for optimal treatment alternatives for HIV/AIDs patients.
The findings of this study therefore confirmed the potential of newly developed lipid-based 
approaches to overcome the barrier properties of the SC and deliver therapeutically relevant 
doses of TNF across the skin.  
6.2 Significance of the findings in the study 
All four TNF transdermal permeation enhancement approaches successfully developed in this 
study are novel and have displayed evidence of overcoming the natural barrier properties of the 
skin. The advantages of these novel strategies have the potential to allow a larger variety of 
drugs to be delivered via this route. The novel approaches of this study have successfully 
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demonstrated that therapeutically relevant doses of TNF can be delivered transdermally and this 
route therefore functions as an attractive alternative to overcome the limitations of current oral 
TNF administration. The significance of this study is highlighted below: 
New pharmaceutical products: 
The developed ester dendritic derivatives of PA, LA, LLA and AA and the mono, di and tri-ester 
of OA, LA, LLA and SA which bear β-alanine t-butyl ester head group as well as the TNF 
loaded NEG are new pharmaceutical products that can promote and improve innovate drug 
delivery approaches in industrial pharmaceutical R&D.   
Improved patient therapy and disease treatment: 
All the developed permeation enhancement approaches have successfully decreased the barrier 
properties of the skin and therefore significantly enhanced the transdermal delivery of TNF. This 
should improve patient therapy by minimizing doses, lowering side effects and increasing patient 
compliance. These approaches should therefore improve patient amenability to this treatment 
regimen.   
Creation of new knowledge to the scientific community:  
The research findings of this study have contributed to the dissemination of new scientific 
knowledge within the domains of pharmaceutical sciences and biomaterials chemistry.  
• In the novel dendritic ester derivatives study, new knowledge from the development of
superior biocompatible novel CPEs from parent FAs was generated. Additionally, the
applicability of TNF for transdermal delivery was established, and its possible route of
transport across the skin was elucidated from light and transmission electron microscopy.
• In the UFAs esters of cholesterol study, new knowledge was generated from the
identification and combination of existing materials which possess advantageous inherent
features which contributed favourably to their novel applicability in TDD approaches.
• In the mono, di and tri-ester FA derivatives study, new knowledge was generated from
the design and synthesis of novel biosafe derivatives that targeted the lipid domains of the
SC and successfully decreased the barrier properties of the SC.
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• In the TNF NEG study, new knowledge was generated from the translation of a
previously identified novel CPE into a nano TDD dosage form which was essential in
realising its downstream pharmaceutical applications.
Stimulation of new research: 
The findings of the various studies and the successful development of numerous superior novel 
CPEs and TNEG can stimulate innovative approaches in various research areas including the 
following: 
• All the synthesized dendritic ester derivatives consist of tertiary nitrogen in their structure
and their potential to show pH dependency has been proven experimentally. This pH
dependent property may attract attention, especially in pH based drug targeting.
Therefore, in addition to their use as transdermal CPEs, they also contribute to widening
the pool of novel biocompatible excipients for drug delivery applications. Due to their pH
titratable nature they are potential excipients in the development of pH responsive drug
delivery systems for antimicrobial or cancer therapeutic applications.
• The proven efficacy of the UFAs esters of cholesterol as transdermal CPEs in this study
demonstrate that these ester hybrids of cholesterol and UFAs can also be considered as
multifunctional lipids (as CPEs and membrane stabilizers) in the future formulation
development of transdermal liposomes for the treatment of multiple disease conditions.
• Additionally, the safety profile and lipidic nature of the novel FA dendritic ester
derivatives and the mono, di and tri-esters of FAs can be further exploited for their
potential applications in lipid based colloidal drug delivery systems such as
nanoemulsions, self-microemulsifying drug delivery systems and nanostructured lipid
carriers for several classes of drugs.
• The formulated TNEG successfully demonstrated the translation of a previously
identified CPE into an efficient nano drug delivery system. These positive findings would
encourage further research utilising other such reported materials in the design and
implementation of effective dosage forms for various biomedical applications.
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6.3 Recommendations for future studies 
The various lipid based approaches in this study were successful in decreasing the barrier 
properties of the skin and significantly enhancing the transdermal permeation of TNF, however 
additional studies are necessary to improve/optimize the formulation of these novel lipids to 
ensure eventual regulatory approval for patient use. 
The following studies are therefore suggested: 
• From the dendritic ester derivatives study, apart from LLA1E which was identified as the
optimal enhancer in that series, the remaining UFA dendritic ester derivatives i.e LA1E,
PA1E and AA1E also showed permeation enhancement potential and were able to
considerably increase the amount of TNF delivered across the skin. These biosafe UFA
derivatives can therefore be further exploited for their applications in lipid based colloidal
drug delivery systems such as nanoemulsions, self-microemulsifying drug delivery
systems, nanostructured lipid carriers etc.
• The UFAs esters of cholesterol study confirmed that all of the cholesterol esters serve as
transdermal permeation enhancers. In combination with the reported property of
cholesterol being an efficient liposome membrane stabilizer, these UFA esters of
cholesterol can now be considered as multifunctional lipids (as CPEs and membrane
stabilizers) in the future formulation development of transdermal liposomes.
• All of the derivatives in the mono, di and tri-ester derivatives of FAs study showed the
potential to enhance the transdermal permeation of TNF. The next phase would be to
formulate lipid based colloidal drug delivery systems such as nanoemulsions, self-
microemulsifying drug delivery systems, nanostructured lipid carriers etc. using these
novel biosafe derivatives.
• The successfully developed NEG system for transdermal TNF delivery can be explored
for its in vivo transdermal drug delivery potential and to generate the bioavailability and
the pharmacokinetic data that will be useful to make further modifications to the
formulations.
• Long-term stability studies should be performed on the TNEG system according to ICH
guidelines to confirm its stability and shelf life.
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• All the novel approaches to enhance the transdermal delivery of TNF were successful
using the synthesized lipid derivatives, therefore molecular modelling studies should be
performed to understand the interaction between these lipid derivatives and the
components of the SC/ skin to establish a the exact mechanism of permeation
enhancement.
• A scale up method could be developed for the NEG and TNEG which would facilitate
their translation for pharmaceutical industry.
6.4 Conclusion 
The findings of this study demonstrate the potential of the various lipid based strategies to 
overcome the natural barrier properties of the SC and deliver therapeutically relevant doses of 
TNF via the skin. In addition to this study having contributed significantly to the approaches that 
reversibly decrease the skin’s barrier properties, it has also proven the applicability of TDD as an 
attractive alternate route for administration of TNF. The significant efficacy of FA ester 
derivatives in this study has further confirmed the superiority for this class of CPEs. The 
combination of materials chemistry, nanobiotechnology and formulation science serves an 
effective platform for developing advancements that address the limitations associated with TDD 
and oral TNF administration. This multidisciplinary approach has the potential to stimulate 
innovative strides towards the improvement of HIV and AIDS therapeutics thereby enhancing 
disease management.  
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